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Abstract
Posttraumatic stress disorder (PTSD) is an anxiety disorder that can develop after exposure
to a life or health threatening event and is mainly characterized by re-experiencing of the
traumatic incident, nervous hyperarousal, and avoidance of trauma-related cues. Clinical
and animal studies already identiﬁed PTSD-related alterations inter alia in the stress
hormone-, the neurotransmitter-, and the immune system, but despite these eﬀorts the distinct
pathomechanisms of PTSD still remain elusive. Furthermore, the molecular underpinnings of
the hippocampal volume loss that has been found both in PTSD patients and the mouse model
of PTSD employed in the thesis at hand are so far not completely understood.
This thesis aimed to further elucidate the pathomechanisms of PTSD by two diﬀerent
approaches: ﬁrst, by characterization of an already known candidate molecule for anxiety
disorders, i.e. transmembrane protein 132 D (TMEM132D), and, second, by a screen for
novel candidate molecules for PTSD pathogenesis in a mouse model of PTSD.
In the ﬁrst part of this thesis, a previously identiﬁed anxiety disorder candidate gene of
yet unknown function, i.e. TMEM132D, was further characterized in view of its regulatory
mechanisms. Due to the previously reported association of TMEM132D with mature
oligodendrocytes, an extensive characterization of the TMEM132D promoter was performed
in the oligodendrocytic MO3.13 cell line. This promoter analysis identiﬁed a number of
transcription factors inhibiting TMEM132D gene expression, namely HES1, MYT1, ZNF219,
GCM1, MTF1, NFKB1, MZF1, and SP1. Increased expression of TMEM132D mRNA in
diﬀerentiated versus non-diﬀerentiated MO3.13 cells was paralleled by a reduced expression
of four of these transcription factors, namely ZNF219 and three regulatory factors already
known to be involved in oligodendrocyte diﬀerentiation, i.e. MYT1, HES1, and SP1.
In the second part of this thesis, brain region speciﬁc expression level diﬀerences of selected
marker proteins were assessed in mice subjected to a traumatic electric footshock and a single
stressful re-exposure to trauma-related environmental cues 28 days after shock application or
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in control mice subjected to mock treatment. This analysis revealed an enduring hippocampal
downregulation of the synaptic proteins synapsin Ia-b/IIa, synaptophysin, and homer 1b/c to
accompany the PTSD-like behavior and the hippocampal volume loss in traumatized mice. In
contrast to synaptic proteins, the expression of the dendritic protein MAP-2 and the astroglial
protein GFAP was found to be unaltered in the hippocampus of traumatized mice. This
trauma stress-induced synaptic protein loss might, at least in part, be caused by increased
extracellular glutamate levels as alluded by the here observed decreased expression levels of
hippocampal glutamate transporter proteins, i.e. GLT1 and EAAC1, in traumatized mice.
Treatment with the SSRI antidepressant ﬂuoxetine alleviated the PTSD-like symptoms and,
moreover, counteracted the reduction of synaptic protein and GLT1 expression. Finally, by
serendipity, a trauma stress-induced delayed-onset increase of immunoglobin G (IgG) was
identiﬁed in the hippocampus, where IgG was found to be associated with microglial cells.
Furthermore, decreased expression of the microglial marker Iba1 points at a stress-induced
reduction of microglial cell numbers accompanying the increased IgG expression in traumatized
mice. Alterations in IgG expression were also detected in another mouse model, namely in the
HAB/LAB trait anxiety mouse model, as well as in an in silico analysis of publicly available
peripheral blood mononuclear cell (PBMC) gene expression data of PTSD patients.
In conclusion, this thesis comprises the ﬁrst characterization of the TMEM132D promoter
and revealed several transcription factors to inhibit the expression of the anxiety disorder
candidate gene TMEM132D in an oligodendrocyte cell culture model. The second part of this
thesis demonstrates PTSD-like symptoms in mice to be accompanied by hippocampal synaptic
protein loss. The fact that ﬂuoxetine was found to eﬀectively counteract both behavioral
symptoms and the alterations in synaptic protein expression levels further highlights the
importance of hippocampal synaptic protein loss in the murine PTSD-like syndrome and
the associated hippocampal shrinkage. In addition, reduced levels of distinct glutamate
transporters and alterations of protein levels associated with the immune system were
identiﬁed to occur in the aftermath of the traumatic footshock. However, clinical studies are
clearly needed to analyze the importance of the ﬁndings presented here in patients suﬀering
from PTSD and other anxiety disorders.
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1. Introduction
In 1936, stress was deﬁned by Hans Selye as the unspeciﬁc response to noxious events including
physical trauma, infection, and other adverse life conditions that the organism typically
encounters throughout life (Selye, 1936). Thus, the stress response constitutes a physiological
adaptation process enabling the individual to cope with a constantly changing environment.
Perception of fear and anxiety is essential for the adaptation to threatening situations: while
the fear reaction enables the organism to escape from a life-threatening situation, the emotion
of anxiety is thought to be longer lasting and future-focused, and thus prepares the individual
to adapt to a potential future threat (Barlow, 2000). Whether the organism can handle a
stressful challenge or fails to adapt is determined by a variety of factors including its genetic
and epigenetic predisposition (Cornelis et al., 2010; Schmidt et al., 2011) as well as the
experienced cumulative lifetime stress, i.e. the allostatic load (McEwen and Stellar, 1993). It
is well accepted that pathological alterations of the stress response as well as fear and anxiety
reactions are associated with psychiatric disorders like major depression, panic disorder, and
posttraumatic stress disorder (PTSD) (De Kloet et al., 2005; McEwen, 2007).
1.1. History, epidemiology, and symptomatology of PTSD
In 1980, the term ‘posttraumatic stress disorder’ was ﬁrst oﬃcially noted in the Diagnostic
and Statistical Manual of Mental Disorders III (DSM-III), the classiﬁcation system of
the American Psychiatric Association (American Psychiatric Association, 1980). However,
psychic symptoms following trauma have been described much earlier: Herodotus (490 B.C.)
described an Athenian soldier who was not physically wounded during the Battle of Marathon
but nevertheless became permanently blind after witnessing the death of a fellow soldier
(Schiraldi, 1999). Diﬀerent terms including ‘traumatic neurosis’, ‘fright neurosis’, ‘shell shock’,
‘combat fatigue’, and ‘survival syndrome’ were used to describe a PTSD-equivalent syndrome
1
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(Shorter, 2005; Bronisch, 2010). In the current edition of the DSM, the DSM-IV, PTSD is
assigned to the group of anxiety disorders which also include generalized anxiety disorder,
panic disorder, obsessive-compulsive disorder, acute stress disorder as well as agoraphobia,
social and speciﬁc phobia (American Psychiatric Association, 2000).
The life-time prevalence of PTSD was described by the National Comorbidity Survey (NCS)
to be 10.4 % in females and 5.0 % in males of the U.S. population (Kessler et al., 1995), while
in Germany the prevalence rate was reported to be 2.2 % in females and less than 1 % in males
(Perkonigg et al., 2000). The risk of developing PTSD is inter alia dependent on the type of
trauma, i.e. the stress dose experienced by the aﬀected individual, as it can be deduced from
the fact that PTSD occurs much more frequently after rape and combat than for instance after
accidents (Foa et al., 2006). Additionally, biological vulnerability factors as well as gender,
the socioeconomic background, and secondary posttraumatic stressors have been described to
modulate the probability of PTSD onset (Yehuda et al., 2011; Foa et al., 2006).
To date, as every psychiatric diagnosis, also the diagnosis of PTSD relies on self reports,
clinical expert interviews, and clinical behavioral monitoring. According to the DSM-IV,
PTSD diagnosis requires the respective individual to have been either directly exposed to a
life or health threatening traumatic event or to have instantaneously witnessed another person
being exposed to such an incident. PTSD core symptoms can be classiﬁed into three clusters:
ﬁrst, the re-experiencing symptoms which include recurrent intrusive memories of the event in
form of intrusions and ﬂashbacks as well as distressing dreams. Environmental cues reminding
patients of the traumatic experience usually trigger those re-experiencing symptoms. The
second symptom cluster comprises avoidance and numbing symptoms: aﬀected patients
avoid thoughts, feelings, activities, places, or people associated with the traumatic event.
Furthermore, loss of memory of important aspects of the event and emotional numbing might
occur in PTSD patients. Hyperarousal symptoms consitute the third PTSD symptom cluster
comprising inter alia sleep diﬃculties and an exaggerated startle response. PTSD symptoms
have to last for at least one month to justify a diagnosis of PTSD (North et al., 2009; Foa
et al., 2006; American Psychiatric Association, 2000).
2
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1.2. Neurobiology of PTSD
1.2.1. The neuroendocrine stress response and its alterations in PTSD
It is well accepted that glucocorticoids and catecholamines play a major role in regulating the
stress response of human beings and other mammals. This stress response implies changes in
brain metabolism and behavior. Secretion of the two major stress hormones, i.e. cortisol
and epinephrine, is regulated by the hypothalamic-pituitary-adrenal (HPA) axis and the
sympathetic-adrenal-medullary (SAM) axis, respectively. While catecholamines induce an
immediate response to the stressor, activation of the HPA axis, occurring with a time delay,
rather eﬀects long-term adaption processes.
The hypothalamus, the anterior pituitary, and the cortex of the adrenal gland constitute
the eﬀector organs of the HPA axis (Figure 1.1). Additionally, limbic structures processing
the emotional response to stressors are known to modulate HPA axis activation: while the
hippocampus and the prefrontal cortex inhibit the HPA axis, the amygdala activates it
(Herman et al., 2005). Stress induces the release of corticotropin-releasing hormone (CRH)
from parvocellular secretory neurons which project from the hypothalamic paraventricular
nucleus (PVN) to the median eminence of the hypothalamic-hypophyseal portal circulation
(Figure 1.1). CRH is transported via the blood to the anterior pituitary where it stimulates
the release of adrenocorticotropin (ACTH) (Figure 1.1). Subsequently, ACTH is transported
via the blood circulation to the adrenal cortex where it induces the release of glucocorticoids
(Papadimitriou and Priftis, 2009), that is cortisol in humans and corticosterone in rodents, as
well as the mineralocorticoid aldosterone (Funder, 2010). Glucocorticoids support the body to
cope with the stressor by increasing the energy metabolism and the vascular tone as well as by
inhibiting immune and reproductive functions (Haddy and Clover, 2001; Herman et al., 2003).
HPA axis activation is regulated via a negative feedback inhibition loop, i.e. cortisol exerts
an inhibitory eﬀect on the ACTH-secreting neurons in the pituitary and the CRH-secreting
neurons in the hypothalamus. Under physiological conditions, this negative feedback-loop
results in a temporary well deﬁned upregulation of glucocorticoids in response to stressors
(Herman et al., 2003).
3
1. Introduction
Figure 1.1.: Scheme of the neuroendocrine stress response. HPA axis: stress-induced
cortisol secretion from the adrenal cortex is stimulated by ACTH secreted from
the anterior pituitary (P) which is in turn stimulated by CRH secreted from
the parvocellular secretory neurons of the hypothalamus (HYP). Via a negative
feedback loop, cortisol inhibits both CRH and ACTH secretion. SAM axis: via
the locus coeruleus (LC)-noradrenergic system, stress activates the sympathetic
nervous system and induces the release of epinephrine from the adrenal medulla.
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Besides the HPA axis, stressors activate the release of norepinephrine from locus coeruleus
neurons and immediately activate the sympathetic-adrenal-medullary (SAM) axis, i.e.
an increased activation of sympathetic neurons projecting from the spinal cord to the
adrenal medulla stimulating inter alia the production and release of the catecholamines
epinephrine and norepinephrine (Figure 1.1). Increased catecholamine levels immediately
evoke a physical stress response (the ‘ﬁght-or-ﬂight response’) by increasing blood pressure
and heart rate as well as by inhibiting appetite, digestion, and reproductive functions
(Carrasco and Van de Kar, 2003). During this short-term catecholamine mediated stress
response the immune system is activated (Wong et al., 2011) to enable the organism to cope
with immune challenges that often accompany the stressor (Sorrells and Sapolsky, 2007). In
contrast, upregulation of glucocorticoids, which have been repeatedly reported to mediate the
long-term adaptation to the stressor, are known to have anti-inﬂammatory eﬀects whereby
they attenuate the stress-induced immune activation (Sorrells and Sapolsky, 2007).
There are multiple evidences for a dysregulation of both the HPA and the SAM axis in
PTSD (De Kloet et al., 2006; Bowirrat et al., 2010). HPA axis alterations in PTSD are
controversially discussed in scientiﬁc literature: most studies have reported peripheral cortisol
levels measured in urine, saliva, or plasma to be decreased, while others found unchanged
cortisol levels in PTSD patients (Yehuda, 2009). In contrast, major depression and anxiety
disorders have been found to go along with increased peripheral cortisol levels (Parker et al.,
2003; Lightman, 2008). The discordance of cortisol measurements in PTSD may, at least
in part, be explained by the high comorbidity of PTSD with major depression and other
HPA axis inﬂuencing disorders. Further support for a hypoactivation of the HPA axis in
PTSD pathophysiology is provided by studies reporting PTSD patients to exhibit an increased
suppression of cortisol secretion in the dexamethasone suppression test, i.e. the administration
of the glucocorticoid derivate dexamethasone followed by a measurement of cortisol levels.
The increased suppression of cortisol secretion in this test indicates an enhanced negative
feedback inhibition in PTSD patients which is probably due to an increased glucocorticoid
receptor (GR) sensitivity (Yehuda, 2009). Furthermore, an enhanced feedback inhibition is
also supported by reduced ACTH levels measured upon cortisol injections (Yehuda, 2009; Pace
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and Heim, 2011). The importance of the GR in mediating the pathogenic eﬀects of stress is
inter alia highlighted by a study reporting that antagonism of GR prior to stress exposure
prevents potentiation of fear conditioning in a rat model of PTSD (Kohda et al., 2007).
In contrast to glucocorticoids, central and peripheral catecholamine levels have been found to
be increased in PTSD patients (Dikanović et al., 2011). Additionally, PTSD patients have been
reported to exhibit an increased heart rate, increased blood pressure, and tremor responses
at rest as well as upon trauma reminders (Bedi and Arora, 2007); these symptoms are well
known to be provoked by increased SAM activity. Low cortisol and high plasma catecholamine
levels shortly after the trauma have been recently proposed to serve as predictors for PTSD
development (Pace and Heim, 2011; Yehuda, 2009).
Several behavioral and biological alterations in psychiatric disorders like PTSD have been
attributed to changes in stress hormone levels. It is well known that elevated glucocorticoid
levels can exert toxic eﬀects, and therefore, glucocorticoids are discussed to be involved
in the development of hippocampal shrinkage, which has been associated with PTSD and
other stress-associated psychiatric disorders (McEwen, 1997). This hippocampal volume loss,
described in greater detail in section 1.2.4.1, might at least partially underlie cognitive deﬁcits
found in a majority of PTSD patients (Brewin, 2011; McEwen, 1997). Moreover, both
glucocorticoids and catecholamines have been reported to enhance memory consolidation,
i.e. the stabilization of a memory trace leading to the formation of long-term memory
(Quervain et al., 2009; Roozendaal et al., 2009). Thus, increased stress hormone levels during
and shortly after the trauma might lead to an overrepresentation of emotionally arousing
memories. Furthermore, glucocorticoids also inhibit the retrieval of stored memories, and
thus, low cortisol levels in PTSD patients might facilitate pathological excessive retrieval
of aversive memories (Quervain et al., 2009). Additionally, diminished cortisol levels can
reduce the consolidation of fear extinction memory, i.e. the reduction of the conditioned fear
response following the presentation of a traumatic cue in absence of the aversive stimulus
(Quervain et al., 2009). Impaired fear extinction has been proposed to be responsible for the
persistence of traumatic memories in PTSD patients (Wessa and Flor, 2007). A possible
molecular mechanism of the glucocorticoid enhanced memory (re)consolidation has been
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recently investigated in the hippocampus of rats in a predator scent based model of PTSD:
trauma stress-induced increase in corticosterone secretion and enhanced GR translocation to
the nucleus were found to induce an increased expression of the immediate early gene Zif/268
shortly after stress exposure (Kozlovsky et al., 2009). Zif/268 is a critical factor for synaptic
modiﬁcations and the formation of long-term memory (Guzowski, 2002; Abraham et al., 1991).
Furthermore, the molecular underpinnings of fear extinction have been addressed in a recent
study showing that inhibition of hippocampal cyclin dependent kinase 5 (CDK5) activity
facilitates fear extinction in mice (Sananbenesi et al., 2007).
1.2.2. Neurotransmitter systems in PTSD
Processing of information in neuronal networks of the brain depends on neuron-to-neuron
signaling which is transduced via neurotransmitter release in chemical synapses. As described
below in section 1.2.4, traumatic experiences activate certain neuronal circuits and can also
induce long-lasting changes in neurotransmitter systems. Furthermore, single nucleotide
polymorphisms (SNP), i.e. a DNA sequence variation in a single nucleotide, in genes
associated with neurotransmitter systems have been shown to be associated with the
individuals predisposition to develop PTSD (see also section 1.2.3). Several monoaminergic
transmitters including norepinephrine (see section 1.2.1), dopamine, and serotonin have been
implicated in PTSD pathogenesis: clinical studies identiﬁed increased urinary dopamine
levels in PTSD patients (Glover et al., 2003) as well as an association of SNPs in the
dopamine transporter 1 (DAT1) gene (Valente et al., 2011; Segman et al., 2002; Drury
et al., 2009), the dopamine receptor 2 (DRD2) gene (Comings et al., 1996; Young et al.,
2002; Voisey et al., 2009), and the dopamine receptor 4 (DRD4) gene (Dragan and
Oniszczenko, 2009) with PTSD. In addition, a polymorphism in the catcholamine catabolizing
enzyme Catechol-O-methyltransferase (COMT) has been proposed as a risk factor for PTSD
development (Kolassa et al., 2010b). Furthermore, dysregulation of the serotonin signaling
pathway has been suggested to contribute to PTSD pathophysiology: in PTSD patients
decreased platelet concentrations of serotonin (Mück-Seler et al., 2003; Spivak et al., 1999;
Kovacic et al., 2008) as well as an association of SNPs in the serotonin transporter (SLC6A4)
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gene (Lee et al., 2005; Kolassa et al., 2010a; Kilpatrick et al., 2007; Koenen et al., 2009) and
the serotonin receptor 2A (5-HTR2A) gene with PTSD (Lee et al., 2007) have been reported.
Besides these alterations in monoaminergic pathways, also alterations in amino acid
neurotransmitter pathways have been identiﬁed in PTSD: decreased plasma levels of
γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter of the CNS, have been
found in PTSD patients (Vaiva et al., 2004). Furthermore, genetic variations of GABA
receptor A2 (GABARA2) have been associated with human PTSD (Nelson et al., 2009).
Dysregulation of the GABAergic neurotransmitter system has also been reported in a rat
model of PTSD: a downregulation of the GABAA receptor has been detected in the amygdala
(Ponomarev et al., 2010). Moreover, dysfunction of glutamatergic neurotransmission is known
to play a major role in the stress response and in stress-related disorders (Popoli et al., 2012).
Animal studies have found that acute stress induces a glucocorticoid-dependent increase
in glutamate release that may at least in part be mediated via a cannabinoid receptor
dependent pathway (Popoli et al., 2012). Interestingly, a single nucleotide polymorphism
(SNP) in the cannabinoid receptor 1 (CNR1) gene has recently been associated with PTSD
(Lu et al., 2008). Stress-induced elevation of glutamate release facilitates memory formation
by inducing long-term potentiation (Anwyl, 2009). Excessive glutamate levels, however, can
result in excitotoxicity, i.e. cellular damage (Wang and Qin, 2010). Besides this ﬁnding and
the fact that anti-glutamatergic drugs like lamotrigine have been proven to be eﬀective in
pharmacotherapy of PTSD patients (Berger et al., 2009), there are so far no human studies
showing altered glutamatergic neurotransmission in PTSD patients. However, evidence for a
role of the glutamatergic system in PTSD pathogenesis is provided by rodent studies in which
blocking N-methyl-D-aspartate (NMDA) receptors prior to exposure to a predator scent stress
prevented anxiety-like behavior (Adamec et al., 1999; Blundell et al., 2005). Independent from
that, hypoactivity of the hippocampal inhibitory glycinergic system has been recently linked
to impaired fear extinction in a rat model of PTSD (Yamamoto et al., 2010).
Finally, also altered neuropeptide levels have been found associated with PTSD: besides the
alterations in CRH, described in section 1.2.1, decreased expression of neuropeptide Y (NPY)
has been reported both in PTSD patients (Rasmusson et al., 2000) and in rats exhibiting
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PTSD-like symptoms (Ponomarev et al., 2010; Cohen et al., 2012). NPY is known to stimulate
the secretion of CRH in the hypothalamaus (Haas and George, 1989). In addition, increased
secretion of the neuropeptide PACAP, which inter alia also increases CRH secretion in the
hypothalamus (Grinevich et al., 1997), have been associated with PTSD in female patients
(Ressler et al., 2011). In the same study also a SNP in the PACAP receptor PAC1 has been
associated with PTSD in female patients, and furthermore, the identiﬁed risk genotyp was
linked to decreased PAC1 receptor mRNA expression in cortex samples of healthy females
(Ressler et al., 2011)
1.2.3. Genetic and epigenetic risk factors for PTSD
Only a subset of trauma victims develops PTSD. A recent study in a U.S. patient cohort
has determined that less than 10 % of individuals exposed to any traumatic event develop
PTSD (Breslau, 2009). However, depending on the type and intensity of the traumatic
event the proportion of individuals developing PTSD patients can be substantially higher.
Thus, additional factors, including environmental, genetic, and epigenetic risk factors are
thought to contribute to the individuals predisposition to develop PTSD. Twin studies can
contribute to diﬀerentiate the inﬂuence of environmental and genetic factors on behavior.
Studying trauma-exposed twin pairs it has been estimated that approximately 30 % of the
PTSD symptoms rely on a heritable component (Aﬁﬁ et al., 2010; Skelton et al., 2012). The
identiﬁcation of speciﬁc genes involved in PTSD pathogenesis has been mainly addressed in
candidate gene association studies, while so far no genome-wide association study (GWAS)
has been performed with PTSD patients (Cornelis et al., 2010). In contrast to GWAS, which
investigate genetic variations in the whole genome, the candidate gene association approach
selectively searches for association of single SNPs with certain symptoms or syndromes aiming
to identify genetic regions involved in certain diseases like PTSD (Cornelis et al., 2010). These
candidate gene association studies have so far mainly searched for genetic variations in genes
associated with the HPA axis (summarized in Table 1.1): the PTSD syndrome was found
to be associated with SNPs inter alia in the CRH receptor 1 (CRHR1) gene (Amstadter
et al., 2011), and in the FK506 bindin protein 5 (FKBP5) gene (Binder et al., 2008; Xie
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et al., 2010) which regulates the cortisol-binding aﬃnity of the glucocorticoid receptor. It is
hypothesized that these genetic variations in the CRHR1 and FKBP5 genes contribute to the
dysregulation of the HPA axis in individuals developing PTSD. Furthermore, a polymorphism
in the anxiety-associated gene regulator of G-protein signaling 2 (RSG2) has been reported to
be associated with PTSD symptom severity after trauma exposure (Amstadter et al., 2009).
Finally, SNPs in a variety of neurotransmitter system associated genes have been linked to
PTSD, as described in section 1.2.2 and summarized in Table 1.1.
Besides genetic variations, the risk to develop PTSD is also inﬂuenced by environmental factors
like early-life stress but also trauma type or severity which can modify gene activity inter
alia via epigenetic mechanisms. Epigenetic modiﬁcations are heritable functional changes
of the genetic activities that are not accompanied by alterations of the DNA sequence,
e.g. acetylation of histone proteins or methylation of cytosine residues residing in CpG
dinucleotides that are often found to be enriched in promoter regions (Schmidt et al.,
2011). The transgenerational transmission of potential trauma stress-induced epigenetic
modiﬁcations is alluded by a study showing that maternal PTSD increases the risk of
Holocaust survivors oﬀspring to develop PTSD (Yehuda et al., 2008). This assumption
is further supported by a study reporting decreased salivary cortisol levels in both babies
and their mothers, who developed PTSD after experiencing the World Trade Center attacks
during pregnancy (Yehuda et al., 2005). Epigenetic regulation of HPA axis activity has
been also addressed in a study using human post-mortem hippocampus samples from suicide
victims showing reduced GR expression levels and increased GR promoter methylation in
those individuals that had experienced early-life traumatic stress (McGowan et al., 2009).
Furthermore, a recent study in mice reported early-life stress to decrease methylation of a
regulatory region in the vasopressin gene, which was accompanied by increased vasopressin
expression and HPA axis hyperactivation (Murgatroyd et al., 2009). Importantly, in
the same study neuronal activity was reported to regulate vasopressin transcription by
increasing methyl CpG-binding protein 2 (MeCP2) phosphorylation and thereby preventing
the MeCP2-mediated upregulation of vasopressin expression. Recently, also the methylation
of the stress-related PAC1 receptor gene, measured in blood samples of PTSD patients,
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has been associated with PTSD symptom severity (Ressler et al., 2011). Binding of the
neuropeptide PACAP to the PAC1 receptor is involved in the stress response inter alia by
stimulating CRH gene expression (Grinevich et al., 1997). Furthermore, epigenetic variations
in PTSD patients have been assessed using methylation microarrays with blood samples of
PTSD-aﬀected and PTSD-unaﬀected individuals revealing a reduced methylation of immune
function associated genes in PTSD-aﬀected individuals (Uddin et al., 2010). A second study
using the same patient samples also identiﬁed an interaction between methylation of the gene
encoding mannosidase alpha class2C member 1 (MAN2C1) and the number of potentially
traumatic events; thus, high MAN2C1 methylation rates and a high number of potentially
traumatic events increase the risk of developing PTSD (Uddin et al., 2011). Finally, distinct
alterations in global hippocampal DNA methylation patterns have been identiﬁed in a rat
model of PTSD (Chertkow-Deutsher et al., 2010). In the same PTSD animal model increased
methylation of the Disks Large-Associated Protein (Dlgap2) encoding gene was associated
with decreased Dlgap2 gene expression, which, in turn, was found to be correlated with the
behavioral stress response (Chertkow-Deutsher et al., 2010).
Altogether, environmental and genetic factors as well as gene x environment interactions,
that are inter alia mediated via epigenetic mechanims, modulate the individuals vulnerability
to PTSD (Mehta and Binder, 2011). In particular, the ﬁndings on genetic and epigenetic
variations of HPA axis associated genes underline the importance of this neuroendocrine
stress response system for PTSD susceptibility and pathogenesis. Furthermore, evidence from
genetic and epigenetic studies propose an involvement of both neurotransmitter system and
immune function related genes to contribute to PTSD pathogenesis.
1.2.4. Pathoanatomical alterations associated with PTSD
Structural and functional alterations of several brain regions including the amygdala, the
hippocampus (HC), and the prefrontal cortex (PFC) have been identiﬁed in PTSD patients.
These brain regions form a functional neurocircuit activated during both the stress response
and fear conditioning (Heim and Nemeroﬀ, 2009). Several neuroimaging studies using
mostly positron emission tomography (PET) and functional magnetic resonance imaging
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(fMRI) found a hyperresponsivity of the amygdala in PTSD patients which was correlated
with symptom severity, while hippocampal and prefronto-cortical regions were found to be
hyporesponsive (Shin and Liberzon, 2010).
1.2.4.1. Hippocampus
The hippocampus, which is inter alia involved in the formation and the maintenance of
declarative and spatial memory as well as in memory consolidation processes generating
long-term memory (Elzinga and Bremner, 2002), was found to be hypoactive in PTSD patients.
This hypoactivation inversely correlated with symptom severity (Shin and Liberzon, 2010).
Furthermore, a reduction of hippocampal volume has been repeatedly associated with PTSD
(Shin and Liberzon, 2010). Additionally, decreased levels of hippocampal N-acetylaspartate
(NAA), a marker for neuronal integrity, have been associated with traumatic stress and
argue for dysfunctional hippocampal neuronal networks in PTSD patients (Schuﬀ et al.,
2006). Moreover, in the PTSD mouse model used also in the thesis at hand, hippocampal
NAA measurements in mice have been reported to predict the development of PTSD-like
symptoms (Siegmund et al., 2009). Accordingly, ﬁndings of twin studies suggest hippocampal
volume to represent a predisposition factor rather than a consequence of PTSD pathogenesis
(Gilbertson et al., 2002).
Despite several alterations proposed to underlie trauma stress-induced hippocampal shrinkage
comprising decreased neurogenesis and gliogenesis, apoptosis, and reduction in glial cell
numbers as well as morphological changes of neurons like dendritic retraction (Czeh and
Lucassen, 2007), the exact cellular and molecular correlates of the PTSD associated
hippocampal volume loss still remain elusive. Glucocorticoids and brain-derived neurotrophic
factor (BDNF) are discussed to be involved in the development of hippocampal shrinkage: it
is well known that persistently elevated levels of glucocorticoids have neurotoxic eﬀects (You
et al., 2009; Uno et al., 1994) which are, at least in part, mediated by a glucocorticoid-induced
increase in hippocampal glutamate levels and subsequent excitotoxic eﬀects (McEwen, 1997).
Animal studies further suggest that stress-induced alterations in hippocampal expression levels
of glucocorticoid receptors (Kohda et al., 2007) and NMDA receptors (Yamamoto et al., 2008)
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might further aggravate the toxic eﬀects of increased glucocorticoid and glutamate levels.
Furthermore, clinical studies showing an inverse correlation of cortisol levels with hippocampal
volume (Knoops et al., 2010; Tessner et al., 2007) support the hypothesis of glucocorticoids
playing a major role in stress-associated hippocampal shrinkage. In contrast to glucocorticoids,
BDNF represents an important factor in hippocampal plasticity since it promotes neuronal
growth and survival (Numakawa et al., 2010). Reduced BDNF gene expression has been
found both in plasma of PTSD patients (Dell’osso et al., 2009) as well as in the hippocampus
of rats showing a PTSD-like syndrome (Kozlovsky et al., 2007). An epigenetic mechanism
of BDNF downregulation has been recently reported in a study showing reduced BDNF
expression to be associated with increased BDNF DNA methylation rates in rats exhibiting
PTSD-like symptoms (Roth et al., 2011). BDNF-induced long-term potentiation (LTP) has
been shown to include the activation of the extracellular signal-regulated kinase (ERK) and
p38 mitogen-activated protein kinases (MAPK) which both induce phosphorylation of cAMP
response element-binding (CREB) protein (Ying et al., 2002). Phosphorylated CREB, in
turn, is able to induce the immediate early genes activity-regulated cytoskeleton-associated
protein (Arc) and Zif/268, thereby possibly contributing to changes in synaptic structure
(Ying et al., 2002). Both Arc and Zif/268 have been found to be exhibit increased expression
in diﬀerent PTSD rat models (Kozlovsky et al., 2008; Kozlovsky et al., 2009). Despite these
eﬀorts, however, the molecular correlates of the PTSD associated hippocampal shrinkage are
not completely understood.
1.2.4.2. Prefrontal cortex
The prefrontal cortex integrates sensory information received from numerous brain regions
with inter alia emotional memory from the limbic system (Gray et al., 2002). Based on
these information, the prefrontal cortex plans and initiates goal-directed behavior (Miller
et al., 2002). Decreased activation of the medial prefrontal cortex (mPFC) was found
in PTSD patients in response to both trauma-related and trauma-unrelated stimuli, and
moreover, it was inversely correlated with PTSD symptom severity (Shin and Liberzon, 2010).
Furthermore, a reduction of the PFC volume was found in PTSD patients (Shin and Liberzon,
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2010). The cellular and molecular correlates of this PFC volume loss, however, are poorly
understood. In accordance with these clinical studies, a study that subjected rats to chronic
restraint stress reported reductions in prefronto-cortical dendrite lengths (Radley et al., 2004).
The latter might contribute to the PFC volume loss and cognitive impairments, however, this
still awaits experimental conﬁrmation. On the molecular level, so far only a single study
employing a PTSD rat model showed a prefronto-cortical reduction of phosphorylated ERK1/2
which is inter alia involved in the formation of BDNF-induced LTP (Wang et al., 2010a).
1.2.4.3. Amygdala
The third brain region involved in the neurocircuitry of PTSD is the amygdala which has
been repeatedly shown to be hyperactive in PTSD patients. As HC and PFC exert inhibitory
actions on the amygdala, hypoactivity of these two regions might further enhance the
hyperresponsivity of the amygdala, which is inter alia involved in the emotional processing of
stress (Rauch et al., 2006). Several studies reported that the amygdala volume is reduced in
PTSD patients (Karl et al., 2006; Rogers et al., 2009). Findings of animal studies suggest that
apoptosis contributes largely to this volume loss (Xiao et al., 2011b; Liu et al., 2011; Ding
et al., 2010). On the cellular level, the hyperactivation of the amygdala might be reﬂected by
increased dendritic arborization and increased spine density found in animal models of PTSD
(Mitra et al., 2005; Adamec et al., 2012; Cui et al., 2008). These alterations in dendritic spine
density are thought to aﬀect the storage of fear memories, which is disturbed in PTSD (Mitra
et al., 2005). Interestingly, expression of phosphorylated ERK (pERK) was increased in the
hyperresponsive amygdala (Xiao et al., 2011a), while, as mentioned in the previous section,
pERK expression was decreased in the hyporesponsive prefrontal cortex (Wang et al., 2010a).
Altogether, studies on animal models of PTSD are starting to address the cellular and
molecular correlates of structural and functional neuroanatomical alterations that have been
found in PTSD patients, however, the distinct molecular mechanisms underlying the trauma
stress-induced shrinkage of these brain regions still remain elusive.
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1.3. PTSD Biomarkers
The term biological marker or biomarker was deﬁned by the Biomarker Deﬁnitions Working
Group as ‘a characteristic that is objectively measured and evaluated as an indicator of
normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic
intervention’ (Biomarkers Deﬁnitions Working Group, 2001). In addition to providing a
tool for measuring processes in the clinical setting, the search for new biomarkers aims
at contributing to further elucidation of (patho-)mechanisms underlying the respective
pathogenic processes. A wide variety of indicators can serve as biomarkers: genomic
alterations like single nucleotide polymorphisms (SNPs) have been proposed to predict disease
vulnerability and treatment responsivity of individuals, e.g. a SNP in the FKBP5 gene
has been associated with the response to antidepressant treatment (Binder et al., 2004).
Additionally, alterations in gene or protein expression can serve as measurable tools in normal
biological as well as pathogenic processes and therapeutic treatment responses (Hampel et al.,
2010). Besides genomic, transcriptomic, and proteomic markers, also altered brain activities
determined by PET or fMRI imaging and any physiological parameter like blood pressure,
electrocardiogram (ECG), and heart rate can serve as biomarker (Hampel et al., 2010; Zhang
et al., 2009).
To date, several potential PTSD biomarkers have been proposed, e.g. the startle response,
which positively correlates with the state of nervous hyperarousal (Skelton et al., 2012).
However, so far no PTSD biomarker has been licensed for use in the clinical practice. Table
1.1 summarizes genomic alterations as well as gene and protein expression changes that have
been found to be associated with human PTSD and were proposed to serve as potential
PTSD biomarkers. Several of these potential biomarkers are HPA axis associated factors and
are described in greater detail in chapters 1.2.1 and 1.2.3. In addition, high dexamethasone
binding capacity in peripheral blood mononuclear cells (PBMCs), reﬂecting a measurement of
GR numbers, have been proposed as a vulnerability factor for PTSD development (van Zuiden
et al., 2011). Besides the HPA axis, several genes encoding neurotransmitter system associated
proteins, as described in section 1.2.2, have been associated with PTSD. Additionally,
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Table 1.1.: Potential biomarkers for PTSD. Unless indicated otherwise the cited studies
used blood samples of PTSD patients and control individuals. This list is not
intended to be exhaustive.
Biomarker Type References
HPA-Axis
Glucocorticoid receptor (GR) protein (Gotovac et al., 2003; van Zuiden et al.,
2011)
CRHR1 SNP (Amstadter et al., 2011)
FKBP5 SNP, mRNA (Binder et al., 2008; Xie et al., 2010;
Yehuda et al., 2009)
circulating cortisol levels reviewed in (Yehuda, 2009)
Neurotransmitter Systems
NPY expression protein (Rasmusson et al., 2000; Yehuda et al.,
2006)
PACAP and PAC1 SNP, mRNA,
methylation
(Ressler et al., 2011)
Dopamine transporter (DAT1) SNP (Valente et al., 2011; Segman et al., 2002;
Drury et al., 2009)
Dopamine receptor (DRD2) SNP (Comings et al., 1996; Young et al., 2002;
Voisey et al., 2009)
Dopamine receptor (DRD4) SNP (Dragan and Oniszczenko, 2009)
urinary dopamine increase (Glover et al., 2003)
Serotonin transporter (SLC6A4) SNP (Lee et al., 2005; Kolassa et al., 2010a;
Kilpatrick et al., 2007; Koenen et al.,
2009)
Serotonin receptor (5-HTR2A) SNP (Lee et al., 2007)
Platelet serotonin concentration (Mück-Seler et al., 2003; Spivak et al.,
1999; Kovacic et al., 2008)
GABA receptor (GABARA2) SNP (Nelson et al., 2009)
GABA plasma levels decreased (Vaiva et al., 2004)
Catechol-O-methyltransferase
(COMT)
SNP (Kolassa et al., 2010b)
Cannabinoid receptor (CNR1) SNP (Lu et al., 2008)
p11 (S100-A10) mRNA (Su et al., 2009)
Immunological Factors
IL-6 and IL-6R protein (Maes et al., 1999; Baker et al., 2001; von
Känel et al., 2010)
IL-2 and IL-8 protein (Song et al., 2007)
CRP and serum amyloid A protein (Söndergaard et al., 2004; von Känel et al.,
2010)
Neopterin reduction (Atmaca et al., 2002)
increased inﬂammatory immune
activities
mRNA,
protein, cells
reviewed in (Gill et al., 2009; Vidovic
et al., 2011)
Other Factors
BDNF mRNA (Dell’osso et al., 2009)
MAN2C1 methylation (Uddin et al., 2011)
RGS2 SNP (Amstadter et al., 2009)
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decreased gene expression of p11, which has been linked to neurotransmitter transport, in
blood of PTSD patients has been proposed as a potential biomarker that can distinguish
PTSD from other psychiatric disorders (Su et al., 2009). Moreover, low GABA plasma levels
have been suggested to serve as a predictive factor for PTSD development (Vaiva et al., 2004).
On the protein level, however, so far almost only immunological factors like the cytokines IL-2,
IL-6, and IL-8 have been found to be increased in PTSD patients (Maes et al., 1999; Baker
et al., 2001; von Känel et al., 2010; Song et al., 2007). In contrast, the immunological factors
C-reactive protein (CRP), serum amyloid A (SAA), and neopterin were found to be reduced
in PTSD patients (Söndergaard et al., 2004; von Känel et al., 2010; Atmaca et al., 2002).
The lack of protein expression changes associated with PTSD not related to the immune
system might be at least partially be due to the lack of eﬃcient high-throughput protein array
techniques. Additionally, studies using human material are in most cases limited to blood
samples. Studying expression changes in the blood is especially interesting with regard to
the HPA axis and immunological factors. Besides sporadic studies with human post-mortem
brain samples (McGowan et al., 2009), studies addressing brain speciﬁc expression changes,
however, are so far mainly restricted to the analysis of animal models.
1.4. Pharmacotherapy of PTSD
A combination of trauma-psychotherapy and pharmacotherapy, mainly employing
antidepressants of the serotonin reuptake inhibitor (SSRI) type, is currently considered as the
gold standard in PTSD treatment (Berger et al., 2009). Due to the complex symptomatology
of PTSD, however, there is no medication addressing all of the symptom clusters mentioned
in chapter 1.1, and moreover, there is no drug speciﬁcally acting against re-experiencing and
hyperarousal symptoms which are pathognomonic for this anxiety disorder. The rationale for
treating PTSD patients with SSRIs, which are widely prescribed in depressive and anxiety
disorders, is a presumed dysregulation of the serotonergic neurotransmission (section 1.2.2).
Although their mode of action is so far not completely understood, SSRIs increase the serotonin
concentration in the synaptic cleft by inhibiting its uptake into the presynapse. Currently, only
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the SSRIs sertraline and paroxetine have been oﬃcially approved by the U.S. Food and Drug
Administration (FDA) for treatment of PTSD (Ravindran and Stein, 2009). Besides SSRIs,
other antidepressants, mood stabilizers, and even neuroleptics are employed for symptomatic
treatment of PTSD (Steckler and Risbrough, 2012).
Interestingly, clinical pilot studies demonstrate that anti-adrenergic drugs are suitable for the
treatment of PTSD associated hyperarousal symptoms, especially for the treatment of sleep
disturbances and nightmares: the α2-adrenoreceptor agonist clonidine, the α1-adrenoreceptor
antagonist prazosin, and the β-adrenoreceptor antagonist propranolol, all widely used in
treatment of hypertension, have been proven to eﬀectively counteract PTSD associated
hyperarousal symptoms (Ravindran and Stein, 2009).
As introduced in section 1.2.1, dysregulation of the HPA axis plays an important role in
PTSD and most studies found an HPA axis hypoactivity in PTSD patients. Glucocorticoids
are known to impair memory retrival and to enhance the consolidation of extinction memory
(Quervain et al., 2009), implicating a possible beneﬁcial eﬀect of glucocorticoids in the
treatment of PTSD. Indeed, ﬁrst pilot studies allude that low-dose cortisol treatment improves
re-experiencing and avoidance symptoms (Aerni et al., 2004).
Taken together, the fact that less than 20-30 % of PTSD patients achieve full remission with
the current ﬁrst-line treatment, the SSRI antidepressants, (Berger et al., 2009) accentuates
the need for the discovery of novel PTSD-speciﬁc drugs and hence for further elucidation of
PTSD etiopathology.
1.5. Animal models of anxiety disorders
Modeling psychiatric disorders is challenging since most parameters of the human psyche
are not objectively measurable but only assessable by talking to the patient. Thus, animal
models of psychiatric disorders are limited to the interspecial measurable parameters like fear
or arousal, while symptoms like intrusive thoughts and dreams of course can not be assessed.
A valid animal model has to fulﬁll several criteria: the face validity of an animal model
describes to what extent the animal model reﬂects the human symptomatology, the etiological
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Figure 1.2.: The PTSD mouse model. On day 0 C57BL/6NCrl receive a 1.5 mA footshock
applied for 2 s via a metal grid. After 28 days PTSD-like behavior is tested:
contextual fear is assessed by measuring the freezing response in the shock context,
the grid context, and the neutral context. Arousal is assessed by measuring the
acoustic startle response to a neutral tone. Avoidance behavior can be tested in a
CODA chamber with three compartments: the nest compartment, a compartment
with a smell reminding of the shock context and a neutrally smelling compartment.
validity results from the comparison of factors that trigger the disease pathogenesis in animals
and humans, the construct validity represents the similarity of etiopathological correlates
in humans and the model organisms employed, and the predictive validity represents the
similarity of successful treatment options between model organisms and humans (Chadman
et al., 2009; Siegmund and Wotjak, 2006).
1.5.1. The PTSD mouse model
The PTSD mouse model used in this study meets many of the criteria mentioned above
(Siegmund and Wotjak, 2007). In this PTSD mouse model, a 2 s long 1.5 mA footshock that
cannot be anticipated by the mouse represents the traumatic event. 28 days after application
of the traumatic footshock a set of behavioral tests is performed to assess PTSD-like symptoms
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(Figure 1.2). Both the conditioned fear response and the generalized fear response are
increased in footshocked mice. The conditioned fear response is rated by observation of
the freezing reponse in the shock context, and the generalized fear response is assessed by
measuring the freezing response in a context resembling the shock context in its dominant
feature (i.e. the metal grid) as well as in a completely neutral context (Siegmund and
Wotjak, 2007). Furthermore, footshocked mice show an hyperarousal phenotype. The latter is
evaluated by assessing the intensity of the acoustic startle response to a neutral tone of diﬀerent
intensities (Siegmund and Wotjak, 2007). The avoidance behavior can be analyzed in a CODA
chamber consisting of three compartments: the nest compartment, one compartment smelling
like the shock context (ethanol), and one compartment with a diﬀerent, but also intense smell
representing the neutral stimulus (acetic acid). Due to their inquisitive nature, mice usually
spend approximately the same amount of time in each compartment. Mice having received
a footshock avoid the compartment smelling like the shock context and spend an increased
amount of time in the nest compartment (Pamplona et al., 2011). Taken together, the etiologic
validity (traumatic event =̂ traumatic footshock) and the face validity (increased contextual
fear, hyperarousal phenotype and avoidance of the trauma context) are met.
As introduced in section 1.4, so far no PTSD speciﬁc pharmacotherapy exists, and SSRIs
like for instance ﬂuoxetine currently represent the treatment of choice. Chronic ﬂuoxetine
treatment of traumatized mice has been shown to ameliorate PTSD-like symptoms (Siegmund
and Wotjak, 2007) pointing at a high predictive validity of this PTSD mouse model.
As so far the distinct biological mechanisms of PTSD are elusive, the construct validity
criterion is diﬃcult to fulﬁll. One biological correlate found in PTSD patients but also in
patients with other aﬀective disorders like major depression is the hippocampal volume loss
(section 1.2.4). Indeed, in the PTSD mouse model used here, traumatized mice also exhibit a
reduced hippocampal volume (Golub et al., 2011). However, the pathomechanisms underlying
this trauma stress-induced hippocampal shrinkage still remain elusive.
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1.5.2. The HAB/LAB mouse model
In contrast to the PTSD mouse model in which the anxiety phenotype is caused by an external
factor, i.e. the electric footshock, the HAB/LAB mouse model represents a model for trait
anxiety. In contrast to the state anxiety paradigm, trait anxiety reﬂects the permanent
disposition for enhanced anxiety responses. High anxiety (HAB) and low anxiety (LAB)
mouse strains were generated by selective breeding of CD1 outbred mice showing high or
low anxiety-like behavior on the elevated plus maze, that is a plus-shaped apparatus with
two open and two closed armes (Krömer et al., 2005). As mice typically avoid open space,
low anxiety-like behavior is represented by an increased time spent on the open arms.
The maximum of behavioral divergence between HAB and LAB mice was reached after 9
generations with the HAB mice spending less than 10 % of the test period on the open arms
and the LAB mice spending more than 50 % of the test period on the open arms (Krömer et al.,
2005). Furthermore, isolated HAB pups showed an increased ultrasonic vocalization that is
used as an index of anxiety, while prior diazepam treatment was able to reduce the ultrasonic
vocalization. In the tail-suspension test and in the forced swim test, both well-accepted tests
for the assessment of depression-like behavior in rodents, HAB mice showed more immobility
than LAB mice (Krömer et al., 2005; Landgraf et al., 2007).
Several molecular alterations, e.g. glyoxalase-I and vasopressin expression changes (Krömer
et al., 2005; Kessler et al., 2007), have been reported in the HAB/LAB mouse model. Of
importance for the thesis at hand is in particular the increased expression of the potential
anxiety disorder biomarker transmembrane protein 132 D (TMEM132D) (see section 1.6) in
the cingulate cortex of HAB mice (Erhardt et al., 2011).
1.6. Transmembrane protein 132D - a candidate gene for
anxiety phenotypes
TMEM132D was recently identiﬁed as a new candidate gene for anxiety phenotypes (Erhardt
et al., 2011): in detail, in a clinical study with 909 cases and 915 controls, the SNPs rs7309727
and rs11060369 located in intron 3 of the TMEM132D gene were identiﬁed to be associated
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with panic disorder, and in addition, the SNPs rs900256, rs879560, and rs10847832 located
in intron 4 of the TMEM132D gene were found to be associated with symptom severity of
anxiety in both panic disorder and major depression. Furthermore, in the same study it
was shown that mice exhibiting a high anxiety phenotype (HAB) express higher levels of
TMEM132D in the cingulate cortex than mice exhibiting a low anxiety phenotype (LAB).
Accordingly, humans expressing the panic disorder associated genotype at SNP rs11060369
exhibited increased TMEM132D mRNA expression in the frontal cortex (Erhardt et al., 2011).
The precise functions of TMEM132D and its paralogs TMEM132A, TMEM132B,
TMEM132C, and TMEM132E have not been identiﬁed so far. The function of TMEM132A, a
transmembrane protein also known as glucose regulated protein 78 (GRP78) binding protein,
was investigated in a few studies proposing it to be involved in the embryonic and postnatal
development of the rat brain (Oh-hashi et al., 2003). In addition, TMEM132A was reported
to inhibit the expression of the astrocytic cytoskeleton protein glial ﬁbrillary acidic protein
(GFAP) in an astrocytic cell line (Oh-hashi et al., 2006) and to aﬀect neurite outgrowth and
serum-starvation induced cell death in a neuronal cell line (Oh-hashi et al., 2010). Thus,
TMEM132A probably plays a critical role in cell survival during development of the brain.
A potential role of TMEM132D in psychiatric disorders as postulated by the ﬁndings of
Erhardt et al. (2010) is further supported by a recent report identifying TMEM132D as
a possible candidate gene for attention deﬁcit hyperactivity disorder (ADHD) (Mick et al.,
2011). The function of TMEM132D has so far only been investigated in one single study
which demonstrates mature oligodendrocytes to express higher TMEM132D mRNA levels
than oligodendrocytic precursor cells (Nomoto et al., 2003). Although the contribution
of myelinating oligodendrocytes to the pathogenesis of anxiety disorders is not completely
understood, increased expression of myelin proteins and lipids in the amygdala and the
hippocampus have been linked with early weaning induced anxiety-like behavior in rodents
(Ono et al., 2008; Kodama et al., 2008). In addition, a lack of myelin in galectin-3 knockout
mice was found to be associated with decreased anxiety-like behavior (Pasquini et al., 2011).
Finally, immunization of mice with a myelin-related peptide reduced trauma stress-induced
anxiety (Lewitus et al., 2008). These studies show that oligodendrocytes might be involved in
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the development of anxiety-like behavior. Moreover, it can be hypothesized that TMEM132D
might be crucial for oligodendrocyte function as well as their involvement in anxiety disorder
pathogenesis. Altogether, the candidate gene TMEM132D as well as a potential TMEM132D
dependent oligodendrocyte diﬀerentiation might contribute to the pathogenesis of anxiety
disorders including PTSD.
1.7. Aim of the thesis
The thesis at hand aimed to contribute to the elucidation of the still unknown molecular
mechanisms of PTSD pathogenesis:
1. by promoter analysis of TMEM132D, an already identiﬁed anxiety disorder candidate
molecule, with the aim to identify regulatory mechanisms of TMEM132D gene expression
(chapter 3).
2. by screening for novel PTSD candidate proteins in a mouse model of PTSD (chapter 4).
• A secondary goal of this screen was to identify the molecular underpinnings of the
PTSD associated hippocampal shrinkage by analyzing a set of neurostructural and
glutamate system associated proteins in the hippocampus, and additionally also in
the prefrontal cortex and in the cerebellum (chapter 4.2.1 and 4.2.2).
• Motivated by the serendipitous ﬁnding of a trauma stress-induced increase in
immunoglobin G expression, another aim of this thesis was to further elucidate
the immune system’s contribution to PTSD pathogenesis (chapter 4.2.3).
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2. Materials and Methods
If not indicated otherwise, chemicals were purchased from Carl Roth (Karlsruhe, Germany)
and plastic disposables were obtained from Peske GmBH & Co KG (Aindlingen-Arnhofen,
Germany). General lab equipment is listed in Table 2.1. Speciﬁc materials and buﬀer
compositions are given in the sections of the respective methods.
Table 2.1.: General lab equipment. Listed are names and manufacturers of equipment used
in the experiments of this thesis.
Equipment Manufacturer
Eppendorf Research pipette 100-1000 μl Eppendorf (Hamburg, Germany)
Eppendorf Research pipette 20-200 μl Eppendorf (Hamburg, Germany)
Eppendorf Research pipette 10-100 μl Eppendorf (Hamburg, Germany)
Eppendorf Research pipette 2-20 μl Eppendorf (Hamburg, Germany)
Eppendorf Research pipette 0.5-10 μl Eppendorf (Hamburg, Germany)
Eppendorf Research pipette 0.1-2.5 μl Eppendorf (Hamburg, Germany)
Multichannel pipette Transferpette-12 10-100 μl Brand (Wertheim, Germany)
Multichannel pipette Transferpette-8 5-50 μl Brand (Wertheim, Germany)
Multichannel pipette ExactaCruz 50-300 μl Santa Cruz Biotechnology Inc. (Santa
Cruz, CA, USA)
Pipettor pipetus for 0.1 ml to 200 ml pipettes Hirschmann Laborgeräte GmbH & Co.
KG (Eberstadt, Germany)
Vortex REAXtop Heidolph (Schwabach, Germany)
Mini-centrifuge for PCR-tubes Fisherbrand (Schwerte, Germany)
Centrifuge 5415R, refrigerated microcentrifuge Eppendorf (Hamburg, Germany)
Centrifuge Sigma 2-6 Sigma Zentrifugen (Osterode am Harz,
Germany)
Beckman Coulter Allegra X-22R centrifuge Beckman Coulter (Krefeld, Germany)
Beckman Coulter J2-MC Beckman Coulter (Krefeld, Germany)
Beckman Coulter XL-90 ultracentrifuge Beckman Coulter (Krefeld, Germany)
Thermoshaker TS-100 Peqlab (Erlangen, Germany)
Thermoshaker HLC 13 MS-L GmbH Laborgeräte (Dielheim,
Germany)
Balance Pioneer Serie PA4102C OHaus (Pine Brook, NJ, USA)
Balance Voyager 50228 OHaus (Pine Brook, NJ, USA)
Magnetic stirrer with heater VMS-A VWR (Darmstadt, Germany)
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2.1. Animals
All animal experiments were carried out with the approval of local authorities and conducted
according to current regulations for animal experimentation in Germany and the European
Union (European Communities Council Directive 86/609/EEC). An overview of all mouse
batches employed in this thesis is provided in Table 2.2.
Table 2.2.: Overview of employed mouse batches. Abbreviations: WB = Western blot ,
IHC = immunohistochemistry
Batch name Molecular analyses Batch size (n = number of
mice per group)
Acute Restraint Stress
(RS0)
WB n = 9
Repetitive Acute Stress
(RSI/RSII)
WB n = 6
PTSD I (d2, d28, d60) WB (neurostructural and
glutamate transporter proteins)
n = 6
PTSD II (d60) WB (neurostructural proteins),
IHC (synapsin)
n = 6
PTSD III (d60) WB (immune system proteins) n = 6
PTSD IV (d2, d28, d60) WB (immune system proteins) n = 7
PTSD V behavior only n = 16
Fluoxetine in PTSD WB n = 16 (ctrl), n = 14
(ﬂuoxetine) for behavior;
n = 6 for WB
HAB/LAB WB n = 4 (HAB), n = 7 (LAB)
2.1.1. Combined restraint and forced swim stress experiments
The combined restraint and forced swim stress animal experiments were performed in
collaboration with the research group of Chadi Touma from the Max Planck Institute of
Psychiatry. Here, 10-16 weeks old male 129SvJ/C57BL/6 mice from the FKBP5 knockout
breeding line (Touma et al., 2011) homozygote for the FKBP5 WT allele were obtained from
the animal facility at the Max Planck Institute of Psychiatry and single housed two weeks
prior to the experiments under standard laboratory conditions (light-dark cycle 12:12 h, lights
on: 08:00 a.m.) with food and water ad libitum.
In a ﬁrst experiment short-term eﬀects of acute restraint stress were analyzed. For this
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purpose, mice were subjected to a 15-min restraint stressor by conﬁning the mice in cylindrical
plastic tubes. The mice were sacriﬁced by cervical dislocation 24 h later (RS0 paradigm,
n = 9). To study long-term eﬀects of acute repetitive stress, in a second experiment two
diﬀerent stress paradigms were applied (RSI/RSII paradigm). In the RSI paradigm, mice
(n = 6) were either subjected to a 15-min restraint stressor which was, after a 15-min interval
in the home cage, followed by a 6-min forced swim stressor (FSS) accomplished in a glass
beaker ﬁlled with 23 ◦C warm water. Then, after 24 h in the home cage, the mice were
subjected to a second 6-min forced swim stressor. For the RSII paradigm, mice (n = 6) were
subjected to a 60-min restraint stressor followed by a 6-min forced swim stressor 24 h later.
Mice of the RSI and RSII paradigm were sacriﬁced 8 days after application of the last stressor.
Subsequently, bilateral hippocampus (HC), prefrontal cortex (PFC), and cerebellum (CER)
were dissected from all mice, shock-frozen in methyl butane on dry ice, and stored at -80 ◦C
before subjection to immunoblot analyses.
2.1.2. PTSD mouse model
All behavioral experiments with the PTSD mouse model were performed in collaboration
with the reasearch group of Carsten Wotjak from the Max Planck Institute of Psychiatry. The
PTSD mouse model was established by Siegmund and Wotjak (2007) and fulﬁlls the criteria for
face and predictive validity as explained in section 1.5.1. For this thesis, male C57BL/6NCrl
mice aged 4-5 weeks (see Table 2.2 for overview of employed mouse batches) were purchased
from Charles River Germany GmbH (Sulzfeld, Germany). Animals were housed in groups of
4 animals for 6 weeks under an inverse 12:12 h light-dark cycle (lights oﬀ: 09:00 a.m.) with
food and water ad libitum before starting the experiments. All experiments were performed
during the activity phase of the animals (9:30 a.m. to 6:00 p.m.).
The traumatic stress was induced by applying an inescapable footshock: after a 198 s
acclimatization interval in the shock chamber, that is a cubic-shaped transparent box with
a metal grid for shock application, mice received a single scrambled electric footshock (2 s,
1.5 mA) which was administered via the metal grid. Animals remained in the shock chamber
for another 60 s before they were returned to their home cages. Control mice were placed
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into the shock chamber for the total of 260 s, but no electric footshock was administered
(Kamprath and Wotjak, 2004).
Behavioral experiments were performed on days 28-30 after footshock (batch PTSD I, II, III)
or on days 59-61 after footshock (batch PTSD V); batch PTSD IV was not subjected to the
behavioral test battery. The details of the behavioral protocols are displayed in Figure 2.1.
First, hyperarousal was tested by measuring the acoustic startle response of mice in startle
chambers (SR-LAB, San Diego Instruments SDI, San Diego, CA, USA). Mice were exposed
to 20 ms long white noise burst stimuli of diﬀerent intensities (75 dB, 90 dB, 105 dB, and
115 dB) presented against the background of continuous white noise of 50 dB. After 5 min of
acclimatization, 16 control trials in which only background noise was presented and 30 white
noise burst stimuli of each intensity were presented in a pseudorandom order with an average
interstimulus interval of 15 s. Startle chambers were cleaned thoroughly after each session.
Then, fear generalization was tested by measuring the freezing behavior during a 3-min
exposure to the neutral context (a cylindrical-shaped transparent box without a metal grid)
or the grid context (a hexagonal-shaped non-transparent box with a metal grid ﬂoor as a
dominant reminder of the shock context). Finally, conditioned fear was assessed by measuring
the freezing behavior during a 3-min exposure to the shock chamber. After each experiment,
all boxes were cleaned thoroughly with neutrally smelling detergents.
Mice were sacriﬁced at least 10 days after terminating the last behavioral experiment. To
obtain hippocampus, prefrontal cortex, and cerebellum, mice were sacriﬁced by cervical
dislocation on days 2, 28, or 60 after footshock. First, total brains were isolated, and
then, hippocampus, prefrontal cortex and cerebellum were dissected on ice. The tissue was
shock frozen in methyl butane on dry ice and stored at -80 ◦C for subsequent analyses.
In addition, trunk blood was collected for the analysis of immune system proteins. For
immunohistochemical analysis mice were perfused transcardially with PBS followed by 15 min
perfusion with 4 % paraformaldehyde (PFA). Finally, total brains were dissected and processed
as described in section 2.2.2.
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Figure 2.1.: Protocols of behavioral tests (PTSD mouse model). The diﬀerent phases
of the behavioral test protocols are indicated in Roman numerals. Mouse behavior
was scored in the phase highlighted in gray. On day 0 a 1.5 mA single electric
footshock was applied (A). After 198 s in the shock chamber, the footshock
was administered for 2 s, followed by additional 60 s in the shock chamber.
Control mice remained in the shock chamber for 260 s without administration
of the electric shock. The acoustic startle response (B) was assessed in startle
chambers. Brieﬂy, after 300 s of habituation, 16 control trials and 30 startle
stimuli of 20 ms duration of each intensity (INT), 75, 90, 105, and 115 dB, were
presented in a pseudorandom order with an interstimulus interval of 15 s. For
analysis of generalized fear (C), mice were exposed to a neutral context for 180s.
Then a neutral tone (80 dB, 9 kHz) was presented for 180 s and mice remained
for additional 60 s in the neutral context before returning to their home cage.
Generalized fear was further tested in a context with the grid as a dominant
reminder of the shock context (D) and conditioned fear (E) was assessed by scoring
the freezing response for 180 s in the shock context. To test for treatment eﬃcacy
of the ﬂuoxetine treatment, after 180 s in the neutral context, the freezing response
was assessed during a 60 s presentation of a neutral tone in a neutral context (F).
After additional 60 s in the neutral context, mice returned to their home cage.
Figure adopted from (Herrmann et al., 2012)
29
2. Materials and Methods
2.1.2.1. Fluoxetine treatment
A group of 30 male C57BL/6NCrl mice aged 10 weeks (batch ‘Fluoxetine in PTSD’, Table
2.2) was exposed to a single inescapable footshock as described above. On day 1 after the
footshock, the treatment group (n = 14) was subjected to chronic ﬂuoxetine (Ratiopharm,
Ulm, Germany) treatment which was administered in a dose of 20 mg/kg body weight per day
for 4 weeks via drinking water, while the control group (n = 16) received drug-free drinking
water. On day 28 after shock, ﬂuoxetine eﬃcacy was assessed by evaluating the generalized
fear response for 60 s during the presentation of a neutral tone (80 dB, 9 kHz) in the neutral
context. This was followed by 10 mg/kg ﬂuoxetine per day for 3 days and a 4 week washout
period, where mice received pure drinking water. On days 59 to 61, animals were tested
for PTSD-like symptoms as described above. On day 74, mice were sacriﬁced by cervical
dislocation and the hippocampus was dissected as described above and stored at -80 ◦C for
subsequent immunoblot analyses (section 2.2.1).
2.1.3. HAB/LAB mouse model
Female HAB and LAB mice aged 19 weeks (section 1.5.2, batch ‘HAB/LAB’ Table 2.2) were
obtained from the animal facility at the Max Planck Institute of Psychiatry. Mice were
single housed under a 12:12 h light-dark cycle with food and water ad libitum. Without
further behavioral testing, HAB (n = 4) and LAB (n = 7) mice were sacriﬁced by cervical
dislocation. Subsequently, hippocampus and cerebellum were dissected, immediately shock
frozen in methyl butane and stored at -80 ◦C for subsequent molecular analyses. In addition,
trunk blood was collected in EDTA-supplemented tubes, centrifuged at 6000 x g for 10 min
at 4 ◦C and supernatants were stored at -20 ◦C for further molecular analyses.
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2.2.1. Western blot
Homogenization buﬀer
50 mM Tris-HCl pH 7.6
150 mM NaCl
5 mM EDTA
4 x proteinase inhibitor
4 x Extraction buﬀer
50 mM Tris-HCl pH 7.6
150 mM NaCl
2 % NP40
2 % deoxycholate
For western blot analysis hippocampal and prefronto-cortical tissues were homogenized in
150 μl homogenization buﬀer using a Turrax disperser (Turrax homogenizer VDI12, VWR,
Darmstadt, Germany); for cerebellar tissue samples 300 μl homogenization buﬀer was used.
Then, proteins were extracted by mixing the homogenate with 50 μl extraction buﬀer (100 μl
for cerebellar samples). Subsequently, the lysates were sonicated and centrifuged for 30 min
at 16000 x g at 4 ◦C. Finally, supernatants were transferred to new reaction tubes and protein
concentration was determined using a BCA assay.
2.2.1.1. Bicinchoninic acid (BCA) assay
To determine the protein concentration of tissue lysates a commercially available BCA
protein assay kit (Thermo scientiﬁc, Waltham, MA, USA) was employed according to the
manufacturer’s instructions. Brieﬂy, 10 μl of bovine serum albumine (BSA) standards ranging
from 2 mg/ml to 0.025 mg/ml as well as tissue lysate samples diluted 1:10 with H2O were
pipetted into wells of a 96 well plate. Then, 200 μl of a 1:50 mix of solution B and solution
A of the BCA assay kit were added to the 96 well plate which was then incubated for 30 min
at 37 ◦C for color development. The purple color was then measured at 562 nm using the
Dynatech MR5000 plate reader (Dynatech Laboratories, Denkendorf, Germany).
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2.2.1.2. Sodium dodecyl sulfate polyacrylamid gel electrophoresis (SDS-PAGE)
5 x Lämmli sample buﬀer
5 % SDS
40 % glycin
160 mM Tris pH 6.8
5 % β-mercaptoethanol
0.04 % bromphenol blue
in H2O
4 x Lämmli upper Tris
0.5 M Tris pH 6.8
in H2O
10 x Lämmli running buﬀer
25 mM Tris
192 mM glycin
0.5% SDS
in H2O
4x Lämmli lower Tris
1.5 M Tris pH 8.8
in H2O
Electrophoretic separation of proteins was performed using the Mini-PROTEAN
Electrophoresis System (Bio-Rad, München, Germany). SDS-polyacrylamid gels (1 mm x
8.6 cm x 6.8 cm) were casted with the following composition:
Table 2.3.: Composition of SDS-polyacrylamid gels
10 % separation gel (4x) 4 % stacking gel (4x)
H2O 10.5 ml 6.5 ml
30 % Acrylamid-Bis solution 8.5 ml 1.3 ml
4 x Lämmli lower Tris 6.25 ml 2.3 ml (Lämmli upper Tris)
20 % SDS 0.25 ml 0.1 ml
10 % APS 65 μl 35 μl
TEMED 65 μl 35 μl
To cast a SDS-polyacrylamid gel H2O, acrylamid-bisacrylamid solution, Tris buﬀer, and
SDS were mixed. Then, for initiation of the polymerization reaction ammonium persulfate
(APS) and N, N, N’, N’-tetramethylethylenediamine (TEMED) were added to the mix just
before casting the gels. The separation gel was casted ﬁrst and overlayed with isopropanol
to inhibit evaporation. In a second step, after polymerization of the separation gel and
removal of isopropanol the stacking gel was casted and a 15 well comb was inserted. For
ﬁnal polymerization gels were wrapped in a moist tissue and stored in a plastic bag at 4 ◦C.
To run the SDS-polyacrylamid gels, protein lysates were mixed with Lämmli sample buﬀer
and boiled for 5 min at 95 ◦C. Equal amounts of protein (10 μg, for proteins with low
expression levels 20 μg) were loaded on to the gels using a 50 μl Hamilton syringe (Hamilton
Bonaduz AG, Bonaduz, Switzerland). 5 μl of peqGOLD prestained protein marker VI (Peqlab
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Biotechnologie GMBH, Erlangen, Germany) was loaded on each gel for monitoring protein
separation during electrophoresis and subsequent size determination of the protein bands. The
electrophoresis was performed in Lämmli running buﬀer at 120 V (Power-Pac 400, Bio-Rad,
München, Germany).
2.2.1.3. Western blot transfer
10 x TBS
100 mM Tris
1.5 mM NaCl
pH 7.6
in H2O
1 x TBS/T
1 l 10x TBS + 10 ml Tween-20 (0.1 %)
add H2O to a ﬁnal volume of 10 l
10 x Wet-blot buﬀer
250 mM Tris
1900 mM glycin
in H2O
1 x Wet-blot buﬀer
100 ml 10 x Wet-blot buﬀer
700 ml H2O
200 ml methanol
After separating the protein lysates by SDS-PAGE, the proteins were electrotransferred to
nitrocellulose membranes (Carl Roth GmbH + Co. KG, Karlsruhe) using the Mini Trans-Blot
System (Bio-Rad, München, Germany). For this purpose, a ‘sandwich’ was assembled in a
blotting cassette composed of a sponge, two layers of ﬁlter paper, the nitrocellulose membrane,
the gel, again two layers of ﬁlter paper, and a sponge. Everything was equilibrated in 1 x
Wet-blot buﬀer. The transfer was then conducted in 1 x Wet-blot buﬀer for 2 h at 400 mA.
A subsequent Ponceau staining of the nitrocellulose membrane conﬁrmed the eﬀectiveness
of the transfer. For this, the nitrocellulose membrane was incubated in a 0.2 % solution of
Ponceau S in 1 % acetic acid. The membrane was then rinsed with water until protein bands
appeared.
For immunodetection the membranes were then incubated for 1 h in 5 % non-fat dried milk
in Tris-buﬀered saline supplemented with Tween-20 (TBS/T) on an orbital shaker (Shaker
Gyro-rocker SSL3, Stuart, Staﬀordshire, UK) to block unspeciﬁc antibody binding. Then,
the membranes were incubated overnight at 4 ◦C with the primary antibody diluted in 2.5 %
non-fat dried milk in TBS/T supplemented with 0.01 % NaN3 on an overhead-shaker (Roto
shake genie, Scientiﬁc Industries, Bohemia, NY, USA). Primary antibodies used in this thesis
and the respective dilutions are indicated in Table 2.4. Subsequently, the membranes were
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Table 2.4.: Primary antibodies. Abbreviations: WB = Western blot, IHC =
immunohistochemistry
Antibody Manufacturer Species Application Dilution
CD31 Santa Cruz Biotechnology
(Santa Cruz, CA, USA)
rabbit IHC, WB 1:500
CD68 Santa Cruz Biotechnology rabbit WB 1:500
EAAC1
(EAAT3)
Santa Cruz Biotechnology rabbit WB 1:500
FcγRI (CD64) Santa Cruz Biotechnology rabbit WB 1:500
GAPDH Santa Cruz Biotechnology mouse WB 1:2000
GFAP DAKO (Hamburg, Germany) rabbit IHC, WB 1:1000 (IHC)
1:2000 (WB)
GLT1
(EAAT2)
Santa Cruz Biotechnology goat WB 1:1000
homer 1b/c Santa Cruz Biotechnology rabbit WB 1:1000
Iba1 WAKO Pure Chemical
Industries, Ltd. (Osaka,
Japan)
rabbit IHC, WB 1:500
Igκ light chain Jackson ImmunoResearch
Laboratories (Newmarket,
Suﬀolk, UK)
goat IHC, WB 1:500
Igλ light chain Santa Cruz Biotechnology rabbit WB 1:500
IgG Fc Jackson ImmunoResearch
Laboratories
goat IHC, WB 1:2000
neuroﬁlament Abcam (Cambridge, UK) mouse WB 1:1000
MAP-2 Sigma-Aldrich (St. Louis,
MO, USA)
mouse WB 1:1000
synapsin I/II Synaptic Systems (Göttingen,
Germany)
rabbit IHC, WB 1:1000
synaptophysin Santa Cruz Biotechnology rabbit WB 1:2000
washed in TBS/T 5 times for at least 5 minutes on an orbital shaker. Next, the membranes
were incubated with an appropriate horseradish-peroxidase (HRP) conjugated secondary
antibody diluted in 2.5 % non-fat dried milk in TBS/T (see Table 2.5) for 1 h at room
temperature, followed by 5 washing steps for 5 min with TBS/T. Finally, the membranes
were incubated with a chemoluminescence substrate solution (Immobilon HRP Substrat
Luminol Reagenz, Millipore) for 5 minutes, and the chemoluminescence of the immunoreactive
complexes was detected on X-ray ﬁlms (FujiFilm X-Ray 18x24 100NF, Bender). 2-3 technical
replicates of each western blot experiment were performed.
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Table 2.5.: Secondary antibodies. Abbreviations: WB = Western blot, IHC =
immunohistochemistry
Antibody Manufacturer Species Application Dilution
HRP conjugated anti-goat Santa Cruz
Biotechnology
donkey WB 1:10000
anti-goat AlexaFluor594 Invitrogen
(Grand Island,
NY, USA)
donkey IHC 1:300
HRP conjugated anti-mouse Sigma-Aldrich goat IHC, WB 1:1000 (IHC)
1:50000 (WB)
anti-mouse AlexaFluor488 Invitrogen donkey IHC 1:300
HRP conjugated anti-rabbit Sigma-Aldrich goat WB 1:30000
anti-rabbit AlexaFluor488 Invitrogen donkey IHC 1:300
anti-rabbit AlexaFluor594 Invitrogen goat IHC 1:300
2.2.1.4. Densitometry
For quantiﬁcation of immunoreactive bands, the X-ray ﬁlms were digitalized, and the pixel
density was measured using the ImageJ software (Rasband, W.S., ImageJ, U.S. National
Institutes of Health Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009).
2.2.2. Immunohistochemistry (IHC)
Phosphate-buﬀered saline (PBS)
140 mM NaCl
10 mM Na2HPO4
1.75 mM KH2PO4
2.5 mM KCl
adjust to pH 7.4
Isoﬂurane-anesthetized mice were perfused transcardially on day 60 after footshock with
phosphate-buﬀered saline (PBS) followed by 4 % paraformaldehyde (PFA) in PBS for 15 min
using a peristaltic pump (n = 6 per group). For post-ﬁxation total brains were dissected and
kept in 4 % PFA overnight and one week in 30 % sucrose in PBS at 4 ◦C. Then, the brains
were shock frozen in methyl butane on dry ice and stored at -80 ◦C. 40 μm coronal sections
were cut, and sections were kept in storage medium (25 % glycerol and 25 % ethylenglycol in
PBS) at -20◦C.
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For immunohistochemistry, sections were washed with PBS and blocked with a 10 % bovine
serum albumin (BSA) solution containing 1 % Triton X-100 in PBS. Then, sections were
incubated overnight at room temperature with primary antibodies (see Table 2.4) which
were diluted in a BSA buﬀer solution containing 1 % BSA and 0.3 % Triton X-100 in
PBS. The next day, sections were washed with PBS and incubated for 2 h at room
temperature with a ﬂuorophore-conjugated secondary antibody (see Table 2.5), diluted
1:300 in BSA buﬀer solution containing 1 % BSA and 0.3 % Triton X-100 in PBS.
Subsequently, sections were washed with PBS, including 0.2 mg/ml of the nuclear stain
DAPI (4’,6-diamidino-2-phenylindole) in one washing step. Finally, sections were mounted
on slides and covered with embedding medium (ImmuMount, Thermo Scientiﬁc, Waltham,
MA, USA). Images were obtained using an Olympus IX81 confocal microscope (Olympus,
Hamburg, Germany).
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2.3.1. Cultivation of E. coli bacteria
LB medium
20 g LB Broth Base
in 1 l dH2O
autoclave
LB-Agar plates
20 g LB-Broth
15 g Agar-Agar (1.5 %)
in 1 l dH2O, autoclave
cool down to approximately 50 ◦C
add antibiotics (100 μg/ml ampicillin; 50 μg/ml
kanamycin)
cast plates
Escherichia coli (E.coli) DH5α bacteria were cultivated in LB medium supplemented with the
appropriate antibiotic (100 μg/ml ampicillin or 50 μg/ml kanamycin) at 37 ◦C. To sub-culture
a single colony, bacteria were streaked onto LB-Agar plates containing the appropriate
antibiotic. Then, LB-medium was inoculated with a single colony from the LB-Agar plate
using a sterile pipette tip and cultured at 37 ◦C shaking at 200 rpm. For long-term storage,
glycerolstocks were prepared by adding 20 % glycerol to the bacterial culture which was then
stored at -80 ◦C.
2.3.1.1. Preparation of competent cells
TFBI buﬀer
30 mM kaliumacetate
50 mM MgCl2
100 mM KCl
10 mM CaCl2
adjust to pH 5.8 with 0.2 M acetic acid
ﬁlter sterile
TFBII buﬀer
10 mM Na-MOPS pH 7.0
75 mM CaCl2
10 mM KCl
20 % glycerol
add H2O to a volume of 100 ml
ﬁlter sterile
E. coli have to be in a ‘competent state’ to incorporate plasmid DNA eﬃciently during
transformation. To prepare competent cells, 5 ml LB medium was inoculated with 10 μl
E. coli DH5α bacteria and cultured overnight at 37 ◦C shaking at 200 rpm. The next day,
400 ml LB medium was added and bacteria were cultured at 37 ◦C shaking at 200 rpm until
the OD550 was 0.480. Then, bacteria were centrifuged at 1000 x g for 10 min at 4 ◦C, and
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the pellet was resuspended in 80 ml TFBI buﬀer. After 5 min incubation on ice, bacteria
were centrifuged at 1000 x g for 5 min at 4 ◦C. Finally, the pellet containing the bacteria was
resuspended in 16 ml TFBII buﬀer and incubated on ice for 15 min. Aliquots of competent
E. coli DH5α bacteria were stored at -80 ◦C.
2.3.1.2. Transformation of E. coli bacteria
Transformation was performed by exposing E. coli DH5α bacteria in presence of plasmid
DNA to a 42 ◦C heatshock. For this purpose, 100 μl competent DH5α cells were incubated
with the respective plasmid DNA for 30 min on ice. The heatshock was then performed for
45 s at 42 ◦C. Subsequently, the cells were cooled down on ice for 2 min. Then, 900 μl
LB-medium was added and the bacteria were incubated for 60 min at 37 ◦C to develop their
speciﬁc antibiotic resistance encoded on the transformed plasmid DNA. The bacteria were
plated on an agar plate containing the respective antibiotic and incubated overnight at 37 ◦C.
The next day, single colonies were picked using a sterile pipette tip and incubated in 3 ml
of antibiotic-containing LB-medium for 8 h at 37 ◦C. Finally, the plasmid DNA was either
isolated using a Mini-preparation kit (section 2.3.2) or for large scale preparation bacteria
were cultured in 100 ml LB-medium which was subsequently subjected to Midi-preparation
for plasmid DNA isolation (section 2.3.2).
2.3.2. Isolation of plasmid DNA
Depending on the required amount of plasmid DNA either Mini or Midi cultures (3 ml or 100 ml
LB-Medium) were prepared as described above. Mini cultures were mainly used during cloning,
while Midi cultures were used to produce larger amounts of plasmid DNA for subsequent
transfection into eukaryotic cells. From the Mini or Midi bacteria cultures plasmid DNA was
isolated using a Mini Prep Kit or Midi Prep Kit (Promega, Madison, WI, USA) according to
the manufacturer’s speciﬁcations. The isolated plasmid DNA was then analyzed by restriction
digest or sequencing (GATC Biotech AG, Konstanz, Germany) and was stored at -20 ◦C.
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2.3.3. Cloning of reporter plasmids and transcription factor expression
plasmids
For the generation of TMEM132D promoter constructs, the region 5066 bp upstream of the
start codon was ampliﬁed from human genomic DNA by polymerase chain reaction (PCR)
and cloned into the commercially available pGL3 basic vector (Promega, Madison, WI, USA).
The other 5’ deletion mutants were generated using the primers indicated in Table 2.7 and
the pGL3T5066 plasmid as a template for PCR. Ampliﬁed fragments were cloned into the
pGL3 basic vector via restriction digest of vector and insert followed by sticky end ligation.
Sequence identities were veriﬁed by sequencing (GATC Biotech, Konstanz, Germany). All
generated constructs are listed in Table 2.6.
Expression plasmids of the transcription factors HAML (PlasmID CloneID: HsCD00342124),
SP1 (PlasmID CloneID: HsCD00338893), WT1 (PlasmID CloneID: HsCD00333689), MZF1
(PlasmID CloneID: HsCD00330552), MYT1L (PlasmID CloneID: HsCD00342588), GCM1
(PlasmID CloneID: HsCD00346282), and NFKB1 (PlasmID CloneID: HsCD00340105) were
purchased from PlasmID (Boston, MA, USA). The transcription factor expression plasmids of
HES1, NRF1, ZFP161, ZNF219, MTF1, and ZFX were generated (Table 2.6) by ampliﬁcation
of the coding sequence from the reverse transcribed mRNA isolated from human MO3.13 cells
using the primers indicated in Table 2.8. Subsequently, the ampliﬁed fragments were inserted
into the pcDNA3.1(-) vector (Invitrogen) via restriction digest of vector and insert followed
by sticky end ligation. Sequence identities were conﬁrmed by sequencing.
2.3.3.1. RNA isolation
Before starting the work with RNA, instruments were cleaned with ethanol. Filtered pipette
tips were used to minimize contamination. Total RNA isolation from eukaryotic cells was
performed using the NucleoSpin RNA II kit (Macherey-Nagel, Düren, Germany) according to
the manufacturer’s instructions. The concentration of the isolated RNA was subsequently
measured at a spectrophotometer (Nanophotometer Implen, München, Germany). The
isolated RNA was stored at -80 ◦C.
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2.3.3.2. Concentration measurements of nucleic acids
The concentration of nucleic acids was measured spectrophotometrically using an Implen
Nanophotometer (Implen, München, Germany). 3 μl of nucleic acid solution was subjected to
the spectrophotometrical measurement at 260 nm. Additionally, the extinction at 280 nm
was measured and the OD260/OD280 ratio was calculated. This ratio indicates possible
contamination with proteins and should ideally be 1.8 for pure DNA and 2.0 for pure RNA.
Based on the fact that the OD260 is 1 at a concentration of 50 μg/ml DNA or 40 μg/ml RNA
the concentrations can be calculated by multiplying the OD260 with the dilution factor and
either 50 μg/ml for DNA or 40 μg/ml for RNA.
2.3.3.3. Reverse transcription (RT)
RNA was reversed transcribed to cDNA employing the Omniscript RT kit (Qiagen, Hilden,
Germany) according to the manufacturer’s instructions. In general, 2 μg of total RNA were
reverse transcribed using oligo-dT primer (Promega, Madison, WI, USA) which anneal to the
poly-A tail of mRNAs and thus exlude the reverse transcription of other non-coding RNAs.
The reverse transcription was performed for 1 h at 37 ◦C in a thermocycler (Thermocycler
Tprofessional Standard, Biometra, Göttingen, Germany). The cDNA was then stored at
-20 ◦C.
2.3.3.4. Polymerase chain reaction (PCR)
Regions of interest for cloning were ampliﬁed in a polymerase chain reaction (PCR) using the
Herculase II DNA polymerase (Agilent Technologies, Santa Clara, CA, USA). Herculase II
DNA polymerase is a Pfu-based polymerase optimized for the ampliﬁcation of long GC-rich
targets. The primers were designed to speciﬁcally bind to the ﬂanking sites of the regions
of interest, and for further processing restriction sites were attached to the primer sequence
(primers and restriction sites indicated in Table 2.7 and 2.8). For ampliﬁcation, 200 ng
of template DNA was added to the reaction mix containing 1 x Herculase reaction buﬀer,
10 pmol of each forward and reverse primer, 500 μM of each desoxynucleotide-triphosphate
(dNTP), 8 % dimethyl sulfoxide (DMSO), 1 μl Herculase, and H2O in a total volume of 50 μl.
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The thermal cycling comprised a 5 min interval at 98 ◦C for initial denaturation, followed by
40 cycles consisting of a 30 s denaturation step at 98 ◦C, a 1 min annealing step at 60 ◦C and
an elongation step at 68 ◦C for 1 min per kilo-bases of template DNA. This was followed by
a ﬁnal 3 min elongation interval at 68 ◦C. Finally, the amplicon was analyzed by agarose gel
electrophoresis.
Table 2.7.: Cloning primers for reporter plasmid generation. Restriction sites are
indicated in brackets behind the primer name.
Name Sequence 5’ → 3’
SV40_for (BglII) cga ata gat ctt gtg tgt cag tta ggg tgt gg
SV40_rev (HindIII) cta gta agc ttg gaa tag ctc aga ggc cga g
TMEM-5066 (BglII) cga ata gat ctg ctt ctg ttg gca gtg atg a
TMEM-3060 (BglII) cga ata gat ctc gct caa agt tgc cat ttc t
TMEM-2493 (BglII) cga ata gat ctc ttc tgc aat ggc aaa aag a
TMEM-1498 (BglII) cga ata gat ctt aca gga cgg tgc tta ggg a
TMEM-829 (BglII) cga ata gat ctc ttg cgg agc gga gc
TMEM-604 (BglII) cga ata gat ctc gca ccc gcc aaa ct
TMEM-300 (BglII) cga ata gat ctg gaa ata ccc cct gtg gat ta
TMEM-210 (BglII) cga ata gat ctg gag agc aac tca gga gcc
TMEM-150 (BglII) cga ata gat cta aga ggg agc agg gcg
TMEM-1 (HindIII) cta gta agc ttc ctg gag acc cgg agc
Table 2.8.: Cloning primers for generation of transcription factor expression
plasmids. Restriction sites are indicated in brackets behind the primer name.
for = forward primer, rev = reverse primer
Name Sequence 5’ → 3’
HES1_cl_for (EcoRI) cgc gaa ttc tat gcc agc tga tat aat gga gaa
HES1_cl_rev (BamHI) gat gga tcc tca gtt ccg cca cgg c
ZNF219_cl_for (EcoRI) cgc gaa ttc tat gga ggg ctc acg tcc c
ZNF219_cl_rev (BamHI) gat gga tcc cta ccg ttc ttg ccc ccc
ZFP161_cl_for (EcoRI) cgc gaa ttc tat gga gtt ttt cat cag tat gtc tg
ZFP161_cl_rev (BamHI) gat gga tcc cta gct aca ggc tat cgt ctc ca
ZFX_cl_for (EcoRI) cgc gaa ttc tat gga tga aga tgg gct tga
ZFX_cl_rev (NheI) cta ggc taa gct tag ggc agg cca act tct
MTF1_cl_for (EcoRI) cgc gaa ttc tat ggg gga aca cag tcc a
MTF_cl_rev (NheI) cta ggc tag ctc act tgg aga agc tgc tgg
NRF1_cl_for (XhoI) tcg act cga gta tgg agg aac acg gag tga c
NRF1_cl_rev (BamHI) gat gga tcc tca ctg ttc caa tgt cac cac
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2.3.3.5. Gel electrophoresis
1 x TBE buﬀer
90 mM Tris 8.3
90 mM boric acid
2.5 mM EDTA pH 8
adjust to pH 8.3
5 x sample loading buﬀer
60 % glycerol
50 mM Tris-HCl pH 7.6
50 mM EDTA
0.025 % bromphenol blue
0.0025 % xylene cyanol
For separation of DNA by gel electrophoresis, 0.7 - 2 % agarose (Agarose Universal peqgold,
peqlab, Erlangen, Germany) was dissolved in TBE buﬀer by heating it in a microwave oven.
After cooling the dissolved agarose down to approximately 65 ◦C, 0.5 μg/ml ethidiumbromide
was added, and the gel was casted. For subsequent gel electrophoresis the Bio-Rad DNA
Subcell System was employed (Bio-Rad, München, Germany). The DNA samples were ﬁrst
mixed with 5 x sample loading buﬀer and then loaded on to the gel. Electrophoretic separation
was accomplished by running the gel in TBE buﬀer at 100 - 150 V for approximately 30 min.
Finally, the gel was analyzed and documented using the Protean GelDoc2000 System (Bio-Rad,
München, Germany).
2.3.3.6. DNA puriﬁcation from agarose gels
To extract DNA from an agarose gel, the respective band was cut out from the gel using a
scalpel. The DNA was then puriﬁed from the gel fragment using the Qiaquick gel extraction
kit according to the manufacturer’s instructions (Qiagen, Hilden, Germany). Extracted DNA
was kept for short term storage at 4 ◦C and for long term storage at -20 ◦C.
2.3.3.7. Restriction digest of DNA
Restriction digest of plasmid DNA or PCR fragments was performed using 2-5 μg DNA,
1.5 μl restriction enzyme (NEB, Ipswich, MA, USA), and 5 μl of 10 x restriction buﬀer
in a 50 μl reaction volume. In case of a double digest, the compatibility of both
restriction enzymes was ﬁrst checked using the double digest ﬁnder tool at the NEB website
(http://www.neb.com/nebecomm/DoubleDigestCalculator.asp). The reaction was incubated
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for 2 h at 37 ◦C. Finally, the restriction digest was examined and puriﬁed by gel electrophoresis
and subsequent DNA gel extraction.
2.3.3.8. Ligation
Ligation was performed using T4 Ligase (NEB, Ipswich, MA, USA) and approximately 1 μg of
insert, 0.4 μg of vector, and 2 μl 10 x reaction buﬀer in a total volume of 20 μl. The reaction
was incubated for 10 min at room temperature. For transformation into DH5α competent
cells, 10 μl of the ligation reaction was used. The rest was stored at 4 ◦C.
2.3.3.9. Site-directed mutagenesis
Transcription factor binding sites (TFBS) in the TMEM132D promoter sequence determined
by in silico analysis (see section 2.5.3) were mutated by site-directed mutagenesis. For
this, primers introducing the mutation were designed using the QuikChange Primer Design
Program (Agilent Technologies, Böblingen, Germany) assuring that no alternative putative
transcription factor binding sites arise from mutagenesis. PCR with pGL3T604, pGL3T829,
or pGL3T300 template ampliﬁed in dam+ E. coli bacteria, i.e. expressing the DNA adenine
methyltransferase gene, was performed using the long range polymerase Herculase II DNA
polymerase (Agilent technologies). Here, 100 ng of template was added to the reaction mix
that comprised 10 μl reaction buﬀer, 125 ng of each forward and reverse primer, 500 μM of
each dNTP, 1 μl Herculase II DNA polymerase, and H2O in a total volume of 50 μl. The
thermal cycling consisted of a 5 min initial denaturation step at 98 ◦C followed by 18 cycles
of a 30 s denaturation step, a 1 min annealing step at 60 ◦C, and an elongation step at 68 ◦C
for 1 min/kb. Subsequently, the template was digested by adding 20 U/ml restriction enzyme
dpnI, which speciﬁcially recognizes dam-methylated DNA sequences, to the reaction mix and
incubating it at 37 ◦C for 1.5 h resulting in a degradation of the template DNA but not
the PCR product. Finally, the mutated plasmid DNA was transformed into DH5α bacteria,
ampliﬁed, and checked for successful mutagenesis by sequencing.
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Table 2.9.: In-vitro-mutagenesis primers. Primer listed induce either a deletion (del) or
a point mutation (mut); for = forward primer, rev = reverse primer
Name Sequence 5’ → 3’
GCMFdel_for cgg cct ggg atg ctg cgg gcc agg
GCMFdel_rev cct ggc ccg cag cat ccc agg ccg
MyTdel_for cgc acc cgc caa tgg gtg ccg
MyTdel_rev cgg cac cca ttg gcg ggt gcg
HESFdel_for gca aaa ctt tgg gtg ccg gac ccg agc ccc
HESFdel_rev ggg gct cgg gtc cgg cac cca aag ttt gg
MTFdel_for ctc cga gcc gcc tct gcg tcc cg
MTFdel_rev cgg gac gca gag gcg gct cgg ag
NRF1.2del_for cgc cgc ctg cgc cac cgc tag cc
NRF1.2del_rev ggc tag cgg tgg cgc agg cgg cg
ZFXYdel_for gtc gtc gcc tcc ctg gcc atg gac tg
ZFXYdel_rev cag tcc atg gcc agg gag gcg acg ac
NRF1mut_for cgc caa act ttg ggt gcc gga ttt tgc gcg cgc ccg
NRF1mut_rev cgg gcg cgc gca aaa tcc ggc acc caa agt ttg gcg
HESFmut_for ccg gag cgc gct tgc gcc cga gcc
HESFmut_rev ggc tcg ggc gca agc gcgc tcc gg
ZF5Fmut_for ccg gag cgc gct ctc tcc cga gcc ccg
ZF5Fmut_rev cgg ggc tcg gga gag agc gcg ctc cgg
EGRFmut_for gtc ctt gcg gag cgg agc caa aaa acc tgc tgg cag gag gca gc
EGRFmut_rev gct gcc tcc tgc cag cag gtt ttt tgg ctc cgc tcc gca agg ac
NFKBmut_for ccc ccg ggc gca gga aaa agc ccc gcg tct cc
NFKBmut_rev gga gac gcg ggg ctt ttt cct gcg ccc ggg gg
SP1mut_for ccc cag ccg ggc ccg gaa aaa agc ggg ccg agg cgg cg
SP1mut_rev cgc cgc ctc ggc ccg ctt ttt tcc ggg ccc ggc tgg gg
HAMLmut_for gtc gaa gga ggg agg taa agt ttg cct gcg cgc gt
HAMLmut_rev acg cgc gca ggc aaa ctt tac ctc cct cct tcg ac
2.3.4. RT-PCR for semi-quantitative detection of gene expression
RNA was isolated from eukaryotic cells as described in section 2.3.3.1 and reverse transcribed
to cDNA as described in section 2.3.3.3. PCR was performed using the Taq DNA polymerase
(Invitrogen, Grand Island, NY, USA). Up to 5 μl of cDNA was added to the reaction mix that
comprised 1 x reaction buﬀer, 0.2 mM of each dNTP, 10 pmol of each forward and reverse
primer, 1.5 mM MgCl2, 2 units Taq DNA polymerase, and H2O. The thermal cycling included
an initial denaturation interval of 5 min at 95 ◦C and 30-40 cycles of 30 s denaturation at 95 ◦C,
30 s primer annealing at 58-62 ◦C, and 30 s elongation at 72 ◦C. A ﬁnal elongation of 3 min
at 72 ◦C concluded the thermal cycling. For each primer pair the annealing temperature, the
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cycle number and the amount of cDNA template input were optimized to assure that the PCR
remained in the linear ampliﬁcation phase. Finally, the sample was mixed with 5 x sample
loading dye and analyzed by agarose gel electrophoresis. Bands on the documented gel image
were quantiﬁed using the ImageJ software (Rasband, W.S., ImageJ, U.S. National Institutes
of Health Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2009).
Table 2.10.: RT-PCR primers. Primers for detection of gene expression levels amplifying
short, 100-500 bp long, fragments; for = forward primer, rev = reverse primer
Name Sequence 5’ → 3’
GAPDH_for gag tca acg gat ttg gtc gt
GAPDH_rev ttg att ttg gag gga tct cg
β-actin_for cta caa tga gct gcg tgt ggc
β-actin_rev cag gtc cag acg cag gat ggc
TMEM132D_for cat aca gcc tca gcc aat ga
TMEM132D_rev cat gga tgc tcc acc tga gt
HES1_for gca gat gac ggc tgc gct ga
HES1_rev ggc tgc ccg ggg tag gtc at
ZNF219_for gtt gct gga gtt gga aga gc
ZNF219_rev cta tgc agg atg tgc agg tg
ZFP161_for tgg tga gtg gtt gac caa ga
ZFP161_rev ggg caa tca aga ttg agg aa
ZFX_for cat ccc ctg tgt gct tag gt
ZFX_rev att tgg gct gga gtt cac ac
MTF1_for atc tga agg ctg cag caa at
MTF1_rev cca tta ctg ggg cag aag aa
NRF1_for ctt aca agg tgg ggg aca ga
NRF1_rev ggt gac tgc gct gtc tga ta
MYT1_for atg aca agg acg agg aca cc
MYT1_rev tca cgc ttc tca gct ctt ga
SP1_for gcc acc atg agc gac caa gat ca
SP1_rev ctc ggg ccc tgg gag ttg ttg
HAML_for ccg caa gtc gcc acc tac ca
HAML_rev ctc cag ggt gct gtg tct tcc tcc
MZF1_for gtc cag agg tac gct cca ag
MZF1_rev tct gga gtt gga ggc tca gt
NFKB1_for ctg gaa gca cga atg aca ga
NFKB1_rev tga ggt cca tct cct tgg tc
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2.4. Cell culture
The MO3.13 cell line was a kind gift from Neil Cashman, University of Toronto, Canada; the
HOG cell line was a kind gift from Glyn Dawson, University of Chicago, IL, USA. The cell
lines used in this thesis were cultivated in Roswell Park Memorial Institute (RPMI) medium
(Invitrogen) supplemented with 10 % fetal calf serum (FCS) (Invitrogen, Grand Island, NY,
USA) and 1 % antibiotic-antimycotic (Invitrogen) in case of MO3.13 cells or in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) medium (Invitrogen) supplemented with 10 % FCS, 1 %
antibiotic-antimycotic, and 1 % sodium-pyruvat (Invitrogen) in case of HOG, HEK293, A172,
or SK-N-MC cells. All cells were cultured at 37 ◦C and 5 % CO2 in an incubator (CO2
Incubator Heracell 240i, Thermo Scientiﬁc, Waltham, MA, USA or CO2 Incubator, Heraeus,
Mannheim, Germany). All work with cell lines was performed in a LaminAir HB2448 ﬂow
hood (Heraeus, Mannheim, Germany) to reduce the risk of contamination. All solutions
were prewarmed to 37 ◦C in a waterbath (Waterbath Typ 1003, GFL, Burgwedel, Germany).
Cell growth was examined visually using an Olympus CK30 microscope (Olympus, Hamburg,
Germany)
2.4.1. Cell line subcultivation
For passaging of cells the growth medium was removed, cells were washed once with prewarmed
PBS (Invitrogen), and incubated shortly with trypsin-EDTA (Invitrogen). When cells
detached they were suspended in prewarmed growth medium and seeded out into a new
culture plate in an appropriate dilution.
2.4.1.1. Freezing and thawing of cells
For cryopreservation cells were detached from the dish with trypsin-EDTA, collected in growth
medium, and centrifuged. The cell pellet was resuspended in 1 ml freezing medium (FCS
supplemented with 10 % DMSO) and transferred into a cryo-tube. The cells were frozen
as fast as possible at -80 ◦C. For long term storage the cells were later transferred to a
nitrogen-tank.
47
2. Materials and Methods
For thawing a new batch of cells, a 15 ml falcon tube was ﬁlled with growth medium and
cryopreserved cells were thawed as fast as possible in a 37 ◦C water bath. Thawed cells
were transferred immediately into the 15 ml falcon tube and centrifuged. The cell pellet
was resuspended in growth medium and transferred to a 10 cm dish ﬁlled with 9 ml growth
medium.
2.4.1.2. Mycoplasma test
To test cultured cells for contamination with mycoplasmae, a commercially available
Mycoplasma Test Kit was applied according to the manufacturer’s instructions (Biological
Industries, Kibbutz Beit-Haemek, Israel). Here, mycoplasma contamination was analyzed by
a PCR-based method using cell culture supernatant.
2.4.1.3. Cell counting
To seed out a deﬁned number of cells, the concentration of a cell suspension has to be
estimated. After trypsinization and resuspension of the cells in growth medium an aliquot of
the cell suspension was diluted in growth medium and supplemented with trypan blue dye
(Sigma-Aldrich, St. Louis, MO, USA) to stain dead cells. The cell concentration of this
suspension was then determined using a Neubauer counting chamber (Paul Marienfeld GmbH
& Co. KG, Lauda Königshofen, Germany).
2.4.2. TMEM132D overexpression
For overexpression of TMEM132D, MO3.13 cells were seeded on cover slips placed in a 12 well
plate at a concentration of 40000 cells per well to reach a conﬂuency of 70 % the next day.
Then 0.7 μg of a murine TMEM132D-pEGFP N1 construct (gift from J. Deussing, MPI
of Psychiatry, Munich) or empty pEGFP N1 vector as control diluted in 100 μl 150 mM
NaCl solution was transfected by lipofection using 2.2 μl of the linear polyethylenimine
(PEI) solution ExGen500 (Fermentas, St-Leon-Rot, Germany). After thorough vortexing, the
reaction mix was incubated for 20 min at room temperature and 100 μl was then transferred
to each well. After 48 h incubation at 37 ◦C and 5 % CO2, the cells were ﬁxed in 4 % PFA,
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counterstained with the nuclear stain DAPI, and the cover slips were mounted on glass slides
for analysis at an Olympus IX81 confocal microscope (Olympus, Hamburg, Germany).
2.4.3. Reporter gene assay
Phosphate buﬀer pH 7.8
0.5 M KH2PO4
0.5 M K2HPO4
adjust to pH 7.8
Passive lysis buﬀer
100 mM Phosphate buﬀer pH 7.8
0.2 % Triton X-100
Fireﬂy substrate solution
2.5 mM MgCl2
2 mM ATP
100 μM D-Luciferin
in H2O
Phosphate buﬀer pH 5.1
0.5 M KH2PO4
0.5 M K2HPO4
adjust to pH 7.8
Gaussia substrate solution
1.1 M NaCl
2.2 mM Na2EDTA
0.22 M Phosphate buﬀer pH 5.1
0.44 mg/ml BSA
3 μg/ml Coelenterazin
TMEM132D promoter activity was studied using reporter gene assays. To perform a reporter
gene assay the promoter region of interest was cloned upstream of a ﬁreﬂy luciferase (from
Photinus pyralis) encoded in the pGL3 basic plasmid (section 2.3.3 and Figure 3.11). When
this promoter-containing pGL3 plasmid is transfected into a eukaryotic cell, the reporter
gene, i.e. ﬁreﬂy luciferase, is expressed proportionally to the promoter activity. To minimize
variations due to slight diﬀerences in transfection eﬃciencies or cell numbers, a reference
plasmid containing a constitutively active promoter, in this case a CMV promoter-driven
gaussia luciferase plasmid (Gaussia-KDEL, gift from T. Rein, Max Planck Institute of
Psychiatry), was co-transfected for normalization of the ﬁreﬂy luciferase signals. The gaussia
luciferase (from Gaussia princeps) expressed by the Gaussia-KDEL plasmid was modiﬁed
by a C-terminal KDEL amino acid sequence, which serves as a retention signal for the
endoplasmatic reticulum. This inhibits the secretion of gaussia and enables the measurement
of both gaussia and ﬁreﬂy luciferase in the cell lysate. Importantly, ﬁreﬂy and gaussia luciferase
catalyze the oxidation of diﬀerent substrates, namely D-Luciferin and Coelenterazin, resulting
in the emission of light. This bioluminescence can be detected in the luminometer and,
provided that the enzyme is saturated with substrate, reﬂects the reporter gene expression
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which is proportional to the promoter activity.
For the reporter gene assays performed in this study, 8000 MO3.13 cells per well were seeded
in a 96-well plate. The next day, when cells reached a conﬂuency of approximately 70 %, both
the reporter gene and reference plasmids were transfected by lipofection: 50 ng/well of the
TMEM132D promoter driven ﬁreﬂy luciferase plasmid and 10 ng/well of the CMV promoter
driven gaussia luciferase plasmid were diluted in 150 mM NaCl solution and supplemented
with 0.6 μl of the linear polyethylenimine (PEI) solution ExGen500 (Fermentas, St. Leon-Rot,
Germany). The reaction mix was then thoroughly vortexed and incubated for 20 min at room
temperature allowing formation of liposomes. The mix was then added to the cells leaving
some wells untransfected as a background control. Finally, the 96-well plate was centrifuged
for 5 min at 250 x g at room temperature to improve transfection eﬃciency before the cells
were then incubated for 48 h at 37 ◦C and 5 % CO2.
Finally, luciferase activity was measured at a Tristar luminometer (Berthold, Bad Wildbad,
Germany). For this, the cells were lysed in passive lysis buﬀer for 30 min at room temperature
shaking at 700 rpm. Subsequently, 20 μl of the lysate was transferred into wells of a
white Nunc96 plate (Nunc GmbH & Co. KG, Langenselbold, Germany). The luminometer
ﬁrst injected 100 μl of ﬁreﬂy substrate solution and after shaking for 1 s, measured the
bioluminescence over the period of 10 s. Then, 100 μl gaussia substrate solution was injected
into the same well, thereby quenching the ﬁreﬂy signal by decreasing the pH. The plate was
shaken for 1 s and after a 2 s delay, the bioluminescence was measured over a period 5 s.
For data analysis, the background signal intensity generated by lysates of untransfected cells
was subtracted from each data point. Then, for normalization the ﬁreﬂy/gaussia ratio was
calculated. The data are presented normalized to the expression value of the constitutive
active ﬁreﬂy luciferase plasmid (pGL3SV40) that was transfected in each experiment. In all
performed assays each experimental conditioned was represented in triplicates.
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2.4.4. MO3.13 diﬀerentiation assay
MO3.13 cells were grown to approximately 70 % conﬂuency. Then, to induce diﬀerentiation
normal growth medium was exchanged to FCS-free RPMI medium containing 100 nM phorbol
12-myristate 13-acetate (PMA) according to previously described protocols (Buntinx et al.,
2003). Diﬀerentiation was monitored by assessing the morphological change using an inverted
microscope (Olympus CK30 microscope, Olympus, Hamburg, Germany). After three days of
diﬀerentiation RNA was isolated as described in section 2.3.3.1. RT-PCR for TMEM132D
mRNA and the candidate transcription factor mRNAs was performed in diﬀerentiated versus
non-diﬀerentiated MO3.13 cells as described in section 2.3.4. For visualization of the
morphological changes, diﬀerentiated and non diﬀerentiated MO3.13 cells were stained with
the TexasRed-labeled cell surface marker wheat germ agglutinin (WGA) (Invitrogen). For
this purpose, MO3.13 cells were grown on glass cover slips. After diﬀerentiation, cells were
ﬁxed in 4 % PFA, washed with PBS, stained with TexasRed-WGA and counterstained with
the nuclear stain DAPI. Finally, cover slips were mounted on slides and analyzed using an
Olympus IX81 confocal microscope (Olympus, Hamburg, Germany).
2.4.5. siRNA mediated knock-down of TMEM132D
To answer the question if TMEM132D is necessary for oligodendrocyte diﬀerentiation,
a knock-down using TMEM132D-speciﬁc siRNA was performed (Dharmacon, Lafayette,
CO, USA), and transfected MO3.13 cells were subsequently subjected to PMA-induced
diﬀerentiation (see section 2.4.4). For this purpose, 120000 MO3.13 cells were plated into
each well of a 6 well plate. The next day, when cells had reached approximately 70 %
conﬂuency, TMEM132D-speciﬁc or control siRNA was transfected via lipofection using the
DharmaFECT reagent (Dharmacon, Lafayette, CO, USA) according to the manufacturer’s
speciﬁcations. 6 h later, the medium was exchanged to either control (normal growth medium)
or 100 nM PMA containing medium and cells were cultivated for at least three more days.
Then, cell morphology was analyzed using an Olympus CK30 microscope (Olympus, Hamburg,
Germany) and cells were harvested for RT-PCR analysis (see section 2.3.4).
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2.5. Bioinformatical methods
A comprehensive in silico analysis was performed to study TMEM132D. Sequence information
was retrieved from the databases at the National Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov), the UCSC Genome Browser (http://genome.ucsc.edu/),
the Ensemble Genome Browser (http://www.ensembl.org/), and the UniProtKB database
(http://www.uniprot.org). Sequence alignments were performed with the NCBI Basic local
alignment tool (BLAST), e.g. for analyzing sequence results during cloning. Primers (see
Tables 2.7, 2.8, 2.9, 2.10) were designed using the NCBI Primer-BLAST program.
Table 2.11.: Employed bioinformatical tools. Listed are all bioinformatical tools used in
this study, their developers, as well as a description of the intended use.
Tool Developed by Application
Sequence databases
NCBI gene,
nucleotide, and
protein databases
National Center for Biotechnology
Information (NCBI)
Sequence retrieval
UniProtKB European Bioinformatics Institute
(EBI), Swiss Institute of
Bioinformatics (SIB), Protein
Information Resource (PIR)
Protein sequence retrieval
UCSC Genome
Browser
Genome Bioinformatics Group of
UC Santa Cruz
Sequence retrieval
Ensembl Genome
Browser
European Molecular Biology
Laboratory - European
Bioinformatics Institute
(EMBL-EBI) and Sanger Institute
Sequence retrieval
NCBI GEO
DataSets
National Center for Biotechnology
Information (NCBI)
Retrieval of gene expression
data
Sequence alignments and phylogenetic analysis
BLAST National Center for Biotechnology
Information (NCBI)
Comparison of protein
sequences (blastp, psi-blast),
nucleotide sequences (blastn),
or for primer design
(Primer-BLAST)
T-Coﬀee Center for Genomic Regulation
(CRG), Barcelona (Notredame
et al., 2000)
Multiple sequence alignment
of TMEM132D paralogs
BOXSHADE 3.21 K. Hofmann and M. Baron, Swiss
Institute of Bioinformatics
Illustration of multiple
sequence alignment
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WebLogo University of California, Berkeley
(Crooks et al., 2004)
Illustration of consensus
sequence of multiple sequence
alignment
Phylogeny.fr
platform (MUSCLE
+ PhyML +
TreeDyn)
A. Dereeper, V. Guignon (Dereeper
et al., 2008)
Phylogeny analysis:
MUSCLE multiple sequence
alignment + PhyML
phylogenetic analysis +
TreeDyn Tree rendering
HHPred Max-Planck Institute for
Developmental Biology (Soding
et al., 2005)
Detection of homologous
protein domains
COILS/PCOILS Max-Planck Institute for
Developmental Biology (Lupas
et al., 1991)
Detection of coiled-coil
domains
In silico TMEM132D promoter analysis
Gene2Promoter Genomatix Software GmbH
(Munich, Germany)
Extraction of the TMEM132D
promoter sequence
MatInspector Genomatix Software GmbH
(Munich, Germany) (Cartharius
et al., 2005)
Identiﬁcation of transcription
factor binding sites
DiAlignTF/GEMS
Launcher
Genomatix Software GmbH
(Munich, Germany) (Cartharius
et al., 2005)
TFBS in aligned regions of
orthologous promoters
TFSEARCH Yutaka Akiyama,
http://www.rwcp.or.jp/papia/
Identiﬁcation of transcription
factor binding sites
EMBOSS CpGPlot European Molecular Biology
Laboratory - European
Bioinformatics Institute
(EMBL-EBI) (Rice et al., 2000)
Detection of CpG Islands
ECR Browser NCBI Dcode.org Comparative
Genomics Developments (Loots and
Ovcharenko, 2007)
Evolutionary conservation
of multiple genomes;
conservation of human and
murine TMEM132D promoter
2.5.1. Analysis of phylogenetic conservation of TMEM132D proteins
Human TMEM132D paralogs were identiﬁed by blastp search of the TMEM132D protein
sequence against the UniProtKB/Swiss-Prot databse (http://blast.ncbi.nlm.nih.gov). A
multiple sequence alignment of TMEM132D was performed to identify conserved regions
employing the T-Coﬀee method (www.tcoﬀee.org). The multiple sequence alignment was
illustrated using BOXSHADE3.21 (http://www.ch.embnet.org/software/BOX_form.html)
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and a graphical representation was produced applying the WebLogo tool
(http://weblogo.berkeley.edu/). Orthologs of the TMEM132D protein were retrieved
from the ENSEMBL database (http://www.ensembl.org). The sequences of homologous
proteins were submitted to phylogeny analysis at http://www.phylogeny.fr (Dereeper et al.,
2008).
2.5.2. Identiﬁcation of homologous protein domains of TMEM132D
As so far the protein function of TMEM132D is unknown, an in silico
analysis of functional protein domains was performed using the HHpred tool
(http://toolkit.tuebingen.mpg.de/hhpred). Based on a hidden markov model (HMM)-
hidden markov model (HMM) comparison the HHpred tool detects homologous
protein domains (Söding, 2005). Only protein domain hits with a probability higher
than 60 were taken into account. Subsequently, the COILS/PCOILS program
(http://toolkit.tuebingen.mpg.de/pcoils) was applied to conﬁrm a potential coiled-coil
domain identiﬁed by HHPred.
2.5.3. TMEM132D in silico promoter analysis
The prediction of the TMEM132D promoter region was performed using the Genomatix
Gene2promoter tool (http://www.genomatix.de/products/Gene2Promoter) by entering the
human TMEM132D mRNA sequence (NCBI Reference Sequence: NM_133448.2) into the
input mask. Subsequently, the retrieved TMEM132D promoter sequence was analyzed
for the presence of transcription factor binding site motifs using either the Genomatix
MatInspector tool (http://www.genomatix.de/products/MatInspector) or the TFSEARCH
program (http://www.cbrc.jp/research/db/TFSEARCH.html). To restrict further analyses
to the most important transription factor binding sites (TFBS), phylogenetic conservation
of transcription factor binding sites was analyzed using the Genomatix DiAlignTF tool of
the GEMS Launcher Package (http://www.genomatix.de/products/GEMSLauncher). This
tool identiﬁes TFBS motifs in a multiple alignment of the human and murine TMEM132D
promoter sequence. Additionally, conservation of the more distally located human and murine
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promoter regions (position chr12:128953500-128959000 of the human genome) was analyzed
using the ECR Browser (http://ecrbrowser.dcode.org/). Finally, analysis of CpG islands was
performed by entering the human TMEM132D promoter sequence into the EMBOSS CpG
Plot input mask (http://www.ebi.ac.uk/Tools/emboss/cpgplot).
2.5.4. NCBI GEO DataSet analyses
The NCBI GEO DataSets (http://www.ncbi.nlm.nih.gov/gds/) store gene expression data
from microarray experiments. In a ﬁrst analysis, TMEM132D expression data from a published
microarray study were retrieved from NCBI GEO DataSets (accession number GDS2044)
(Vallender and Lahn, 2006). For the array experiments, primary dermal ﬁbroblasts have
been treated with the DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine (Aza-dC) for
96 hours followed by gene expression analysis on an Aﬀymetrix Mouse Genome 430 2.0 Array.
Here, TMEM132D expression values were retrieved from the NCBI GEO DataSets website
and were analyzed for statistical signiﬁcance by applying a student’s t-test.
In a second analysis, data on immunoglobin gene expression in human blood samples of PTSD
patients and controls were retrieved from NCBI GEO DataSets (accession number GDS1020).
In the respective study blood from trauma survivors admitted to the emergency room has been
collected few hours and 4 months after exposure to a traumatic event. Subjects have been
assigned to control and PTSD groups based on the expression of PTSD symptoms (Segman
et al., 2005). Here, expression values for Igκ light chain (IGK), Igλ light chain (IGL), IgG1
heavy chain (IGHG1), IgA2 heavy chain (IGHA2), and IgM heavy chain (IGHM) transcripts
were extracted and analyzed for statistical signiﬁcance by applying a two-way ANOVA and
Bonferroni post-tests.
2.6. Statistics
Statistical analyses were performed using the software Excel 2003TM (Microsoft Deutschland
GmbH, Unterschleißheim, Germany) and GraphPad Prism 5TM (GraphPad Software Inc., La
Jolla, CA, USA). Statistical signiﬁcance was calculated using the two-tailed student’s t-test
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or ANOVA and Bonferroni post-hoc tests when appropriate. The p-values were classiﬁed into
four groups: t p < 0.1, * p < 0.05, ** p < 0.01, *** p < 0.001.
2.6.1. Pearson correlation
Correlation studies were performed according to published procedures (Wu et al., 2007; Zink
et al., 2010) employing GraphPad Prism 5TM : For each individual mouse its mean relative
synapsin, synaptophysin, or homer 1b/c protein expression value on day 60 after shock
(calculated from three technical replicates) was correlated with the values representing the
intensities of either its contextual fear, generalized fear, or acoustic startle response on days
28-30 after shock by calculating the Pearson correlation coeﬃcient.
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This thesis aimed at analyzing the hitherto completely unknown transcriptional regulation of
transmembrane protein 132 D (TMEM132D), a recently identiﬁed candidate gene for anxiety
disorders. Changes in TMEM132D expression have been associated to anxiety phenotypes
(Erhardt et al., 2011) as well as oligodendrocyte diﬀerentiation (Nomoto et al., 2003) as
described in section 1.6. In order to identify mechanisms leading to these expression changes,
this thesis concentrated on elucidating the hitherto completely unexplored transcriptional
regulation of TMEM132D and in particular the structure and regulatory mechanisms of the
TMEM132D promoter.
3.1. Analysis of TMEM132D gene structure and prediction of
possible protein functions
Prior to analyzing the TMEM132D promoter region in detail, a brief in silico analysis of the
TMEM132D gene and protein was performed. As listed in the gene database of the National
Center for Biotechnology Information (NCBI) (http://www.ncbi.nlm.nih.gov), TMEM132D
(Gene ID: 121256) is a nine exon containing gene located on chromosome 12q24.32-q24.33
and spans a region of about 830 kb. Transcription results in a 5777 bp long mRNA (NCBI
accession number NM_133448.2) with a 328 bp spanning 5’ untranslated region, an open
reading frame of 3300 bp, and a 3’ untranslated region of 2149 bp. Translation produces a
1099 amino acid long protein (NCBI accession number NP_597705.2). TMEM132D has been
predicted to be a single-pass type I transmembrane protein, i.e. a protein anchored in the lipid
membrane with the N-terminus oriented towards the extracellular space, with a 30 amino acid
signal peptide, a long extracellular domain (885 amino acids), a short transmembrane region
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Figure 3.1.: Schematic illustration of the human TMEM132D gene and protein
structure based on information retrieved from the NCBI and
UniProtKB databases. (A) The TMEM132D gene locus spanning 830
kilobases (kb) on chromosome 12q24.32-q24.33 is depicted. (B) TMEM132D is a
potential type I transmembrane protein with a short cytoplasmatic residue and a
long extracellular region.
(amino acids 916-936), and a short cytoplasmic domain (163 amino acids) (www.uniprot.org;
accession number Q14C87-1), as illustrated in Figure 3.1. Translation of an alternative splice
variant of the TMEM132D transcript described in the uniprot database (www.uniprot.org;
accession number Q14C87-2) is predicted to result in a protein that lacks the ﬁrst 462 amino
acids and thus, exhibits a shorter extracellular domain.
Here, the transmembranous localization of TMEM132D was experimentally conﬁrmed by
overexpression of an EGFP-tagged murine TMEM132D (construct was a generous gift
from J. Deussing, MPI of Psychiatry, Munich, Germany) in MO3.13 oligodendroglial cells:
while control cells overexpressing EGFP only show an evenly distributed green ﬂuorescence
across the cell, in TMEM132D overexpressing cells the green ﬂuorescence was predominantly
restricted to the cell membrane (Figure 3.2), thereby visualizing the numerous small cellular
processes that are characteristic of these cells (cf. Figure 3.21).
As besides displaying a cell surface marker during oligodendrocyte diﬀerentiation (Nomoto
et al., 2003), the protein function of TMEM132D is hitherto unknown, an in silico analysis
of homologous sequences of TMEM132D was performed: a search for human TMEM132D
paralogs using the NCBI protein-protein BLAST (blastp) or the NCBI position speciﬁc
iterative (PSI)-BLAST (both accessed via the webpage http://blast.ncbi.nlm.nih.gov) on the
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Figure 3.2.: Overexpression of EGFP-tagged TMEM132D reveals its
transmembranous localization. Murine TMEM132D-EGFP was
overexpressed in MO3.13 cells, control cells overexpressed EGFP only. After 48
h of overexpression, cells were prepared for analysis by confocal microscopy.
swiss-prot protein database revealed the ﬁve known members of the TMEM132 protein family,
namely TMEM132A, TMEM132B, TMEM132C, TMEM132D, and TMEM132E. UniProtKB
database search (http://www.uniprot.org) furthermore revealed that all of the TMEM132
proteins (TMEM132A - accession Q24JP5, TMEM132B - accession Q14DG7, TMEM132C -
accession Q8N3T6, TMEM132D - accession Q14C87, and TMEM132E - accession Q6IEE7)
are predicted to be single-pass type I transmembrane proteins with a large extracellular
domain and a short intracellular domain and have an approximate size of 1000 amino
acids. Subsequent phylogenetic analysis demonstrated TMEM132D to exhibit the highest
conservation with TMEM132C and TMEM132B, and the lowest similarities with TMEM132A
(Figure 3.3). According to the blastp results, sequence identity of TMEM132D was 61 % with
TMEM132C, 51 % with TMEM132B, 36 % with TMEM132E, and 30 % with TMEM132A.
Conserved regions in the TMEM132D paralogs were analyzed by performing a multiple
sequence alignment. Interestingly, TMEM132D paralogs showed a high conservation of
the putative transmembrane region (Figure 3.4, see Appendix A.1 for detailed sequence
information). Moreover, the regions ﬂanking the predicted transmembrane region were not
very well conserved in the TMEM132D paralogs, while in the extracellular region multiple
segments exhibited high sequence similarity (Figure 3.4, see Appendix A.1 for detailed
sequence information). However, so far not much is known about the protein function of these
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Figure 3.3.: Phylogenetic tree of human TMEM132D paralogs. Sequence
information of TMEM132D paralogs were extracted from the
blastp database search and submitted to phylogeny analysis at
http://www.phylogeny.fr/version2_cgi/phylogeny.cgi. The length of the
branches is scaled to the degree of change in amino acid sequence.
TMEM132D homologous proteins. Only the function of TMEM132A has been previously
studied revealing it to play a role in neurite-like process formation as well as cell survival
(Oh-hashi et al., 2010).
Next, to study the inter-species conservation of TMEM132D, phylogenetic conservation
of TMEM132D orthologs was analyzed. For this purpose, all TMEM132D orthologous
protein sequences were extracted from the ENSEMBL database (only complete sequences,
Figure 3.4.: Illustration of conserved regions in a multiple sequence alignment
of TMEM132D paralogs. Multiple sequence alignment was performed
employing the multiple sequence alignment server T-Coﬀee (www.tcoﬀee.org/).
The consensus sequence was illustrated as a sequence logo using the weblogo tool
at http://weblogo.berkeley.edu/. The N- and C-terminus as well as the sequence
positions are indicated. The highly conserved potential transmembrane region is
highlighted and depicted in the magniﬁcation.
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Figure 3.5.: Phylogenetic conservation of the TMEM132D orthologs. TMEM132D
protein orthologs were retrieved from the ENSEMBL database and submitted to
phylogeny analysis at http://www.phylogeny.fr/version2_cgi/phylogeny.cgi. The
length of the branches is scaled to the degree of change in amino acid sequence of
TMEM132D orthologs.
i.e. no sequence fragments, were taken into account) and a phylogenetic tree was generated
employing the phylogeny.fr tool (http://www.phylogeny.fr/version2_cgi/phylogeny.cgi). So
far, TMEM132D homologs have been found in several vetebrates including mammals and birds
as well as amphibians (Xenopus tropicalis) and ﬁsh (Danio rerio). However, no homologs have
been found in invertebrates yet (Figure 3.5).
As conventional BLAST analysis did not reveal any signiﬁcant homologous proteins with
known function, a search for conserved protein domains was performed next. For this purpose,
the HHpred tool at http://toolkit.tuebingen.mpg.de/hhpred was employed, which is based on
a diﬀerent algorithm than blastp and PSI-BLAST, i.e. the Hidden Markov Model (HMM)
(Söding, 2005). In contrast to blastp, which performs a sequence-sequence comparison,
and PSI-BLAST, which compares protein proﬁles to protein sequences, the HHpred tool
compares HMM proﬁles to HMM proﬁles. In addition to amino acid sequence information,
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Figure 3.6.: Prediction of conserved protein domains employing the HHpred
tool. (A) Schematic illustration of the localization of the cohesin-like
domain and the coiled coil domain predicted by HHpred. (B) Results of
the HMM-HMM comparison retrieved by submitting the TMEM132D protein
sequence (NP_597705.2) to the HHpred tool at http://toolkit.tuebingen.mpg.de/.
The cut-oﬀ is indicated and probability values are highlighted in gray. (C)
Results of the COILS/PCOILS analysis of the TMEM132D protein sequence
(NP_597705.2) at http://toolkit.tuebingen.mpg.de/.
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this method also includes position-speciﬁc probability values for insertions and deletions of
amino acids along the alignment, which was reported to improve the alignment sensitivity
(Söding, 2005). Subjection of the TMEM132D protein sequence (NCBI accession number
NP_597705.2) to HHpred analysis resulted in 12 conserved protein domain hits. Only 6
hits exhibited a probability higher than 60, which was deﬁned as a cut-oﬀ criterion: 4 of
these hits pointed at a cohesin-like domain at amino acid position 286-392 in the extracellular
domain of TMEM132D (Figure 3.6 A, B). Due to the extracellular localization and strong
and highly speciﬁc interactions of bacterial cohesins with dockerins (Bayer et al., 2004), a
cohesin-like domain might be important for cell adhesion processes. Interestingly, the ﬁfth
hit, the transmembrane domain of the integrin α-IIB protein, another single-pass type I
transmembrane protein, is homologous to the potential transmembrane domain of TMEM132D
at amino acid position 916-936 (Figure 3.6 A, B) and thus further conﬁrms the identity
of this region. The HHpred tool further indicated the presence of a coiled coil domain at
the C-terminus of the TMEM132D protein, which was subsequently conﬁrmed by applying
the COILS/PCOILS tool (http://toolkit.tuebingen.mpg.de/pcoils). Coiled coil domains can
mediate oligomerization and are predominantly found in proteins involved in intracellular
transport (Burkhard et al., 2001) (Figure 3.6 C).
Taken together, in silico analyses revealed TMEM132D to constitute a nine exon containing
gene located on chromosome 12q24.32-q24.33 and encoding a 1099 amino acid long predicted
transmembrane protein. The transmembranous localization was experimentally conﬁrmed
by microscopic analysis of cells overexpressing a EGFP-tagged TMEM132D. Addressing
TMEM132D protein function, a blastp-search of homologous proteins revealed TMEM132A,
TMEM132B, TMEM132C, and TMEM132E to be paralogs of TMEM132D, as was to be
expected from their classiﬁcation into the same protein family. However, as these proteins
are as poorly characterized as TMEM132D itself, they could not contribute to the elucidation
of TMEM132D protein function. Finally, prediction of conserved protein domains using an
alternative method revealed a cohesin-like domain in the extracellular region of TMEM132D,
which might point at a potential role of TMEM132D in cell adhesion processes.
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3.2. In silico analysis of the TMEM132D promoter
After in silico analysis of the TMEM132D protein and gene structure, the TMEM132D
promoter was analyzed to decipher the regulatory mechanisms of TMEM132D expression.
Experimental analysis of the TMEM132D promoter was preceded by an extensive in silico
analysis that is illustrated in Figure 3.7. For this purpose, ﬁrst the TMEM132D promoter
was predicted employing the Gene2Promoter tool (www.genomatix.de), which has been
successfully employed in previous promoter studies (Lindermayr et al., 2008; Palmieri
et al., 2008). By mapping the TMEM132D mRNA sequence (NCBI Reference Sequence
NM_133448) to the human genome, the Genomatix Gene2Promoter tool (www.genomatix.de)
detected four possible promoters for TMEM132D, which were all located on the minus strand
(Figure 3.7 A). For further analyses one of the predicted possible promoters was selected, i.e.
that one that was considered to be the most important since it regulates the expression of
the primary transcript of the TMEM132D gene, that is the nine exon containing transcript
(Figure 3.1/Figure 3.7). This promoter spans the region of 829 bp upstream to 101 bp
downstream of the start codon (Figure 3.8). Second, the TMEM132D promoter identiﬁed
in silico, i.e. promoter I, was screened for the presence of transcription factor binding sites
(TFBS) using the MatInspector tool (www.genomatix.de), that is widely used in promoter
studies, e.g. in the characterization of promoter polymorphisms in the serotonin transporter
gene (Ehli et al., 2012). Employing this tool yielded approximately 170 hits (Figure 3.7 B).
To select the most important TFBS, human and murine promoter sequences were aligned
and a TFBS search was conducted in the aligned sequence. Alignment and subsequent TFBS
identiﬁcation were performed using the DiAlignTF tool (www.genomatix.de) and resulted in 9
conserved TFBS (Figure 3.7 C) that were then analyzed in vitro. Finally, to identify additional,
non-conserved TFBS, the TMEM132D promoter region was screened using the alternative tool
TFSEARCH that contributed successfully to previous promoter characterizations (Wu et al.,
2012; Banerjee and Nandagopal, 2007) and here, identiﬁed 30 hits in the TMEM132D promoter
(Figure 3.7 D). TFBS identiﬁed by both TFSEARCH and MatInspector were selected for
further in vitro analysis.
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Figure 3.7.: Workﬂow of in silico TMEM132D promoter analysis. A) Employing
the Gene2Promoter tool (www.genomatix.de) 4 possible TMEM132D promoters
were identiﬁed. Promoter I (highlighted in orange) was selected to be the
most important and was subjected to further analyses. B) Transcription
factor binding site (TFBS) motifs were identiﬁed using the MatInspector tool
(www.genomatix.de) resulting in 170 TFBS hits, listed in Appendix, Table A.1.
C) TFBS search in a sequence alignment of the human and murine TMEM132D
promoter identiﬁed 9 conserved TFBS (Figure 3.14), that were subjected to
in vitro analysis (Figure 3.17). D) For identiﬁcation of additional TFBS,
the TFSEARCH tool (http://www.cbrc.jp/research/db/TFSEARCH.html) was
employed, resulting in 30 TFBS hits (listed in Appendix, Table A.2). TFBS
identiﬁed by both MatInspector and TFSEARCH were subjected to in vitro
analysis (Figure 3.18 and 3.19).
The promoter, that is the DNA sequence involved in regulation and initiation of transcription
of a gene, comprises both binding sites for general transcription factors and RNA polymerase II
for the formation of the initiation complex as well as binding sites for other regulatory proteins,
i.e. transcription factors that control the rate of assembly of the initation complex (Riethoven,
2010). Among the 170 TFBS hits of the MatInspector analysis, several core elements for
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Figure 3.8.: Core elements required for transcription initiation in the TMEM132D
promoter. The core sequence of core promoter elements in the TMEM132D
promoter is highlighted by red frames. The start codon is printed in bold.
Abbreviations: XCPE = Activator-, mediator- and TBP-dependent core promoter
element for RNA polymerase II transcription from TATA-less promoters; TF2B =
RNA polymerase II transcription IIB; MTEN = core promoter motif ten elements;
Inr = core promoter initiator element
initiation of RNA Polymerase II-driven transcription were identiﬁed (Figure 3.8). Similar to
other human promoters, in the human TMEM132D promoter sequence no TATA-box was
identiﬁed. Instead, a core promoter initiator element (Inr), typically located at position -2 to
+4 relative to the transcription start site (TSS) (Jin et al., 2006), was found approximately
75 bp upstream of the TMEM132D start codon. In general, the ﬁrst step in the assembly of
the initiation complex is the binding of the general transcription factor TFIID to the DNA. In
presence of a TATA box, TFIID binds via its TATA binding protein (TBP) subunit, while in
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TATA-less promoters the TBP-associated factor (TAF) subunits of TFIID bind to the initiator
element (Inr) (Smale, 1997). This is followed by assembly of the other general transcripton
factors, namely TFIIB, TFIIE, TFIIF, and TFIIH as well as the RNA polyermerase II to
the initiation complex. Finally, transcription is induced by TFIIH mediated unwinding
of the DNA and phosphorylation of RNA polymerase II (Baumann et al., 2010). Besides
binding of general transcription factors, core promoter elements also integrate the activating
and repressive inﬂuences of transcription factors bound at distal sites (Smale and Kadonaga,
2003). Several core promoter motif ten elements (MTEN) were identiﬁed in the TMEM132D
promoter sequence. In general, MTENs are located at position +18 to +27 relative to the
TSS and and have been reported to promote initiation of transcription in the presence of
an Inr (Lim et al., 2004). In the TMEM132D promoter sequence, however, all identiﬁed
MTENs were located upstream of the identiﬁed Inr. In addition to Inr and MTEN, the in
silico analysis performed here identiﬁed two activator-, mediator- and TBP-dependent core
promoter elements for RNA polymerase II transcription from TATA-less promoters (XCPE).
XCPEs are typically located at position -8 to +2 relative to the TSS (Tokusumi et al., 2007):
here, in the TMEM132D promoter one XCPE site was found to be located approximately 32
bp upstream of the potential TSS whose presumable existence was concluded from the presence
of the Inr. The second XCPE was located far more upstream, approximately 740 bp upstream
of the start codon. This second XCPE site was found to overlap with a RNA polymerase
II transcription IIB (TF2B) binding site, that is typically located -37 to -32 bp upstream of
the TSS and is an important element involved in the RNA polymerase II recruitment (Jin
et al., 2006). Taken together, from the core promoter elements identiﬁed by MatInspector
analysis it is not possible to reach an ultimate conclusion on the transcription start site of
TMEM132D: the localization of the identiﬁed Inr suggests a TSS at position -75 of the start
codon. In contrast, the transcription start site that can be deduced from the 5’ sequence of the
TMEM132D transcript NM_133448.2 listed in the NCBI nucleotide data base is at position
-329 of the start codon, however, MatInspector analysis detected no core promoter elements
that supported the presence of this TSS.
In general, besides the core promoter elements important for recruitment of RNA polymerase
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Figure 3.9.: Conservation of the 5 kb region upstream of the TMEM132D start
codon. Conservation of the human and murine TMEM132D promoter region was
analyzed using the ECR Browser (http://ecrbrowser.dcode.org/). Three clusters
(I-III) of evolutionary conserved regions were detected.
II and initiation of transcription which are located in close proximity to the transcription
start site, also both proximal and distal enhancer and repressor elements can substantially
inﬂuence promoter activity. Striving to identify distal regulatory elements, a conservation
analysis of the region spanning 5 kb upstream of the start codon was performed employing
the ECR Browser (http://ecrbrowser.dcode.org/) (Figure 3.9). Comparing human and murine
TMEM132D promoter sequences, three conserved regions emerged (Figure 3.9). The ﬁrst
one (630 to 401 bp upstream of the start codon) lies within the promoter identiﬁed by
Gene2Promoter (Figure 3.7), the second is located in close proximity to the latter (1036
to 903 bp upstream of the start codon) and the third cluster lies more distal (3012 to 2830
bp upstream of the start codon) (Figure 3.9). Evolutionary conserved regions often contain
essential functional elements regulating promoter activity (Loots and Ovcharenko, 2007). The
third cluster of conservation might thus harbour functional distal regulatory elements like
enhancers or silencers, while cluster I and II probably contain more proximal regulatory
elements (Figure 3.9).
Besides the presence of core promoter elements and evolutionary conserved regions, CpG
islands, i.e. genomic regions with a high frequency of CG dinucleotides, are well-known
indicators of promoter regions (Yamashita et al., 2005). A CpG island reaching from
1118 bp upstream to 285 bp downstream of the start codon was identiﬁed using the
EMBOSS CpG Island Plot (http://www.ebi.ac.uk/Tools/emboss/cpgplot/) (Figure 3.10 A)
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Figure 3.10.: Identiﬁcation of a CpG island in the TMEM132D promoter.
(A) EMBOSS CpG Island Plot of the TMEM132D promoter region
(http://www.ebi.ac.uk/Tools/emboss/cpgplot/). The CpG island identiﬁed
reached from -1118 to +285 relative to the start codon of TMEM132D.
(B) Results of the statistical analysis of TMEM132D expression data
extracted from a microarray dataset (from NCBI GEO DataSets (GDS2044);
http://www.ncbi.nlm.nih.gov/geo/) showing an upregulation of TMEM132D
mRNA after Aza-dC treatment (leading to DNA demethylation) of primary
mouse ﬁbroblasts. Data represent means ± SD, n = 3. Statistical signiﬁcance
was calculated using a student’s t-test and is indicated by * p < 0.05.
which further supports the identity of the here identiﬁed TMEM132D promoter region.
Additionally, a potential role of CpG methylation in transcriptional regulation of TMEM132D
was concluded from publicly available microarray data retrieved from NCBI GEO DataSets
(Accession number: GDS2044) (http://www.ncbi.nlm.nih.gov/geo/): samples of primary
mouse ﬁbroblasts treated with the DNA methyltransferase inhibitor 5-aza-2’-deoxycytidine
(Aza-dC) were submitted to the microarray. For the analysis performed in the thesis
at hand, TMEM132D expression data were extracted from the database and statistically
analyzed revealing an increased TMEM132D gene expression in Aza-dC treated, i.e.
DNA-demethylated, ﬁbroblasts (Figure 3.10 B; t = 3.314, df = 4, p = 0.030), indicating that
epigenetic mechanisms play an important role in the regulation of TMEM132D expression.
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Figure 3.11.: Cloning strategy of the TMEM132D promoter luciferase constructs.
TMEM132D promoter segments or, for cloning of a corresponding positive
control vector, the simian virus 40 (SV40) promoter were inserted into
the multiple cloning site (MCS) of the pGL3-Basic Vector that comprises
a ﬁreﬂy luciferase element downstream of the MCS, followed by a SV40
polyadenylation site (SV40pA). The vector backbone additionally contains an
ampicillin resistence element for selective ampliﬁcation in E. coli; the origin of
replication (ori) in E. coli and origin of replication derived from ﬁlamentous
phage (f1 ori) are labeled.
3.3. Analysis of TMEM132D promoter activity in the
oligodendrocytic MO3.13 cell line
In order to experimentally verify the promoter region identiﬁed in silico, a reporter gene
analysis was performed with progressive 5’ deletion mutants of the region spanning 5 kb
upstream of the start codon, and thus including all three evolutionary conserved regions
identiﬁed in this thesis (Figure 3.9). For this purpose, segments of the TMEM132D promoter
region were isolated from human genomic DNA by PCR and cloned into the pGL3-basic
reporter vector that encodes a ﬁreﬂy luciferase downstream of the multiple cloning site (MCS)
and contains no further promoter or enhancer elements (Figure 3.11 A). As a positive control,
the constitutively active simian virus 40 (SV40) promoter was inserted into the MCS of the
pGL3-basic reporter vector (Figure 3.11 B), while the pGL3-basic vector without any inserts
was used to determine the background ﬁreﬂy luciferase signal.
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Figure 3.12.: TMEM132D mRNA expression in neuronal and non-neuronal cell
lines. mRNA extracted from either the oligodendroglial cell lines MO3.13 or
HOG, the astroglial cell line A172, the neuroblastoma cell line SK-N-MC, or the
embryonic kidney cell line HEK293 was analyzed for expression of TMEM132D
and, for control, β-actin mRNA by RT-PCR. n = 1; 2 technical replicates.
Due to the reported association of TMEM132D with oligodendrocyte diﬀerentiation (Nomoto
et al., 2003), the reporter gene assays were performed in the human oligodendrocyte MO3.13
cell line (Buntinx et al., 2003), even though RT-PCR analyses performed here revealed also
other neural (SK-N-MC, A172) and non-neural (HEK293) cell lines to express TMEM132D
(Figure 3.12). TMEM132D expression has so far not been studied in cell lines but it has been
previously reported to be expressed not only in brain tissue, but also in lung, pancreas, and
testis (Nomoto et al., 2003).
To perform the reporter gene assay, both the ﬁreﬂy luciferase plasmid containing either the
TMEM132D or the SV40 promoter (positive control) and the gaussia luciferase plasmid, which
served as a control for normalization, were co-transfected into MO3.13 cells. The activity
of the luciferases expressed by the transfected MO3.13 cells was assessed by measuring the
bioluminescence emitted during enzymatic conversion of the respective luciferase substrates.
For data evaluation the ﬁreﬂy luciferase activity was normalized to the gaussia luciferase
activity resulting in a data value that corresponds to the activity of the promoter element
tested. The diﬀerent segments upstream of the TMEM132D start codon analyzed here
exhibited promoter activity, i.e. were able to induce the expression of the luciferase gene in the
reporter gene assay (Figure 3.13). Moreover, the ﬁrst 604 bp upstream of the TMEM132D start
codon were identiﬁed as the most potent promoter activating region (Figure 3.13). However,
compared to the positive control, the SV40 promoter driven luciferase construct, TMEM132D
promoter activity was rather low, reaching a maximum of approximately 7 % of the SV40
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Figure 3.13.: Reporter gene assay of 5’ deletion mutants of the TMEM132D
promoter sequence in MO3.13 cells. Left site: scheme of 5’ deletion
constructs, indicated are the start sites of the construct relative to the start
codon (position -1). The ‘basic’ construct contains no promoter sequences, i.e.
is identical to the empty pGL3-basic vector representing the background signal.
Right site: promoter activity of 5’ deletion constructs is presented as percentage
of the SV40 promoter activity set at 100 %. Values plotted are means ± SEM
of 3 independent experiments performed in triplicates.
promoter activity (Figure 3.13). Interestingly, the construct containing the 300 bp region
upstream of the start codon exhibited no major decrease in luciferase activity when compared
to the luciferase activity of the 604 bp construct, although the transcription start site (TSS)
reported in the NCBI database is located at position 329 upstream of the start codon and
thus is lacking in the 300 bp construct (Figure 3.14). Without expressing the core promoter
elements for recruiting RNA polymerase II and for subsequent initiation of transcription, one
would expect the promoter activity of the 300 bp construct to be considerably reduced. The
fact that this was not the case points at the importance of the alternative TSS which was
identiﬁed by Gene2Promoter analysis and is identical with the start codon (Figure 3.7) as
well as the potential TSS that is located approximately 75 bp upstream of the start codon
and was suggested by the presence of the initiator element identiﬁed by MatInspector analysis
(Figure 3.8). In addition, the functionality of these alternative TSS are further supported by
the 150 bp TMEM132D promoter construct which still exhibits considerably higher promoter
activity than the empty pGL3-basic luciferase construct (Figure 3.13).
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Figure 3.14.: Conserved transcription factor binding sites in the TMEM132D core
promoter. Alignment of the murine and human nucleotide sequence of the
TMEM132D promoter sequence identiﬁed by Gene2Promoter. Indicated are
the start sites of the 5’ deletion constructs (arrowheads) as well as conserved
transcription factor binding sites (colored, core sequence is underlined) subjected
to deletion analysis as depicted in Figure 3.17. The start codon of the human
sequence is printed in bold.
Next, the impact of diﬀerent regulatory elements on promoter activity was addressed. For
this purpose, the impact of transcription factor binding sites conserved in the human and
murine promoter sequence (highlighted in Figure 3.14 and described in Table 3.1; see also
Figure 3.7) on TMEM132D promoter activity was analyzed in reporter gene assays. To
analyze the functionality of the conserved TFBSs identiﬁed in silico, reporter gene assays
using TMEM132D promoter constructs with mutated, i.e. dysfunctionalized, TFBS were
performed. Mutated TMEM132D promoter constructs were generated by site-directed
mutagenesis (Figure 3.15): primers introducing the dysfunctionalizing mutation were designed.
Using these primers and the long-range DNA polymerase Herculase the complete TMEM132D
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Table 3.1.: Conserved transcription factor binding sites in the TMEM132D
promoter. Listed are transcription factor binding sites conserved in the human
and murine sequence of the TMEM132D promoter shown in Figure 3.14 as well
as the description of their biological functions according to the respective gene
ontology (GO)-terms.
Transcription factor family Transcription factors Description
HESF (Vertebrate homologues
of enhancer of split complex)
BHLHB2, BHLHB3,
HELT, HES1, HES2,
HES3, HES4, HES5,
HES6, HES7, HEY1,
HEY2, ITGB3BP
notch signaling, negative
regulation of neuron
diﬀerentiation
NRF1 (Nuclear respiratory
factor 1)
NRF1 response to cold and stress
ZF5F (ZF5 POZ domain zinc
ﬁnger)
ZFP161 negative regulation of
transcription
MYT1 (Myelin transcription
factor)
MYT1, MYT1L, ST18 regulates oligodendrocyte
diﬀerentiation;
downregulation in mature
oligodendrocytes
ZBPF (Zinc binding protein
factors)
ZNF148, ZNF202,
ZNF219, ZNF281
negative regulation of
transcription; cellular defense,
lipid metabolism
GCMF (Chorion-speciﬁc
transcription factors with a
GCM DNA binding domain)
GCM1, GCM2 astrocyte fate, anatomical
structure morphogenesis,
absence of GCM: neuron
development; presence
of GCM: development of
neurons and glia (astrocytes)
MTF1 (Metal induced
transcription factor)
MTF1, MTF2 response to metal ion, positive
regulation of transcription
ZFXY (Zfx and Zfy
- transcription factors
implicated in mammalian
sex determination)
ZFX endocrine system, embryonic
structures
promoter plasmid was ampliﬁed generating a TFBS mutation containing plasmid. Finally, the
template plasmid was enzymatically degraded as schematically illustrated in Figure 3.15.
Except for the ZFXY site, all TFBS were located in the region 300 bp to 604 bp upstream of the
start codon. According to the results of the reporter gene assay performed with the 5’ deletion
mutants, in which promoter activity of the 300 bp construct was slightly lower compared to the
604 bp construct, it was expected that the conserved TFBS exert at least in part activating
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Figure 3.15.: Site-directed mutagenesis of selected transcription factor binding sites.
PCR-based ampliﬁcation of the template plasmid using primers introducing the
respective mutation was followed by subsequent enzymatic degradation with the
restriction endonuclease dpnI, which recognizes DNA adenine methylase (dam)
methylation of DNA introduced during replication in E. coli.
eﬀects on promoter activity, i.e. that mutation of these binding sites would decrease the
activity of the 604 bp promoter construct. Surprisingly, the promoter activity was found to
be increased when the conserved transcription factor binding sites for MYT1, HESF, GCMF,
ZBPF, and MTF1 were mutated in the 604 bp TMEM132D promoter construct (Figure 3.17 A;
MYT1del: t = 3.048, df = 34, p = 0.004; HESFdel: t = 2.990, df = 34, p = 0.005: HESFmut:
t = 1.807, df = 25, p = 0.083; GCMF/ZBPF: t = 3.059, df = 34, p = 0.004; MTF1: 2.094,
df = 34, p = 0.044), indicating an inhibitory eﬀect of these binding sites on TMEM132D
promoter activity. Mutation of binding sites for ZF5F and ZFXY, however, had no eﬀect
on promoter activity (Figure 3.17 A; ZF5Fmut: t = 0.367, df = 25, p = 0.717; ZFXYdel:
t = 0.991, df = 34, p = 0.329). Two conserved NRF1 sites were mutated, the more distal
one increased promoter activity (Figure 3.17 A; NRF1mut: t = 2.065, df = 25, p = 0.049),
while the more proximal did not inﬂuence it (Figure 3.17 A; NRF1del: t = 0.691, df = 34,
p = 0.494).
To further conﬁrm these results, selected transcription factors (TF) binding to the conserved
binding sites (TF → TFBS: MYT1L → MYT1, HES1 → HESF, NRF1 → NRF1, ZFP161 →
ZF5F, ZNF219 → ZFBP, GCM1 → GCMF, MTF1 → MTF1, ZFX → ZFXY) were cloned
into a pcDNA3.1(-) expression vector and were overexpressed together with the wildtype
604 bp TMEM132D promoter construct in MO3.13 cells to study the inﬂuence of these
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Figure 3.16.: Cloning strategy of transcription factor expression plasmids. The
coding sequence (open reading frame) of the human HES1, NRF1, ZFP161,
ZNF219, MTF1, or ZFX gene was inserted into the multiple cloning site (MCS) of
the pcDNA3.1(-) vector. A constitutively active CMV promoter element (PCMV )
is located upstream of the MCS, and a bovine growth hormone polyadenylation
(BGHpA) is located downstream of the MCS. The vector backbone additionally
contains an ampicillin resistence gene for selective ampliﬁcation in E. coli, as
well as a neomycin resistence gene for selective ampliﬁcation in eukaryotic
cells. Additional abbreviations used: f1 ori - origin of replication derived from
ﬁlamentous phage; SV40 ori - simian virus 40 promoter and origin of replication;
SV40pA - simian virus 40 polyadenylation site; pUC ori - origin of replication of
pUC vector
transcription factors on TMEM132D promoter activity in a reporter gene assay (Figure 3.17
B). For cloning, the coding sequence of human HES1, NRF1, ZFP161, ZNF219, MTF1, and
ZFX was ampliﬁed from reverse transcribed human mRNA and inserted into the multiple
cloning site of the pcDNA3.1(-) vector (Figure 3.16). Expression plasmids for MYT1L and
GCM1 were purchased from PlasmID (see section 2.3.3). The subsequently performed reporter
gene assay conﬁrmed the inhibitory eﬀect of MYT1L/MYT1, HES1/HESF, ZNF219/ZFBP,
GCM1/GCMF, and MTF1/MTF1 that was suggested previously by the TFBS mutation
analysis (Figure 3.17 B; MYT1L: t = 5.863, df = 13, p < 0.001; HES1: t = 4.008, df = 25,
p < 0.001; ZNF219: t = 3.301, df = 25, p = 0.003; GCM1: t = 6.518, df = 13, p < 0 .001;
MTF1: t = 4.735, df = 16, p < 0.001). Additionally, the inactivity of the ZF5F site, as shown
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Figure 3.17.: Reporter gene assays in MO3.13 cells analyzing the eﬀect of conserved
transcription factor binding sites. (A) Left site: scheme of transcription
factor binding site mutation, empty boxes indicate deletion mutations, x
indicates point mutations. Right site: results of the reporter gene assay showing
the promoter activity of the mutated TMEM132D promoter constructs. (B)
Overexpression of transcription factors binding to the respective binding sites
and measurement of the activity of the wildtype T604 promoter construct in the
reporter gene assay. Promoter activity (after normalization to SV40 promoter
activity) is represented as percentage of the wildtype T604 promoter construct
set at 100 %. Values plotted are means ± SEM of 3 independent experiments
in triplicates. Statistical signiﬁcance was calculated using student’s t-test to
compare each group to the control group, i.e. the wildtype T604 TMEM132D
promoter, and is indicated by *** p < 0.001, ** p < 0.01, * p < 0.05.
by overexpression of ZFP161, was conﬁrmed (Figure 3.17 B; ZFP161: t = 0.395, df = 25,
p = 0.696). In contrast to the results of the TFBS mutation analyses (Figure 3.17 A), NRF1
overexpression resulted in increased promoter activity (Figure 3.17 B; NRF1: t = 2.276,
df = 15, p = 0.038) and ZFX overexpression led to a weak decrease of promoter activity
(Figure 3.17 B; ZFX: t = 2.778, df = 16, p = 0.013), although the previously performed
mutation of the ZFX site had no eﬀect on promoter activity.
The binding sites analyzed above were all located between 604 bp and 300 bp and thus cannot
elicit the prominent diﬀerences in promoter activity between the T829 and T604 constructs as
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Figure 3.18.: Additional transcription factor binding sites in the TMEM132D
promoter sequence. The core sequence of additional transcription factor
binding sites in the TMEM132D promoter identiﬁed with Matinspector and
TFSEARCH (see also Figure 3.7) is highlighted by red frames. The start sites
of the 5’ deletion mutants are indicated. The start codon is printed in bold.
well as between the T300 and T210 constructs. To address these promoter subregions potential
TFBS identiﬁed by Matinspector were compared with TFBS found by the alternative tool
TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html), as illustrated in Figure
3.7. The TFBS identiﬁed in both Matinspector and TFSEARCH analysis (summarized in
Table 3.2 and Figure 3.18) were then mutated by site-directed mutagenesis as described above
(Figure 3.15), and reporter gene assays were performed.
As expected from the reporter gene assays with the progressive 5’ deletion analysis (Figure
3.13), mutation of the NFKB/MZF1 site as well as the SP1 site in the T829 promoter construct
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Table 3.2.: Additional transcription factor binding sites in the TMEM132D
promoter sequence identiﬁed with Matinspector and TFSEARCH.
Presented are names and abbreviations of the identiﬁed transcription factor families
as well as the description of their biological functions according to the respective
gene ontology (GO)-terms.
Transcription factor family Transcription
factors
Description
MZF1 (Myeloid zinc ﬁnger 1) MZF1 hematopoiesis
EGRF (Early growth response
family)
EGR1, EGR2,
EGR3, EGR4,
WT1
diﬀerentiation, mitogenesis
NFKB (Nuclear factor of kappa
light polypeptide gene enhancer in
B-cells)
NFKB1,
NFKB2
negative regulation of cytokine
production, toll-like receptor
signaling pathway
SP1 (Speciﬁcity protein 1) SP1 trophectodermal cell diﬀerentiation,
ossiﬁcation, liver development
HAML (Human acute
myelogenous leukemia factors)
AML1, AML2,
AML3
induction of apoptosis, axon
guidance, cell proliferation
resulted in an increased promoter activity (Figure 3.19 A; NFKBmut: t = 3.273, df = 16,
p = 0.005; SP1mut: t = 4.801, df = 16, p < 0.001). In contrast, mutating the EGRF site
led to a weak but signiﬁcant decrease in promoter activity (Figure 3.19 A; EGRF: t = 2.700,
df = 16, p = 0.016). Nevertheless, these analyses suggest that overall the TFBS sites in the
region between T829 and T604 analyzed here have an inhibitory eﬀect on promoter activity,
which could explain the increased promoter activity of the T604 construct compared to the
T829 construct (Figure 3.13). However, this does not exlude that also other binding sites that
have not been analyzed here modulate TMEM132D promoter activity. Next, transcription
factors binding to these TFBS were overexpressed: all transcription factor expression plasmids
used in this assay were purchased from PlasmID (see section 2.3.3). Overexpression of MZF1,
NFKB1, and SP1 together with the wildtype T829 promoter construct conﬁrmed the inhibitory
eﬀect of these transcription factors on TMEM132D promoter activity (Figure 3.19 B; MZF1:
t = 14.78, df = 22, p < 0.001; NFKB1: t = 10.26, df = 22, p < 0.001; SP1: t = 11.22,
df = 22, p < 0.001). The activating eﬀect of the EGFR site, however, could not be validated
by overexpressing WT1 (Figure 3.19 B; WT1: t = 2.681, df = 22, p = 0.014). To analyze the
strong decrease in promoter activity of the T210 construct compared to the T300 construct
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Figure 3.19.: Reporter gene assays in MO3.13 cells analyzing the eﬀect of additional
transcription factor binding sites. (A) Left site: scheme of transcription
factor binding site mutation. Right site: results of the reporter gene assay
showing the promoter activity of the mutated TMEM132D promoter constructs.
(B) Overexpression of transcription factors binding to the respective binding
sites and measurement of the activity of the wildtype T829 or T300 promoter
construct in the reporter gene assay. Promoter activity (after normalization to
SV40 promoter activity) is represented as percentage of the wildtype T829 or
T300 promoter construct set at 100 %. Values plotted are means ± SEM of 3
independent experiments in triplicates. Statistical signiﬁcance was calculated
using student’s t-test to compare each group to the control group, i.e. the
wildtype TMEM132D promoter activity, and is indicated by *** p < 0.001,
** p < 0.01, * p < 0.05.
that has been observed in the 5’ deletion analysis (Figure 3.13), the HAML binding site
was mutated in the T300 construct resulting in reduced promoter activity (Figure 3.19 A;
HAMLmut: t = 5.761, df = 16, p < 0.001). This indicates that this activating TFBS might be
responsible for the drop of promoter activity of the T210 promoter construct. Overexpression
of HAML, however, did not conﬁrm this eﬀect (Figure 3.19 B; HAML: t = 2.987, df = 16,
p = 0.009).
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Taken together, reporter gene analysis of the 5’ sequence upstream of the start codon and
mutation of TFBS as well as overexpression of the respective transcription factors revealed
several candidate TFBS important for regulation of TMEM132D gene expression, namely
MYT1, HES1, ZNF219, MTF1, MZF1, NFKB1, and SP1, while the other transcription
factors analyzed here either did not inﬂuence TMEM132D promoter activity (ZFX, ZFP161)
or exhibited variable, contradictory results in the TFBS mutation analysis and the TF
overexpression analysis (NRF1, EGRF, HAML).
3.4. Transcriptional regulation of TMEM132D during
oligodendrocyte diﬀerentiation
Next, the 13 transcription factors analyzed above, namely MYT1, HES1, ZNF219, GCM1,
MTF1, MZF1, NFKB1, SP1, ZFX, ZFP161, NRF1, WT1, and HAML were studied for their
role in regulating TMEM132D expression in the context of oligodendrocyte diﬀerentiation
in a cell culture assay. It has been shown that TMEM132D is expressed in mature
oligodendrocytes, while immature oligodendrocytes lack TMEM132D expression (Nomoto
et al., 2003). To conﬁrm this ﬁnding the human oligodendrocyte cell line MO3.13 was treated
with serum-free medium containing 100 nM phorbol 12-myristate 13-acetate (PMA) for 3
days, which has been previously shown to eﬀectively induce diﬀerentiation in this cell line
(Buntinx et al., 2003). Diﬀerentiation was reﬂected by a substantially changed morphology
mainly characterized by the outgrowth of processes and an overall ﬂattening of the cells
(Figure 3.20).
As expected from the ﬁndings of Nomoto et al. (2003), TMEM132D gene expression was
upregulated in response to PMA treatment (Figure 3.21; t = 4.676, df = 8, p = 0.001).
Next, the expression of transcription factors identiﬁed here to regulate TMEM132D promoter
activity was compared between non-diﬀerentiated and PMA-diﬀerentiated cells. Indeed,
several of the transcription factors identiﬁed as inhibitors of TMEM132D promoter activity,
namely MYT1, HES1, ZNF219, and SP1, were found to be downregulated in diﬀerentiated
MO3.13 cells, which was paralleled by the upregulation of TMEM132D expression in the
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Figure 3.20.: PMA-induced diﬀerentiation of MO3.13 oligodendrocytic cells.
MO3.13 cells were treated with 100 nM PMA to induce diﬀerentiation. After
3 days of treatment, cells were ﬁxed and stained with the ﬂuorescently labeled
cell surface marker wheat-germ-agglutinin (WGA). Nuclei were counterstained
with DAPI (blue). Presented are images of representative cell batches; n = 5
per treatment group from two independent experiments. The scalebar is 50 μm
in (A, B) and 20 μm in (C, D).
diﬀerentiated cells (Figure 3.21; MYT1: t = 3.423, df = 8, p = 0.009; HES1: t = 10.690,
df = 8, p < 0.001; ZNF219: t = 4.604, df = 8, p = 0.002; SP1: t = 2.691, df = 8, p = 0.028).
GCM1 and WT1 could not be detected in MO3.13 cells and all the other detected transcription
factors were not signiﬁcantly altered and thus do not seem to be involved in the oligodendrocyte
diﬀerentiation process (Figure 3.21; MTF1: t = 0.081, df = 8, p = 0.938; NRF1: t = 1.295,
df = 8, p = 0.231; ZFP161: t = 0.244, df = 8, p = 0.813; ZFX: t = 1.556, df = 8, p = 0.158;
NFKB1: t = 1.363, df = 8, p = 0.210; HAML: t = 0.682, df = 8, p = 0.515; MZF1: t = 0.779,
df = 8, p = 0.458). However, they might still have an impact on TMEM132D regulation in
other biological contexts.
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Figure 3.21.: mRNA expression levels of TMEM132D and candidate transcription
factors in diﬀerentiated and non-diﬀerentiated oligodendrocytic
MO3.13 cells. (A) RT-PCR analysis of TMEM132D and the transcription
factors MTF1, MYT1, NRF1, HES1, ZFP161, ZNF219, ZFX, NFKB1, SP1,
HAML, MZF1 in non-diﬀerentiated and PMA-diﬀerentiated MO3.13 cells. (B)
Quantiﬁcation of (A). Expression values were normalized to constitutive GAPDH
expression and are presented as percentage of those of control cells (% of
control). Plotted data are means ± SD, n = 5 from two independent experiments.
Statistical signiﬁcance was calculated using student’s t-test and is indicated by
*** p < 0.001, ** p < 0.01, * p < 0.05.
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Figure 3.22.: Impact of TMEM132D knockdown on oligodendrocyte diﬀerentiation.
(A) RT-PCR analysis of TMEM132D expression in MO3.13 cells treated either
with control or PMA-containing medium and transfected with either control
siRNA or TMEM132D speciﬁc siRNA, n = 3 per treatment group. (B)
Representative images of analyzed samples (n = 3). Microscopic analysis of
cell morphology revealed no inﬂuence of TMEM132D knockdown on MO3.13
diﬀerentiation.
To further analyze the impact of TMEM132D on oligodendrocyte diﬀerentiation, MO3.13
cells were transfected with either TMEM132D siRNA to diminish TMEM132D expression
or with control siRNA, which leaves TMEM132D expression undisturbed, and these
transfected cell batches were compared regarding their diﬀerentiation properties. Although
the siRNA-mediated knockdown clearly reduced, but not completely abolished, TMEM132D
transcript levels in MO3.13 cells by approximately 70 % (Figure 3.22 A), these cells exhibited
no obvious morphological diﬀerences after PMA treatment, i.e. their diﬀerentiation resulted
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in a cellular morphology microscopically indistinguishable from that of diﬀerentiated cells
transfected with control siRNA (Figure 3.22 B). This indicates that either tiny levels of
TMEM132D expression are suﬃcient to mediate oligodendrocyte diﬀerentiation, or, although
TMEM132D expression is upregulated during this diﬀerentiation process, it might not be
absolutely necessary for it - at least in the oligodendrocyte model tested here.
3.5. Summary of Results I
To sum up, experimental analysis of the transcription factor binding sites in the TMEM132D
promoter region predicted in silico revealed eight inhibitory transcriptional regulators of
TMEM132D gene expression, i.e. HES1, MYT1, ZNF219, GCM1, MTF1, NFKB1, MZF1,
and SP1. Employing a cell culture model of oligodendrocyte diﬀerentiation the previously
published increase in TMEM132D gene expression in diﬀerentiated oligodendrocytes (Nomoto
et al., 2003) was conﬁrmed. Furthermore, gene expression levels of a subset of the
identiﬁed inhibitory transcriptional regulators of TMEM132D gene expression, i.e. HES1,
MYT1, ZNF219, and SP1, were found to be decreased in the population of diﬀerentiated
oligodendrocytes suggesting these transcription factors to be essential for the diﬀerentiation
associated upregulation of TMEM132D mRNA levels. The role of TMEM132D in
oligodendrocyte diﬀerentiation, however, remains unclear: searching for conserved protein
domains in silico revealed a conserved cohesin-like domain in the extracellular region of the
TMEM132D protein suggesting a potential role of TMEM132D in cell adhesion processes.
Nevertheless, oligodendrocyte diﬀerentiation could not be prevented by TMEM132D
knock-down, indicating that either the residual TMEM132D levels suﬃce to mediate
diﬀerentiation or that TMEM132D upregulation is not the sole determining factor in the
oligodendrocyte diﬀerentiation process.
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4. Results II: Identiﬁcation of PTSD
candidate proteins in a mouse model of
PTSD
To identify novel PTSD protein biomarkers, expression levels of a set of selected candidate
proteins was compared in diﬀerent brain regions and in the blood of traumatized and mock
treated control mice (PTSD mouse model was introduced in section 1.5.1).
4.1. Behavioral analyses (PTSD mouse model)
Trauma-related symptoms, i.e. the conditioned fear response and the generalized fear response
as well as hyperarousal, were assessed in male C57BL/6NCrl mice 28-30 days after subjecting
them to an electrical footshock or to control treatment (no shock) (Figure 4.1 A), respectively.
As expected and published previously (Siegmund and Wotjak, 2007; Golub et al., 2011),
shocked mice exhibited a PTSD-like syndrome. Here, the behavioral characteristics of this
PTSD-like syndrome are exempliﬁed by showing representative data of mouse batch PTSD I
(see Table 2.2 for an overview of all mouse batches employed in this thesis). In particular,
hyperarousal was assessed by measuring the amplitude of the acoustic startle response to
noise bursts of diﬀerent intensities, namely 50, 75, 90, 105, and 115 dB. The amplitude of
the acoustic startle response was signiﬁcantly increased in shocked mice compared to non
shocked mice (Figure 4.1 B; F1,28shock = 6.39, p = 0.017) and showed an interaction with noise
burst intensity (Figure 4.1 B; F4,116INTxshock = 2.91, p = 0.024), thus conﬁrming previously
published results (Golub et al., 2011). The generalized fear response was tested by measuring
the freezing response in two experimental contexts diﬀering in several features from the shock
context. As expected, shocked mice exhibited a signiﬁcantly increased freezing response in
both environments, i.e. ﬁrst, in a neutral context diﬀering completely from the shock context
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Figure 4.1.: Behavioral analyses in the PTSD mouse model. Course of experiment:
C57BL/6NCrl mice were subjected to a single electric footshock and behavioral
testing was performed on days 28-30 (A-E) or on days 59-61 (F-J): To assess
hyperarousal the acoustic startle response (ASR) was measured at 50 dB
(background, BG), 75, 90, 105, and 115 dB (B,G). Fear generalization was
assessed by measuring the freezing response both in a neutral context (C,H)
and in a grid context similar to the shock chamber (D,I). The conditioned fear
response was tested by measuring the freezing response in the shock context (E,J).
Freezing duration was normalized to the 3 min observation intervals (% freezing).
Presented data are means ± SEM, n = 16 (Batches PTSD I and V, see Table
2.2). Statistical analysis was performed using student’s t-test and, in case of the
acoustic startle response (ASR), using two-way repeated measures ANOVA and
is indicated by t p < 0.1, * p < 0.05, ** p < 0.01, *** p < 0.001. Figure adopted
from (Herrmann et al., 2012)
88
4.2. Screening for PTSD candidate molecules
(Figure 4.1 C; t = 7.442, df = 29, p < 0.001) and second, in an experimental context displaying
the metal grid as a dominant reminder of the shock context (Figure 4.1 D; t = 8.582, df = 28,
p < 0.001), indicating an increased generalized fear response. Finally, the conditioned fear
response, assessed by analyzing the freezing response in the shock context, was increased in
shocked mice (Figure 4.1 E; t = 12.36 df = 29, p < 0.001), conﬁrming previously published data
(Siegmund and Wotjak, 2007). Taken together, 28 days after exposure to the electric footshock,
shocked mice exhibited a PTSD-like syndrome, i.e. an increased acoustic startle response
as well as increased conditioned and generalized fear responses. For subsequent molecular
analyses, these mice were sacriﬁced 30 days after termination of the behavioral testing, i.e. on
day 60 after footshock. In a diﬀerent batch of mice, batch PTSD V, the PTSD-like behavior,
i.e. increased acoustic startle response as well as increased generalized and conditioned fear
responses, was demonstrated to persist for at least 60 days after footshock (Figure 4.1 G,
acoustic startle response d59-61: F1,28shock = 21.490, p < 0.001; F4,140INTxshock = 4.710,
p = 0.001; Figure 4.1 H, neutral context d59-61: t = 4.423, df = 28, p < 0.001; Figure 4.1
I, grid context d59-61: t = 1.787, df = 28, p = 0.085; Figure 4.1 J, shock context d59-61:
t = 4.868, df = 23, p < 0.001).
4.2. Screening for PTSD candidate molecules
Potential candidate proteins were selected and compared between shocked and non shocked
mice at diﬀerent time-points after shock and in diﬀerent brain regions. First, expression levels
of neurostructural marker proteins and proteins of the glutamatergic system, which was found
associated both with animal models of stress (Knox et al., 2010) and animal models of anxiety
(Riaza Bermudo-Soriano et al., 2012) as well as with human PTSD (Heresco-Levy et al., 2009),
were analyzed. Finally, in the last part of this section a serendipitous ﬁnding of a potential
novel immune system associated candidate protein for PTSD is described.
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4.2.1. Neurostructural proteins
The analyzed neurostructural proteins included synapsin and synaptophysin, two presynaptic
vesicle proteins that have been previously found to be regulated in various animal models
of stress (Adlard et al., 2011; Afadlal et al., 2010; Aisa et al., 2009; Alfonso et al., 2006;
Elizalde et al., 2010; Sterlemann et al., 2010), as well as the postsynaptic protein homer
1b/c, the dendritic marker MAP-2, and the pan-neuronal cytoskeleton protein neuroﬁlament
H that have so far been hardly studied in the context of stress. Protein expression levels were
examined in the hippocampus and prefrontal cortex, two brain regions known to be implicated
in the neurocircuitry of PTSD (see section 1.2.4), as well as in the cerebellum (CER), which
is supposed not to be involved in the PTSD pathogenesis.
4.2.1.1. Synapsin and synaptophysin protein expression is diﬀerentially regulated in
mice exposed to repetitive acute stress
In pilot experiments, male 129SvJ/C57BL/6 mice were subjected to repetitive acute stressors,
i.e. diﬀerent restraint as well as combined restraint and forced swim stressors as illustrated
in Figures 4.2 and 4.3, and the expression levels of the presynaptic vesicle proteins synapsin
Ia-b/IIa and synaptophysin were analyzed in the hippocampus, prefrontal cortex, and in the
cerebellum of stressed and mock treated mice.
The synapsin protein family, comprising synapsin Ia-b, IIa-b, and IIIa-c in the adult
mammalian brain (Cesca et al., 2010), is known to be involved in the organization of
presynaptic vesicle pools. In particular, synapsins attach the vesicles to each other and to the
actin cytoskeleton. Upon phosphorylation of synapsin the vesicles detach and may fuse with
the membrane of the active zone to release their neurotransmitter content into the synaptic
cleft (Fdez and Hilﬁker, 2006). The role of synaptophysin, however, is less clear. So far, it is
believed to play a role in synaptic vesicle endocytosis (Gordon et al., 2011).
In a ﬁrst experiment, to analyze short term eﬀects of acute stress, male 129SvJ/C57BL/6
mice were exposed to a 15-min restraint stressor or control treatment and sacriﬁced 24 h later
(Figure 4.2 A). Western blot analyses of synapsin Ia-b/IIa and synaptophysin expression in the
hippocampus (HC), prefrontal cortex (PFC), and cerebellum (CER) revealed no signiﬁcant
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Figure 4.2.: Synapsin and synaptophysin expression 24 h after exposure to acute
restraint stress. 129SvJ/C57BL/6 mice were subjected to a 15-min restraint
stressor and sacriﬁced 24h later (A). Hippocampus (HC), prefrontal cortex
(PFC), and cerebellum (CER) were isolated from sacriﬁced mice for subsequent
western blot analysis (WB) of synapsin Ia-b/IIa (B) or synaptophysin (C)
expression levels: depicted are representative western blots. Graphs show
relative expression levels of synapsin Ia-b/IIa or synaptophysin after normalization
to glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) presented in percent of
those of non stressed mice (set at 100 %). Plotted data represent means ±
SEM, n = 9 (batch Acute Restraint Stress, RS0, see Table 2.2), 2-3 technical
replicates. Statistical analysis was performed using student’s t-test, indicated are
only signiﬁcant changes: * p < 0.05.
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expression level changes of any protein tested (Figure 4.2 B, C; HC – synapsin Ia-b/IIa:
t = 1.242, df = 16, p = 0.233; PFC – synapsin Ia-b/IIa: t = 0.035, df = 16, p = 0.972; CER
– synapsin Ia-b/IIa: t = 1.402, df = 16, p = 0.180; HC – synaptophysin: t = 0.633, df = 16,
p = 0.535; PFC – synaptophysin: t = 0.098, df = 16, p = 0.922), except for a slight signiﬁcant
decrease of synaptophysin in the cerebellum of stressed mice (Figure 4.2 C; t = 2.850, df = 12,
p = 0.015).
In a second experiment, medium-term eﬀects of combined restraint and forced swim stressors
were addressed. The batch of mice employed here for the analysis of synaptic protein
expression has previously been investigated for hippocampal expression of glucocorticoid
receptor and FKBP51, which was published recently (Touma et al., 2011). Here, male
129SvJ/C57BL/6 mice were exposed to a 15-min restraint stressor and to a 6-min forced
swim stressor (FSS) followed by an additional exposure to a 6-min FSS 24 h later (Figure
4.3 A, RSI paradigm). A diﬀerent group of mice was exposed to a 60-min restraint stressor
combined with a 6-min forced swim stressor 24 h later (Figure 4.3 A, RSII paradigm), which
was considered to be more stressful as indicated by higher plasma corticosterone levels (Touma
et al., 2011). In both paradigms, mice were sacriﬁced 8 days after stress exposure and
hippocampus, prefrontal cortex, and cerebellum were dissected (Figure 4.3 A). Western blot
analysis revealed a signiﬁcantly decreased protein expression of synapsin Ia-b/IIa in both
the hippocampus and the prefrontal cortex of mice subjected to the RSI or RSII paradigm
compared to mock treated control mice (Figure 4.3 B; HC: F2,17 = 8.626, p = 0.003; PFC:
F2,17 = 8.813, p = 0.002). In the cerebellum, synapsin expression was not altered (Figure
4.3 B; CER: F2,17 = 1.925, p = 0.180). In contrast, synaptophysin protein expression in
the hippocampus and the prefrontal cortex was not aﬀected by the RSI stress paradigm,
and interestingly, synaptophysin protein levels increased 8 days after subjecting the mice to
the RSII stress paradigm (Figure 4.3 C; HC: F2,17 = 12.62, p < 0.001; PFC: F2,17 = 8.813,
p = 0.002). As expected, synaptophysin expression was not altered in the cerebellum of
mice subjected to the RSI or the RSII paradigm compared to mock treated control mice
(Figure 4.3 C; CER: F2,17 = 0.507, p = 0.611).
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Figure 4.3.: Synapsin and synaptophysin expression 8 days after exposure to
combined restraint and forced swim stress paradigms. To study
medium-term eﬀects, 129SvJ/C57BL/6 mice were stressed with either a 15-min
restraint stressor followed by two intervals of forced swim stress (FSS) (RSI
paradigm) or by a 60-min restraint stressor followed by one interval of FSS (RSII
paradigm) and sacriﬁced 8 days later (A). Hippocampus (HC), prefrontal cortex
(PFC), and cerebellum (CER) were isolated from sacriﬁced mice for subsequent
western blot analysis (WB) of synapsin Ia-b/IIa (B) or synaptophysin (C)
expression levels. Shown are representative western blots and graphs as described
in Figure 4.2. Plotted data represent means± SEM, n = 6 (batch Repetitive Acute
Stress, RSI/RSII, see Table 2.2), 2-3 technical replicates. Statistical analysis
was performed using one-way ANOVA and Bonferroni post-hoc tests. Signiﬁcant
changes of Bonferroni post-hoc tests are indicated by * p < 0.05, **p < 0.01, ***p
< 0.001.
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4.2.1.2. Traumatic footshock stress reduces hippocampal synaptic protein expression
Synapsin and synaptophysin expression analyses presented above point at an involvement of
the synapse or synaptic plasticity in the brain’s adaptation processes to repetitive acute stress.
Reduction of synaptic proteins might also contribute to the hippocampal shrinkage that was
recently found in footshocked mice of the PTSD mouse model employed here (Golub et al.,
2011). Motivated by this assumption and by the ﬁndings of the pilot experiments, expression
levels of synaptic proteins were analyzed in the PTSD mouse model. Traumatized and control
mice were sacriﬁced either 2, 28, or 60 days after footshock or control treatment. Then,
hippocampus, prefrontal cortex, and cerebellum were dissected for subsequent western blot
analysis (Figure 4.4 A), which revealed that cerebral synapsin Ia-b/IIa levels were reduced
in traumatized mice. Interestingly, this was true only for the hippocampus, but not for the
prefrontal cortex and, as expected, also not for the cerebellum (Figure 4.4 B-D; d2: PFC
t = 0.603, df = 10, p = 0.560, CER t = 0.398, df = 10, p = 0.698; d28: PFC t = 1.279,
df = 10, p = 0.229, CER t = 0.044, df = 10, p = 0.965; d60: PFC t = 1.408, df = 22,
p = 0.173, CER t = 0.540, df = 10, p = 0.601). Downregulation of hippocampal synapsin
levels in shocked mice were detectable already 2 days after footshock (Figure 4.4 B; t = 2.631,
df = 10, p = 0.025). The hippocampal synapsin reduction in traumatized mice maintained
in the long-term, namely until day 60 after shock, although on day 28 after footshock only a
trend towards a reduction was measured (Figure 4.4 C, D; d28: t = 1.963, df = 10, p = 0.078;
d60: t = 4.332, df = 22, p < 0.001).
To analyze if traumatic stress induces a speciﬁc downregulation of synapsin or if it rather
results in an overall alteration of the synaptic structure, additional synaptic marker proteins
were tested. Since synapsin Ia-b/IIa expression was altered only in the hippocampal region,
and motivated by the ﬁnding that the hippocampal volume is reduced both in traumatized
patients and in footshocked mice of the PTSD mouse model used in this study (Golub et al.,
2011), further analyses concentrated on the hippocampus.
Next, synaptophysin was analyzed in hippocampal lysates prepared from mice sacriﬁced on
days 2, 28, or 60 after footshock. Synaptophysin is located together with synapsin on vesicles of
the presynapse (Wiedenmann and Franke, 1985). Results from the pilot experiments indicated
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Figure 4.4.: Synapsin expression in the PTSD mouse model. (A) C57BL/6NCrl mice
were subjected to a single electric footshock and sacriﬁced either 2, 28, or 60
days later. At each time-point, hippocampus (HC), prefrontal cortex (PFC),
and cerebellum (CER) were isolated for subsequent western blot analysis (WB).
(B–D) Shown are representative western blots of synapsin Ia-b/IIa or, for control,
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) of shocked and non shocked
mice. Graphs show expression levels of synapsin Ia-b/IIa after normalization to
GAPDH presented in percent of those of non shocked mice (set at 100 %). Plotted
data represent means ± SEM, n = 6 for d2 and d28 (batch PTSD I), n = 12 for d60
(batch PTSD I + II, see Table 2.2), 2-3 technical replicates. Statistical signiﬁcance
was calculated using student’s t-test and is indicated by t p < 0.1, * p < 0.05,
*** p < 0.001. Figure adapted from (Herrmann et al., 2012)
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an increased expression of synaptophysin in stressed animals (Figure 4.3). In contrast to those
ﬁndings, the single electric footshock induced a reduction of hippocampal synaptophysin levels
in the long-term: while on day 2 a trend in reduction was detectable (Figure 4.5 B; t = 1.869,
df = 10, p = 0.091), and on day 28 again no signiﬁcant protein level changes were present
(Figure 4.5 B; t = 1.209, df = 10, p = 0.254), synaptophysin levels were signiﬁcantly decreased
on day 60 after footshock (Figure 4.5 B; t = 2.351, df = 10, p = 0.040). These results indicate
that rather than a speciﬁc reduction of synapsin protein levels, overall changes in the synaptic
vesicle number or even in the number of synapses might be induced by the traumatic footshock.
To further explore this, a postsynaptic marker protein, namely homer 1b/c, was analyzed
next. Homer 1b/c is located in the postsynaptic density and is involved in the clustering and
traﬃcking of metabotropic glutamate receptors (mGluR) (Kammermeier, 2006). Western blot
analyses revealed that in hippocampal lysates of traumatized and control mice homer 1b/c
expression was signiﬁcantly decreased on day 60 after footshock (Figure 4.5 C; t = 3.552,
df = 22, p = 0.001), while at earlier time-points no signiﬁcant alterations in homer 1b/c
expression were detected (Figure 4.5 C; d2: t = 1.573, df = 10, p = 0.147; d28: t = 0.259,
df = 8, p = 0.801). Thus, in the long-term not only pre- but also post-synaptic proteins
are reduced suggesting a loss of synaptic structures in mice showing a PTSD-like phenotype.
The fact that all proteins that were found to be reduced on day 60 after footshock were not
signiﬁcantly changed on day 28 after footshock suggests that the behavioral testing on days
28-30 might constitute at least a minor stressor leading to an ampliﬁcation of the stress-induced
molecular alterations.
Next, to obtain more information on the involvement of the diﬀerent hippocampal subregions
in stress-mediated synapsin reduction, immunohistochemical stainings for synapsin I/II were
performed in brain slices of traumatized and control mice sacriﬁced on day 60 after shock
(Figure 4.6). The cornus ammonis area 3 (CA3) and the hilus region of the dentate gyrus
(DG) exhibited the most intense staining, while the CA1 region showed a weaker intensity.
These ﬁndings correspond well with ﬁndings of other rodent studies analyzing hippocampal
synapsin protein expression using immunohistochemistry (Melloni et al., 1993; Vaynman et al.,
2004; Nowicka et al., 2003). The pronounced expression in the CA3 and hilus region of the
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Figure 4.5.: Hippocampal synaptophysin and homer 1b/c expression in the PTSD
mouse model. Synaptophysin and homer 1b/c expression was analyzed in
hippocampal lysates of C57BL/6NCrl mice subjected to a single electric footshock
and sacriﬁced either 2, 28, or 60 days later (A). Shown are representative
western blots of synaptophysin (B) and homer 1b/c (C) or, for control,
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) analyzed in shocked and
non shocked mice. Graphs show relative expression levels after normalization to
GAPDH presented in percent of those of non shocked mice set at 100 %. Plotted
data represent means ± SEM, n = 6 for d2 and d28 (batch PTSD I, see Table
2.2), n = 12 for d60 (batch PTSD I + II)(except for synaptophysin where only
one batch n=6, batch PTSD I was employed), 2-3 technical replicates. Statistical
signiﬁcance was calculated using student’s t-test and is indicated by t p < 0.1,
* p < 0.05. Figure adapted from (Herrmann et al., 2012)
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Figure 4.6.: Immunohistochemical assessment of synapsin expression in the PTSD
mouse model. Shown are representative images (n = 6, batch PTSD II, see Table
2.2) of coronal hippocampal sections from shocked and non shocked mice sacriﬁced
60 days after shock and stained with anti-synapsin I/II antibody followed by a
ﬂuorescently labeled secondary antibody (left panel). Slices were counterstained
with DAPI (middle panel). The overlay of DAPI and anti-synapsin stained
sections is presented in the right panel (merge). Abbreviations used: Cornu
ammonis areas 1 and 3 (CA1, CA3), dentate gyrus (DG), hilus region (hi). Figure
adopted from (Herrmann et al., 2012)
DG furthermore suggests that these regions possibly contribute more than other hippocampal
areas to the trauma stress-induced reduction of hippocampal synapsin expression and possibly
also to the trauma stress-induced hippocampal volume reduction.
4.2.1.3. Hippocampal expression of neuroﬁlament H, but not MAP-2, is reduced in
mice subjected to a single electric footshock
To investigate if a loss of neurons contributes to the trauma stress-induced hippocampal
volume loss, the pan-neuronal marker protein neuroﬁlament H and the dendritic marker
protein microtubule-associated protein 2 (MAP-2) were analyzed. Both proteins constitute
major elements of the neuronal cytoskeleton and are therefore crucial for the neuronal cell
morphology. Interestingly, a slight reduction in neuroﬁlament H expression was evident on
day 2 after footshock (Figure 4.7 B; t = 2.422, df = 10, p = 0.035), while no changes on day
28 (Figure 4.7 B; t = 0.537, df = 10, p = 0.603), and a statistical trend towards a reduction
on day 60 after footshock (Figure 4.7 B; t = 1.873, df = 21, p = 0.075) were detectable.
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Figure 4.7.: Hippocampal neuroﬁlament H and MAP-2 expression in the PTSD
mouse model. Neuroﬁlament H and MAP-2 expression was analyzed
in hippocampal lysates of C57BL/6NCrl mice subjected to a single electric
footshock and sacriﬁced either 2, 28, or 60 days later (A). Shown are
representative western blots of neuroﬁlament H (B) and MAP-2 (C) or, for control,
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) analyzed in shocked and
non shocked mice. Graphs show relative expression levels after normalization to
GAPDH presented in percent of those of non shocked mice set at 100 %. Plotted
data represent means ± SEM, n = 6 for d2 and d28 (batch PTSD I, see Table
2.2), n = 12 for d60 (batch PTSD I + II), 2-3 technical replicates. Statistical
signiﬁcance was calculated using student’s t-test and is indicated by t p < 0.1 *
p < 0.05. Figure adapted from (Herrmann et al., 2012)
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In contrast, MAP-2 exhibited no signiﬁcant expression level diﬀerences between shocked and
control mice at any time-point tested (Figure 4.7 C; d2: t = 0.155, df = 10, p = 0.879; d28:
t = 0.495, df = 10, p = 0.631; d60: t = 0.152, df = 22, p = 0.881).
The fact that expression of MAP-2 remains unchanged points at a steady number of
neuronal cells and furthermore implicates that dendritic morphology is not excessively altered.
Neuroﬁlament proteins are enzymatically degraded in synaptic structures (Fasani et al., 2004).
Therefore, the reduction in neuroﬁlament H protein levels probably does not reﬂect a synaptic
loss but rather points at a possible retraction of axonal elements.
Interestingly, the expression of none of the protein analyzed here was altered in traumatized
and control mice sacriﬁced on day 28 after footshock, i.e. in mice that received the electric
footshock on day 0 and were sacriﬁced on day 28 after footshock without further behavioral
testing. In contrast, traumatized mice sacriﬁced on day 60 after footshock and subjected to
behavioral testing on days 28 to 30 after footshock exhibited a signiﬁcantly reduced synaptic
protein and neuroﬁlament H expression suggesting an ampliﬁcation of the molecular alterations
by re-exposure to the shock context. However, as between day 28 and day 60 no additional
stressors were presented, the synaptic protein expression changes persisting until day 60 after
footshock can be regarded as stress-induced and re-exposure triggered long-term molecular
alteration, which in case of homer 1b/c occured with delayed onset.
4.2.1.4. Hippocampal synaptic protein expression correlates with the conditioned and
generalized fear response but not with the acoustic startle response
To get an idea of the impact of the hippocampal synaptic protein loss on the development
of distinct PTSD symptoms, a correlation analysis was performed according to previously
published procedures (Wu et al., 2007; Zink et al., 2010). In particular, by calculating the
Pearson correlation coeﬃcients, the intensity of the freezing behavior in either the shock
context or the grid context (conditioned and generalized fear response, respectively), or the
intensity of the startle response (representing the hyperarousal phenotype) of traumatized and
control mice assessed on days 28-30 after footshock was correlated with the protein expression
values of synapsin Ia-b/IIa, synaptophysin, or homer 1b/c assessed on day 60 after footshock.
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Figure 4.8.: Correlation of PTSD-like symptoms with hippocampal synaptic protein
expression. Intensities of PTSD-like behaviors on days 28-30 after shock, i.e.
the conditioned fear response, the generalized fear response, and the acoustic
startle response (ASR), were plotted against the relative day-60 expression levels
(% of no shock) of synapsin Ia-b/IIa (A), synaptophysin (B), and homer 1b/c
(C) of both shocked and non shocked mice. Freezing duration was normalized to
the 3 min observation intervals (% freezing). Pearson correlation coeﬃcients (r)
were calculated, followed by a student’s t-test (p); n = 12 per group for synapsin
Ia-b/IIa and homer 1b/c (batch PTSD I + II, see Table 2.2), n = 6 per group for
synaptophysin (batch PTSD I). Figure adapted from (Herrmann et al., 2012)
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Plotted protein expression values of each mouse were normalized to the mean expression value
of the group of non shocked mice (Figure 4.8; depicted as % of no shock). The analysis revealed
a statistically signiﬁcant negative correlation of the intensity of the conditioned fear response
with the expression of all synaptic proteins analyzed (Figure 4.8; synapsin Ia-b/IIa: r = -0.630,
p = 0.001; synaptophysin: r = -0.657; p = 0.020; homer 1b/c: r = -0.626; p = 0.001).
Furthermore, the analysis detected also a signiﬁcant negative correlation of the intensity of the
generalized fear response with the protein expression levels of both synapsin and synaptophysin
(Figure 4.8; synapsin Ia-b/IIa: r = -0.624, p = 0.003; synaptophysin: r = -0.621, p = 0.031).
The correlation of homer 1b/c expression with the intensity of generalized fear response
was weaker, but still revealed a trend (Figure 4.8; r = -0.413; p = 0.098). In contrast,
the expression of neither protein correlated with the hyperarousal phenotype (Figure 4.8;
synapsin Ia-b/IIa: r = -0.200, p = 0.371; synaptophysin: r = -0.048, p = 0.881; homer
1b/c: r = -0.075, p = 0.737). Thus, the reduction of hippocampal synaptic proteins might
diﬀerentially impact on the distinct symptoms of the PTSD-like syndrome in mice.
4.2.1.5. Chronic ﬂuoxetine treatment increases synaptic vesicle protein expression in
mice subjected to a single electric footshock
Chronic ﬂuoxetine treatment has been previously shown to eﬀectively ameliorate PTSD-like
symptoms in shocked mice of the PTSD mouse model employed here (Siegmund and Wotjak,
2007). As ﬂuoxetine treatment has additionally been reported to increase synaptophysin
expression in a mouse model of learned helplessness (Reinés et al., 2008), it was investigated
next whether chronic ﬂuoxetine treatment is able to repair the footshock-elicited loss of
hippocampal synaptic proteins. For this purpose, shocked mice were subjected to either
20 mg/kg per day ﬂuoxetine treatment via the drinking water or control treatment (normal
tap water) for 4 weeks starting the day after application of the footshock (Figure 4.9 A). The
eﬃcacy of ﬂuoxetine treatment was tested by measuring the freezing response in response
to a neutral tone in the neutral context on day 28 after footshock. As expected, ﬂuoxetine
treatment reduced the generalized fear response on day 28 after footshock (Figure 4.9 B:
t = 7.516, df = 28, p < 0.001). Then, the ﬂuoxetine dose was halved for three more
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Figure 4.9.: Fluoxetine treatment of shocked mice ameliorates PTSD-like behavior.
(A) Course of experiment: C57BL/6NCrl mice were subjected to a single electric
footshock on day 0 and subsequently received 20 mg/kg/d ﬂuoxetine or control
treatment. On day 28, the generalized fear response was assessed (B) during
presentation of a neutral tone in the neutral context. After a 4-week washout
period, mice were tested on days 59-61 for their acoustic startle response, the
generalized, and conditioned fear response (C). Presented data are means ± SEM,
n = 16 (ctrl), n = 14 (ﬂuox) (batch Fluoxetine in PTSD, see Table 2.2). Statistical
signiﬁcance was calculated by two-way ANOVA (startle response) or student’s
t-test (freezing response) and is indicated by * p < 0.05, ** p < 0.01, *** p
<0.001. Figure adapted from (Herrmann et al., 2012)
days before discontinuing the ﬂuoxetine treatment. PTSD-like behavior was tested 4 weeks
later on days 59 to 61 after footshock. As expected, ﬂuoxetine treatment reduced the
acoustic startle response (Figure 4.9 C; two-way ANOVA: F1,112fluoxetine = 2.072, p = 0.161;
F4,112INT = 56.54, p < 0.001; F4,112INTxfluoxetine = 4.325, p = 0.003; Bonferroni post-hoc
test, 115 dB: t = 3.474, p < 0.01) and both generalized (Figure 4.9 C; neutral cylinder:
t = 3.475, df = 28, p = 0.002, grid hexagon: t = 2.607, df = 28, p = 0.015) and conditioned
fear responses (Figure 4.9 C; shock chamber t = 4.736, df = 23, p < 0.001).
Analysis of hippocampal protein expression of the control or ﬂuoxetine treated shocked
mice on day 74 after footshock revealed a signiﬁcant upregulation of synapsin Ia-b/IIa
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Figure 4.10.: Fluoxetine treatment of shocked mice increases hippocampal
presynaptic protein expression. (A) Course of experiment, see
legend of Figure 4.9 for detailed explanation of behavioral analyses.
Representative immunoblots of all candidate proteins and, for control,
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) analyzed in hippocampal
lysates of footshocked control (ctrl) or ﬂuoxetine (ﬂuox) treated mice,
respectively. Graphs show relative expression levels of synapsin Ia-b/IIa (B),
synaptophysin (C), homer 1b/c (D), neuroﬁlament H (E), and MAP-2 (F) after
normalization to GAPDH 74 days after shock in the hippocampus of footshocked
control and footshocked ﬂuoxetine treated mice, respectively. Candidate protein
expression levels of ﬂuoxetine treated mice are presented in percent of those
of control mice set at 100 % (% of control). Plotted data represent means ±
SEM, n = 6 (batch Fluoxetine in PTSD, see Table 2.2), 2-3 technical replicates.
Statistical signiﬁcance was calculated using student’s t-test and is indicated by
* p < 0.05, *** p < 0.001. Figure adapted from (Herrmann et al., 2012)
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and synaptophysin, while the expression of homer 1b/c, neuroﬁlament H, and MAP-2 was
not altered signiﬁcantly (Figure 4.10; synapsin Ia-b/IIa: t = 2.929, df = 10, p = 0.015;
synaptophysin: t = 5.239, df = 10, p < 0.001; homer 1b/c: t = 1.150, df = 10, p = 0.277;
neuroﬁlament H: t = 1.433, df = 10, p = 0.182; MAP-2: t = 0.007, df = 10, p = 0.995). Thus,
the upregulation of presynaptic proteins by ﬂuoxetine treatment paralleled the remission of
PTSD symptoms suggesting that hippocampal synaptic protein loss is causally linked to the
pathogenesis of PTSD-like symptoms in mice.
Taken together, in this section a trauma stress-induced pronounced reduction of hippocampal
synaptic proteins and a decrease in the expression of the cytoskeleton protein neuroﬁlament
H was demonstrated, while further analyses revealed that the expression of the dendritic
marker protein MAP-2 was not altered (summarized in Table 4.1). This points at a trauma
stress-induced hippocampal synaptic protein loss accompanied by axonal degradation, while
the overall number of neuronal cells probably remains constant. Furthermore, decreased
synaptic protein levels correlated with distinct symptoms of the PTSD-like syndrome in mice,
namely with the conditioned and generalized fear response, but not with hyperarousal. Finally,
treatment of shocked mice with ﬂuoxetine counteracted both the PTSD-like behavior and the
footshock-induced reduction of presynaptic proteins.
Table 4.1.: Summary of hippocampal expression changes of neurostructural
proteins. Summarized are signiﬁcant expression changes observed in shocked
(s) versus non shocked (ns) mice of batches PTSD I and II as well as expression
changes observed in footshocked ﬂuoxetine (ﬂuox) versus control (ctrl) treated mice
of batch ‘Fluoxetine in PTSD’. t = statistical trend
PTSD I & II Fluoxetine in PTSD
Candidate protein d2 d28 d60 d74
synapsin Ia-b/IIa s < ns s < ns t s < ns ﬂuox > ctrl
synaptophysin s < ns t s = ns s < ns ﬂuox > ctrl
homer 1b/c s = ns s = ns s < ns ﬂuox = ctrl
neuroﬁlament H s < ns s = ns s < ns t ﬂuox = ctrl
MAP-2 s = ns s = ns s = ns ﬂuox = ctrl
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4.2.2. Glutamate transporters
After the analysis of neurostructural proteins, protein expression levels of glutamate
transporters were analyzed in the PTSD mouse model. Alterations in the glutamatergic
systems are known to play a role in stress-associated and anxiety disorders (Nair and
Singh Ajit, 2008; Sanacora et al., 2012; Riaza Bermudo-Soriano et al., 2012). As glutamate
is the major excitatory neurotransmitter in the brain, the prolonged presence of increased
extracellular glutamate levels can result in toxic eﬀects. Thus, tight regulation of extracellular
glutamate levels is essential. This regulation is mediated mainly by the excitatory amino
acid transporters (EAAT) which remove extracellular glutamate by a Na+- and K+-coupled
mechanism. Most of this glutamate transport is accomplished by the astrocytic glutamate
transporters, that is GLT1 (EAAT2 in humans) in the forebrain and GLAST (EAAT1) in the
cerebellum (Danbolt, 2001). This study concentrated on the analysis of GLT1. In addition
to the vesicular glutamate transporters that are responsible for the uptake of glutamate into
the synaptic vesicles, also neurons express some glutamate transporters in the cell membrane.
The so far best characterized neuronal glutamate transporter, EAAC1 (EAAT3), was analyzed
here (Danbolt, 2001).
4.2.2.1. Hippocampal glutamate transporter expression is reduced in mice subjected to
a single electric footshock
Since signiﬁcant alterations of synapsin expression levels were detected only in the
hippocampus of footshocked mice, and moreover, since this thesis aimed at deciphering the
molecular basis of stress-induced hippocampal shrinkage, most analyses in the thesis at hand
concentrated on the hippocampus, in this chapter on hippocampal glutamate transporter
expression. Protein expression of GLT1 was analyzed in hippocampal lysates of footshocked
and control mice sacriﬁced either 2 days, 28 days, or 60 days after traumatic footshock (batch
PTSD I). GLT1 expression was impressively reduced on day 2 after footshock (Figure 4.11 B;
t = 4.699, df = 10, p < 0.001). However, on day 28 and day 60 after footshock the expression
was not signiﬁcantly altered (Figure 4.11 B; d28: t = 1.666, df = 10, p = 0.126; d60: t = 1.560,
df = 10, p = 0.149).
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Figure 4.11.: Hippocampal glutamate transporter expression in traumatized
and control mice. GLT1 and EAAC1 expression was analyzed in
hippocampal lysates of C57BL/6NCrl mice subjected to a single electric
footshock and sacriﬁced either 2, 28, or 60 days later (A). (B-C)
Shown are representative western blots of GLT1, EAAC1, or, for control,
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) analyzed in shocked and
non shocked mice. Graphs show relative expression levels of GLT1 or EAAC1
after normalization to GAPDH presented in percent of those of non shocked mice
set at 100 %. Plotted data represent means ± SEM, n = 6 (batch PTSD I, see
Table 2.2), 2-3 technical replicates. Statistical signiﬁcance was calculated using
student’s t-test and is indicated by t p < 0.1; * p < 0.05; *** p < 0.001.
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Although the main eﬀect on glutamate clearance is accomplished by the astroglial glutamate
transporters, neuronal glutamate transporter expression was also analyzed. So far, three
neuronal glutamate transporters have been identiﬁed, namely EAAC1 (EAAT3), EAAT4 and
EAAT5. In the adult mammalian brain EAAT4 is predominantly expressed by Purkinje cells
of the cerebellum. In contrast, not much is known on the cellular localization and function of
EAAT5. The third neuronal glutamate transporter EAAC1, however, is mainly expressed in
the hippocampus, cerebellum, and basal ganglia (Danbolt, 2001). As this study focused on
alterations in hippocampal protein expression, the analysis of neuronal glutamate transporters
was restricted to EAAC1. Analysis of EAAC1 expression levels in footshocked and control
mice revealed a trauma stress-induced reduction in EAAC1 protein expression in traumatized
mice on day 2 and day 28 after footshock (Figure 4.11 C; d2: t = 2.398, df = 10, p = 0.037;
d28: t = 2.268, df = 10, p = 0.046), but only showed a trend towards a reduction on day 60
after footshock (Figure 4.11 C; t = 2.207, df = 10, p = 0.051).
4.2.2.2. GFAP protein expression remains unchanged in footshocked mice
As reduced protein levels in GLT1 may also be explained by reduced astrocytic cell numbers,
expression levels of the glial ﬁbrillary acidic protein (GFAP), an astrocyte speciﬁc cytoskeleton
protein, were assessed. However, no changes in hippocampal GFAP expression were detectable
at any time-point analyzed (Figure 4.12 B; d2: t = 1.116, df = 10, p = 0.290; d28: t = 0.666,
df = 10, p = 0.520; d60: t = 0.338, df = 22, p = 0.738) suggesting a stable number of astrocytes
and thus a possibly speciﬁc trauma stress-induced eﬀect on glutamate transporter expression.
Furthermore, the results of the MAP-2 expression analysis presented in section 4.2.1.3 (Figure
4.7), namely that MAP-2 expression remained unchanged after traumatic stress, suggest that
the decreased levels of EAAC1 do not result from reduced neuronal cell numbers.
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Figure 4.12.: Hippocampal GFAP expression in traumatized and control mice.
GFAP expression was analyzed in hippocampal lysates of C57BL/6NCrl mice
subjected to a single electric footshock and sacriﬁced either 2, 28, or 60 days
later (A). (B) Shown are representative western blots of GFAP or, for control,
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) analyzed in shocked and
non shocked mice. Graphs show relative expression levels of GFAP after
normalization to GAPDH presented in percent of those of non shocked mice
set at 100 %. Plotted data represent means ± SEM, n = 6 for d2 and d28 (batch
PTSD I, see Table 2.2), n = 12 for d60 (batches PTSD I, II), 2-3 technical
replicates. Statistical signiﬁcance was calculated using student’s t-test.
4.2.2.3. Fluoxetine treatment increases GLT1 but not EAAC1 and GFAP protein
expression
Finally, it was investigated whether ﬂuoxetine treatment, which has been demonstrated here
to improve PTSD-like symptoms and to increase synaptic protein expression in footshocked
mice (see section 4.2.1.5), also aﬀects glutamate transporter expression. Analyzing the same
hippocampal lysates as in section 4.2.1.5, ﬂuoxetine treatment was found to signiﬁcantly
increase GLT1 expression in footshocked mice (Figure 4.13 B; t = 2.657, df = 10, p = 0.024),
while it did not aﬀect the expression of neither EAAC1 nor GFAP (Figure 4.13 C, D; EAAC1:
t = 0.312, df = 10, p = 0.754; GFAP: t = 0.139, df = 10, p = 0.892).
109
4. Results II: Identiﬁcation of PTSD candidate proteins in a mouse model of PTSD
Figure 4.13.: Expression of glutamate transporter proteins in footshocked ﬂuoxetine
treated and control mice. (A) Course of experiment, see Figure 4.9 for details.
(B-D) Representative western blots of GLT1, EAAC1, GFAP, and, for control,
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) analyzed in hippocampal
lysates of shocked control or ﬂuoxetine (ﬂuox) treated mice sacriﬁced on day
74 after shock. Graphs show relative expression levels after normalization to
GAPDH. Expression levels are presented in percent of those of control mice
set at 100 % (% of control). Plotted data represent means ± SEM, n = 6
(batch Fluoxetine in PTSD, see Table 2.2), 2-3 technical replicates. Statistical
signiﬁcance was calculated using student’s t-test and is indicated by * p < 0.05.
Taken together, the results of the glutamate transporter expression analysis presented here
and summarized in Table 4.2 point towards a trauma stress-induced modulation of the
glutamatergic system.
Table 4.2.: Summary of hippocampal expression changes of glutamate transporter
proteins. Summary of signiﬁcant expression changes observed in shocked (s)
versus non shocked (ns) mice of batch PTSD I and expression changes observed in
shocked ﬂuoxetine (ﬂuox) versus control (ctrl) mice of batch ‘Fluoxetine in PTSD’.
t = statistical trend
PTSD I Fluoxetine in PTSD
Candidate protein d2 d28 d60 d74
GLT1 s < ns s = ns s = ns ﬂuox > ctrl
EAAC1 s < ns s < ns s < ns t ﬂuox = ctrl
GFAP s = ns s = ns s = ns ﬂuox = ctrl
110
4.2. Screening for PTSD candidate molecules
4.2.3. Immune system proteins
As a third group of candidates, proteins associated with the immune system were analyzed
for diﬀerential expression patterns in mice subjected to the electric footshock or control
treatment. Although several lines of evidence suggest a potential role of the immune system in
stress-related disorders (Costa-Pinto and Palermo-Neto, 2010), the eﬀect of the ﬁrst candidate,
immunoglobin G, was found by serendipity.
4.2.3.1. An immunoglobin G immunoreactive band is detected in the C57BL/6 mouse
brain
Using an immunoglobin G (IgG) Fab-speciﬁc anti-mouse antibody in western blot experiments
analyzing murine C57BL/6 total brain tissue samples, a prominent 25 kDa band of unknown
origin was repeatedly detected (Figure 4.14 B). This band possibly represents endogenously
expressed immunoglobin (Ig) light chains, which are known to have a molecular weight of
approximately 25 kD (Schroeder and Cavacini, 2010); this hypothesis is supported by few
studies that have detected immunoglobins in murine brain tissue (Weiner and Chun, 1997;
Yoshimi et al., 2002; Upender et al., 1997; Hazama et al., 2005; Huang et al., 2008). To conﬁrm
this assumption, the western blot analysis was repeated using murine C57BL/6 spleen lysate,
which is known to contain plenty endogenous antibodies. As expected, a similar banding
pattern, i.e. containing the 25 kD band, was found in spleen lysate (Figure 4.14 B). In
addition to the 25 kDa band, a weak 70 kDa band was detected in both the spleen and the
brain lysates, possibly representing a dimer of an Ig light chain (25 kDa) and an Ig heavy
chain (50 kDa). To further validate this ﬁnding of immunoglobin expression in the brain, the
same brain and spleen lysates were analyzed using antibodies speciﬁcally detecting diﬀerent
epitopes of the immunoglobin G molecule. An antibody molecule typically consists of either
two Igκ or Igλ light chains which are linked to two Ig heavy chains determining the isotype
of the antibody (Schroeder and Cavacini, 2010), as illustrated in Figure 4.14 A.
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Figure 4.14.: Immunoglobin expression in total brain and spleen tissue lysate of
wildtype C57BL/6 mice. (A) Schematic drawing of an immunoglobin
molecule. Indicated are the Fab and the Fc regions as well as the heavy chain
(black) and the light chain (grey) that are either of the κ or λ type. The subchains
are connected by disulﬁd bonds (S-S). Western blots using total brain and spleen
lysates of C57BL/6 mice are depicted for IgG Fab (B), IgG Fc (C), Igλ light chain
(D), or Igκ light chain (E) speciﬁc antibodies.
As expected from the analysis of murine C57BL/6 brain and spleen lysates employing the
IgG Fab-speciﬁc antibody (Figure 4.14 B), immunoblot analysis using antibodies speciﬁcally
detecting the Igκ light chain, the Igλ light chain, or the Fcγ heavy chain revealed a comparable
banding pattern of the respective subchains in total brain and spleen lysates of C57BL/6 mice
(Figure 4.14 C-E).
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Figure 4.15.: Immunohistochemical assessment of immunoglobin expression in the
brain. Shown are representative images of the CA1 region in hippocampal slices
of wildtype C57BL/6 mice (n = 2) that were stained with either IgG Fc or the
Igκ light chain speciﬁc antibodies followed by a ﬂuorescently labeled secondary
antibody (middle panel). Slices were counterstained with the nuclear stain DAPI
(right panel). The overlay of the DAPI and anti-IgG Fc or anti-Igκ light chain
stained sections is presented in the left panel (merge). Inserts show a 2-fold
magniﬁcation of the framed area.
To further evaluate the cerebral immunoglobin expression patterns, immunohistochemical
stainings were performed with antibodies detecting the Fcγ heavy chain or the κ light
chain. Remarkably, in both cases the antibodies stained speciﬁc cellular structures exhibiting
numerous branched processes and a small cell body (Figure 4.15).
To identify the cell type in which cerebral IgG expression occurs, immunohistochemical
costainings were performed in brain slices of wildtype C57BL/6 mice using an IgG Fab speciﬁc
antibody and a GFAP speciﬁc antibody staining speciﬁcally astrocytes, which, however,
revealed no colocalization of GFAP with IgG (Figure 4.16). Next, CD31, an endothelial
cell marker, was analyzed for colocalization with IgG. The CD31 speciﬁc antibody stained
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Figure 4.16.: Identiﬁcation of IgG associated cell types. Co-immunostainings were
performed on brain slices of unstressed wildtype C57BL/6 mice (n = 2) aged
18 weeks. The IgG Fab staining (green) was combined with a staining of
either Iba1, CD31, or GFAP (red). All slices were counterstained with the
nuclear stain DAPI (blue). An overlay of the IgG Fab and the respective Iba1,
CD31, or GFAP staining with DAPI is presented in the panels labeled ’merge’,
showing a colocalization of IgG Fab with Iba1 and CD31. Inserts show a 1.5-fold
magniﬁcation of the framed area.
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blood vessels in the brain slices. The blood vessels were also stained with the IgG Fab speciﬁc
antibody resulting in a colocalization of CD31 and IgG in the blood vessels (Figure 4.16). The
small cellular structures of unknown origin that were stained by the IgG Fab speciﬁc antibody,
however, were not stained with the CD31 speciﬁc antibody. This suggests, that in addition
to endothelial cells another cell type in the brain expresses IgG. Finally, costainings using the
IgG Fab speciﬁc antibody together with an antibody detecting the microglial marker protein
Iba1, which is expressed in both resting and activated microglia, were performed. Here, a
clear colocalization of the Iba1 and IgG Fab staining was observed (Figure 4.16). Taken
together, the immunohistochemical analyses performed here identiﬁed IgG to be associated
with microglia and endothelial cells; both of these cell types are known to express the IgG
binding Fcγ receptors (Quan et al., 2009; Montoyo et al., 2009).
4.2.3.2. IgG expression is increased in mice subjected to a single electric footshock
Next, immunoglobin G expression was assessed in hippocampus, prefrontal cortex, and
cerebellum of traumatized and control mice of the PTSD mouse model. Interestingly,
employing the IgG Fab-speciﬁc antibody, on day 2 after application of the traumatic footshock
no changes in hippocampal IgG levels were detectable (Figure 4.17 A; HC d2: t = 0.116,
df = 23, p = 0.909), while at later time-points there was a signiﬁcant increase of IgG in the
hippocampus both on day 28 (Figure 4.17 A; HC d28: t = 2.144, df = 24, p = 0.042) and
on day 60 (Figure 4.17 A; HC d60: t = 2.536, df = 47, p = 0.015). In the prefrontal cortex,
employing the same IgG Fab-speciﬁc antibody, IgG expression did not change signiﬁcantly on
days 2 and 28 (Figure 4.17 B; PFC d2: t = 0.185, df = 24, p = 0.855; PFC d28: t = 0.112,
df = 24, p = 0.912), but increased signiﬁcantly on day 60 (Figure 4.17 B; PFC d60: t = 2.231,
df = 47, p = 0.031). In contrast, using the IgG Fab-speciﬁc antibody no signiﬁcant changes
in IgG levels were detectable in the cerebellum at any time-point analyzed (Figure 4.17 C;
CER d2: t = 0.851, df = 24, p = 0.403; CER d28: t = 1.317, df = 20, p = 0.203; CER d60:
t = 1.510, df = 47, p = 0.138).
Further investigations concentrated on the hippocampal region, where a signiﬁcant increase
was dectable both on day 28 and 60 after footshock. To validate and further characterize
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Figure 4.17.: IgG Fab expression in traumatized and control mice. C57BL/6NCrl
mice were subjected to a single electric footshock and sacriﬁced either 2,
28, or 60 days later. At each time-point hippocampus (HC), prefrontal
cortex (PFC), and cerebellum (CER) were isolated for subsequent western
blot analysis (WB). Shown are representative western blots of IgG Fab or, for
control, glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) of shocked and
non shocked mice in HC (A), PFC (B), and CER (C). Graphs show expression
levels of IgG Fab after normalization to GAPDH presented in percent of those
of non shocked mice (set at 100 %). Plotted data represent means ± SEM from
all batches analyzed, n = 13 (d2, d28; batch PTSD I + IV), n = 25 (d60, batch
PTSD I-IV, see Table 2.2), 2-3 technical replicates. Statistical signiﬁcance was
calculated using student’s t-test and is indicated by t p < 0.1, * p < 0.05.
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Figure 4.18.: Hippocampal immunoglobin expression in traumatized and control
mice. Immunoglobin expression was analyzed in hippocampal lysates of
C57BL/6NCrl mice subjected to a single electric footshock and sacriﬁced 60
days later by employing antibodies speciﬁcally detecting the IgG Fab fragment,
the IgG Fc fragment, the Igλ light chain, or the Igκ light chain. Shown are
representative western blots of IgG Fab, IgG Fc, Igλ, and Igκ light chain or,
for control, glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) analyzed in
shocked and non shocked mice. Graphs show relative IgG expression levels after
normalization to GAPDH presented in percent of those of non shocked mice set
at 100 %. Plotted data represent means ± SEM, n = 6 (batch PTSD III, see
Table 2.2), 2-3 technical replicates. Statistical signiﬁcance was calculated using
student’s t-test and is indicated by ** p < 0.01, *** p < 0.001.
the increase in IgG in hippocampal lysates of mice subjected to the electric footshock,
antibodies detecting diﬀerent epitopes of the immunoglobin molecule were employed in the
western blot analysis: hippocampal lysates of mice sacriﬁced on day 60 after footshock
were analyzed employing antibodies speciﬁcally detecting the Fcγ heavy chain, the Igκ light
chain, or the Igλ light chain. Interestingly, the trauma stress-induced long-term increase in
IgG expression levels determined by employing the IgG Fab speciﬁc antibody (Figure 4.18;
t = 5.914, df = 9, p < 0.001) could be conﬁrmed by using the Igκ light chain speciﬁc antibody
(Figure 4.18; t = 4.164, df = 9, p = 0.002) but not by using the Igλ light chain speciﬁc
antibody (Figure 4.18; t = 0.942, df = 9, p = 0.371) or the Fcγ heavy chain speciﬁc antibody
117
4. Results II: Identiﬁcation of PTSD candidate proteins in a mouse model of PTSD
Figure 4.19.: Immunoglobin expression in blood samples of traumatized and control
mice. Immunoglobin expression was analyzed in blood samples of C57BL/6NCrl
mice subjected to a single electric footshock and sacriﬁced 60 days later by
employing antibodies speciﬁcally detecting the IgG Fab fragment, the IgG Fc
fragment, the Igλ light chain, or the Igκ light chain. Shown are representative
western blots of IgG Fab, IgG Fc, Igλ, and Igκ light chain analyzed in shocked
and non shocked mice. Graphs show relative IgG expression levels presented
in percent of those of non shocked mice set at 100 %. Plotted data represent
means ± SEM, n = 6 (batch PTSD III, see Table 2.2), 2-3 technical replicates.
Statistical signiﬁcance was calculated using student’s t-test and is indicated by
t p < 0.1, * p < 0.05.
(Figure 4.18; t = 1.052, df = 9, p = 0.320). These experiments show for the ﬁrst time a
stress-induced regulation of immunoglobin proteins, and in particular of the κ light chain
containing immunoglobins.
Although sporadic reports exist demonstrating that IgG is produced by neurons (Huang et al.,
2008), most studies investigating the presence of immunoglobin G molecules in the brain
suggest that neurons or microglia take up IgG delivered into the brain via the blood (Yoshimi
et al., 2002; Upender et al., 1997; Hazama et al., 2005), which carries antibodies produced
by plasma cells. Therefore, IgG expression levels were analyzed in blood of traumatized
and mock treated control mice (Figure 4.19). Interestingly, employing the IgG Fab speciﬁc
antibody, the increase in IgG in the blood of traumatized mice was detectable only at the level
of a statistical trend (Figure 4.19; t = 2.250, df = 9, p = 0.051). Moreover, in contrast to
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the results obtained by analyzing IgG expression level diﬀerences in hippocampal lysates, no
protein expression level diﬀerences were found in the blood using the Igκ light chain speciﬁc
antibody (Figure 4.19; t = 0.877, df = 9, p = 0.403), while employing the Igλ light chain
speciﬁc antibody yielded an increase in immunoglobin expression in blood of mice subjected
to the footshock (Figure 4.19; t = 2.297, df = 9, p = 0.047). As expected from analysis of
hippocampal lysates, no IgG expression level diﬀerences were measured in the blood using
the Fcγ heavy chain speciﬁc antibody (Figure 4.19; t = 1.514, df = 9, p = 0.164). Thus,
although the immunoglobins detected in the brain might originate from the blood, trauma
stress diﬀerentially regulates the expression of Igκ and Igλ carrying antibodies in brain and
blood.
4.2.3.3. IgG expression is reduced in HAB compared to LAB mice
To investigate if the regulation of IgG protein expression is a speciﬁc characteristic of traumatic
stress or a general feature of stress and anxiety-related phenotypes, IgG expression was
also assessed in 19 week old mice showing high anxiety-related behavior (HAB) or low
anxiety-related behavior (LAB), representing a model of extremes in trait anxiety (introduced
in 1.5.2) (Krömer et al., 2005). Assessment of IgG expression in the HAB/LAB mouse model
revealed strong diﬀerences between HAB and LAB mice: employing the IgG Fab speciﬁc
antibody HAB mice were found to express considerably lower hippocampal and cerebellar
IgG protein levels than the LAB mice (Figure 4.20 A; HC: t = 8.007, df = 9, p < 0.001;
CER: t = 6.010, df = 9, p < 0.001). The prefronto-cortical samples of this mouse batch were
used in other experiments and were therefore not analyzed for IgG expression. In contrast
to the PTSD mouse model (Figure 4.17), the changes in IgG expression seem to aﬀect the
whole brain, as decreased IgG expression levels were found in HAB mice in all brain regions
tested. Employing the Fcγ heavy chain speciﬁc antibody (Figure 4.20 B; HC: t = 2.870,
df = 9, p = 0.019; CER: t = 4.595, df = 9, p = 0.001) and the Igκ light chain speciﬁc antibody
(Figure 4.20 D; HC: t = 4.347, df = 9, p = 0.002; CER: t = 4.077, df = 9, p = 0.003) revealed
decreased expression levels both in the hippocampus and in the cerebellum of HAB compared
to those of LAB mice. In contrast, increased expression levels were detected in hippocampal
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Figure 4.20.: Immunoglobin expression in HAB and LAB mice. IgG expression was
analyzed employing the IgG Fab, IgG Fc, Igλ, and Igκ light chain speciﬁc
antibody in hippocampal and cerebellar lysates of HAB and LAB mice aged
19 weeks. Shown are representative western blots using the IgG Fab (A), IgG
Fc (B), Igλ (C), and Igκ (D) light chain speciﬁc antibody or, for control, a
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) speciﬁc antibody. Graphs
show relative expression levels after normalization to GAPDH presented in
percent of those of LAB mice set at 100 %. Plotted data represent means
± SEM, n = 7 (LAB), n = 4 (HAB) (batch HAB/LAB, see Table 2.2), 2-3
technical replicates. Statistical signiﬁcance was calculated using student’s t-test
and is indicated by * p < 0.05, ** p < 0.01, *** p < 0.001.
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Figure 4.21.: Immunoglobin expression in the blood of HAB and LAB mice. IgG
expression was analyzed employing the IgG Fab, IgG Fc, Igλ, and Igκ light chain
speciﬁc antibody in the blood of HAB and LAB mice. Shown are representative
western blots using the IgG Fab, IgG Fc, Igλ, and Igκ light chain speciﬁc
antibody. Graphs show relative expression levels presented in percent of those of
LAB mice set at 100 %. Plotted data represent means ± SEM, n = 7 (LAB), n
= 4 (HAB) (batch HAB/LAB, see Table 2.2), 2-3 technical replicates. Statistical
signiﬁcance was calculated using student’s t-test and is indicated by * p < 0.05,
** p < 0.01, *** p < 0.001.
and cerebellar lysates of HAB mice using the Igλ light chain speciﬁc antibody (Figure 4.20 C;
HC: t = 5.399, df = 9, p < 0.001; CER: t = 4.331, df = 9, p = 0.002). Finally, the analysis
of HAB and LAB blood samples yielded results comparable to those gained by analysis of the
brain, i.e. decreased immunoglobin expression levels using the IgG Fab, the IgG Fcγ heavy
chain, and the Ig κ light chain speciﬁc antibody as well as increased immunoglobin expression
levels in HAB mice compared to LAB mice employing the Ig λ light chain speciﬁc antibody
(Figure 4.21; IgG Fab: t = 2.974, df = 12, p = 0.012; IgG Fc: t = 3.824, df = 12, p = 0.002;
Igλ light chain: t = 1.948, df = 12, p = 0.075; Igκ light chain: t = 3.386, df = 12, p = 0.005).
Interestingly, IgG expression analysis employing antibodies speciﬁcally detecting diﬀerent
epitopes of the immunoglobin protein revealed diﬀerences in the trauma stress-induced
regulation of Igκ and Igλ carrying antibodies in the hippocampus and the blood of mice
subjected to the electric footshock, while in the HAB/LAB mouse model IgG expression level
diﬀerences in the blood largely reﬂect the IgG expression level diﬀerences in the brain.
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Figure 4.22.: Expression of microglial and endothelial cell markers in the
PTSD mouse model. Expression of Iba1, CD68, and CD31 was
analyzed in hippocampal lysates of C57BL/6NCrl mice subjected to
a single electric footshock and sacriﬁced 60 days later. Shown are
representative western blots of Iba1, CD68, and CD31 or, for control,
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH) analyzed in shocked and
non shocked mice. Graphs show relative expression levels of Iba1, CD68, and
CD31 after normalization to GAPDH presented in percent of those of non
shocked set at 100 %. Plotted data represent means ± SEM, n = 6 (batch
PTSD III, see Table 2.2), 2-3 technical replicates. Statistical signiﬁcance was
calculated using student’s t-test and is indicated by ** p < 0.01.
4.2.3.4. Analysis of microglial and endothelial marker protein expression levels in the
PTSD and the HAB/LAB mouse model
Immunohistochemical costainings revealed an association of IgG with microglial and
endothelial cells (Figure 4.16). Next, to assess the inﬂuence of state anxiety (PTSD mouse
model) and trait anxiety (HAB/LAB mouse model) on the expression of microglial and
endothelial marker proteins, expression levels of the microglial marker protein Iba1, of CD68,
which speciﬁcally detects activated microglia, and of the endothelial cell marker CD31 were
measured. These analyses revealed no signiﬁcant alterations of CD31 protein levels neither
in the hippocampus of footshocked and mock treated control mice sacriﬁced 60 days after
footshock or mock treatment nor in the hippocampus or the cerebellum of HAB and LAB mice
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Figure 4.23.: Expression of microglial and endothelial cell markers in HAB and
LAB mice. Expression of Iba1, CD68, and CD31 was analyzed in
hippocampal and cerebellar lysates of HAB and LAB mice. Shown are
representative western blots of Iba1 (A), CD68 (B), and CD31 (C) or, for
control, glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH). Graphs show
relative expression levels of Iba1, CD68, and CD31 after normalization to
GAPDH presented in percent of those of LAB mice set at 100 %. Plotted data
represent means ± SEM, n = 4 (HAB), n = 7 (LAB) (batch HAB/LAB, see
Table 2.2), 2-3 technical replicates. Statistical signiﬁcance was calculated using
student’s t-test and is indicated by * p < 0.05, ** p < 0.01.
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Figure 4.24.: IgG is associated to the cell surface of microglia. Shown are representative
images of brain slices of unstressed C57BL/6 wildtype (n = 2) mice that
were stained with an IgG Fc (red) and an Iba1 (green) speciﬁc antibody
followed by appropriate ﬂuorescently labeled secondary antibodies. Slices were
counterstained with the nuclear stain DAPI (blue). The overlay of anti-IgG Fc
and anti-Iba1 staining with DAPI is presented in the left panel (merge).
(Figure 4.22, Figure 4.23 C; HC PTSD: t = 0.789, df = 9, p = 0.450; HC HAB/LAB: t = 1.420,
df = 9, p = 0.189; CER HAB/LAB: t = 0.270, df = 9, p = 0.793). In contrast, protein
expression levels of Iba1 were reduced in the hippocampus of traumatized mice sacriﬁced 60
days after footshock (Figure 4.22; t = 2.990, df = 9, p = 0.015) and increased in the cerebellum
but not in the hippocampus of HAB versus LAB mice (Figure 4.23 A; HC: t = 1.423, df = 9,
p = 0.188; CER: t = 2.317, df = 9, p = 0.045). Interestingly, the decrease of Iba1 expression
levels in traumatized mice was paralleled by increased IgG expression levels (Figure 4.17),
while increased Iba1 expression levels in HAB mice in the cerebellum were accompanied with
a decreased expression of IgG (Figure 4.20). Finally, assessment of CD68 expression levels
revealed no signiﬁcant changes of this marker protein for activated microglia in either mouse
model (Figure 4.22, Figure 4.23; PTSD HC: t = 0.320, df = 9, p = 0.755; HAB/LAB HC:
t = 0.369, df = 9, p = 0.720; HAB/LAB CER: t = 1.812, df = 9, p = 0.103).
Detailed microscopical analysis of immunohistochemical costainings of IgG and the microglial
marker Iba1 suggest that IgG is associated to the cell surface of microglia rather than to
the cytosol which was not stained by the IgG speciﬁc antibody (Figure 4.24). The cell
surface localization of IgG might be mediated via Fc receptors, e.g. FcγRI, that is able
to bind the Fc fragment of IgG antibodies (Sondermann and Oosthuizen, 2002). In microglial
cells, Fcγ receptor signaling induces processes like phagocytosis and cytokine production by
activating the MAPK signaling pathway, Ca+ mobilization and actin reorganization (Takai,
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Figure 4.25.: FcγRI expression analysis in the PTSD and the HAB/LAB mouse
model. FcγRI expression was analyzed in hippocampal lysates of shocked
and non shocked mice sacriﬁced 60 days after footshock (A) and in
hippocampal (HC) and cerebellar (CER) lysates of HAB and LAB mice
(B). Shown are representative western blots of FcγRI or, for control,
glycerinaldehyd-3-phosphat-dehydrogenase (GAPDH). Graphs show relative
expression levels of FcγRI after normalization to GAPDH presented in percent
of those of LAB mice set at 100 % (% of LAB) or of non shocked mice set at
100 % (% of no shock). Plotted data represent means ± SEM, n = 6 (batch
PTSD III, see Table 2.2), n = 4 (HAB), n = 7 (LAB) (batch HAB/LAB, see
Table 2.2), 2-3 technical replicates. Statistical signiﬁcance was calculated using
student’s t-test and revealed no signiﬁcant changes.
2002). Stress-induced microglial FcγR expression changes have so far not been studied. The
analysis of FcγRI levels by western blotting performed here revealed no expression changes in
the PTSD mouse model and also not in the HAB/LAB mouse model (Figure 4.25; HC PTSD:
t = 0.474, df = 9, p = 0.646; HAB/LAB HC: t = 1.227, df = 9, p = 0.250; HAB/LAB CER:
t = 0.989, df = 9, p = 0.348). Nevertheless, this result does not exclude a possible increase in
activation of the Fcγ receptor associated signaling pathway. To clarify this, it will be required
to analyze downstream molecules of the Fcγ receptor, for example the src-family kinases that
play a role in the phosphorylation of the Fcγ receptor (Takai, 2002).
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Table 4.3.: Summary of expression level changes of immune system proteins.
Summary of signiﬁcant expression changes observed in shocked (s) versus non
shocked (ns) mice of batch PTSD III and in HAB versus LAB mice of the
HAB/LAB batch. Iba1, CD68, CD31, and FcγRI were not detected in blood
samples (n.d.). t = statistical trend
PTSD III HAB/LAB
Candidate protein HC d60 blood HC CER blood
IgG Fab s > ns s > ns t HAB < LAB HAB < LAB HAB < LAB
IgG Fc s = ns s = ns HAB < LAB HAB < LAB HAB < LAB
Igλ light s = ns s > ns HAB > LAB HAB > LAB HAB > LAB t
Igκ light s > ns s = ns HAB < LAB HAB < LAB HAB < LAB
Iba1 s < ns n.d. HAB = LAB HAB > LAB n.d.
CD68 s = ns n.d. HAB = LAB HAB = LAB n.d.
CD31 s = ns n.d. HAB = LAB HAB = LAB n.d.
FcγRI s = ns n.d. HAB = LAB HAB = LAB n.d.
Taken together, as summarized in Table 4.3, IgG levels were increased in the hippocampus
and in the blood of traumatized mice 60 days after application of the electric footshock. In
addition, IgG expression levels were also altered in a diﬀerent mouse model, the HAB/LAB
trait anxiety mouse model: high anxiety mice (HAB) expressed considerably lower amounts of
IgG in the hippocampus, the cerebellum, and the blood. Furthermore, IgG was identiﬁed to be
associated with microglial cells, which was paralleled by a decreased hippocampal expression of
the microglial marker protein Iba1 in mice subjected to the electric footshock and an increased
cerebellar expression of Iba1 in HAB mice. The protein expression levels of the microglial IgG
receptor FcγRI, however, remained unchanged in all samples analyzed.
4.2.3.5. In silico analysis of immunoglobin expression in PTSD patients
To translate the ﬁndings of the animal research presented above and summarized in Table 4.3
to the patient, immunoglobin mRNA expression was analyzed in publicly available microarray
data from trauma exposed controls and trauma survivors admitted to the emergency room
displaying PTSD symptoms at admittance and 4 month later (Segman et al., 2005). Assessing
overall peripheral blood mononuclear cell (PBMC) gene expression proﬁles in PTSD, Segman
et al. (2005) have described a distinct alteration in expression of genes involved in immune
activation (Segman et al., 2005). In this thesis, the expression of diﬀerent immunoglobin
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Figure 4.26.: In silico analysis of IgG mRNA expression in human peripheral
mononuclear blood cells (PBMC) of PTSD patients in comparison
to trauma-exposed controls. Microarray gene expression data generated
by Segman et al. (2005) was retrieved from the publicly available NCBI GEO
DataSets (accession number GDS1020). Expression data for Igκ light chain,
Igλ light chain, IgG1 heavy chain, IgA2 heavy chain, and IgM heavy chain
transcripts from trauma survivors with (PTSD) or without (control) PTSD
symptoms either few hours or 4 month after the traumatic event were statistically
analyzed. Plotted data represent mean ± SEM, n = 9. Statistical signiﬁcance
was calculated using two-way ANOVA and Bonferroni post-tests and is indicated
by t p < 0.1; * p < 0.05.
127
4. Results II: Identiﬁcation of PTSD candidate proteins in a mouse model of PTSD
Table 4.4.: Summary of immunoglobin expression changes in animal models and
PTSD patients. Summary of signiﬁcant expression changes observed in the
blood of PTSD patients and controls 4 month after the traumatic event, in blood
of shocked (s) versus non shocked (ns) mice of batch PTSD III, and in blood of
HAB versus LAB mice of the HAB/LAB batch. IgG Fab was not detected in blood
samples of PTSD patients (n.d.), IGHA2 and IGHM were not detected in murine
blood samples (n.d.).
Blood
Candidate
protein
PTSD patients
[mRNA]
mouse batch PTSD
III d60 blood [protein]
mouse batch HAB/LAB
blood [protein]
IgG Fab n.d. s > ns HAB < LAB
IgG Fc PTSD < control s = ns HAB < LAB
Igλ light PTSD < control s > ns HAB > LAB
Igκ light PTSD < control s = ns HAB < LAB
IGHA2 PTSD = control n.d. n.d.
IGHM PTSD = control n.d. n.d.
transcripts were now analyzed in further detail employing an in silico approach. For this,
microarray gene expression data in PBMCs of trauma survivors and trauma exposed controls
were retrieved from the NCBI GEO DataSets (accession number GDS1020). Expression levels
of Igκ light chain, Igλ light chain, IgG1 heavy chain, IgA2 heavy chain, and IgM heavy
chain transcripts were statistically analyzed (Figure 4.26). Igκ light chain and Igλ light chain
mRNA expression was signiﬁcantly reduced in PTSD patients 4 month but not few hours
after the traumatic event (Figure 4.26 A, B; two-way ANOVA plus Bonferroni post-test;
PTSD(fewhours,4month): Igκ light chain: t = 2.555, p < 0.05; Igλ light chain: t = 2.385,
p < 0.05; 4 month(control,PTSD): Igκ light chain: t = 2.205, p < 0.1; Igλ light chain: t = 2.417,
p < 0.05). Among the analyzed heavy chain transcripts only IgG1 showed a signiﬁcant
reduction in PTSD patients 4 month after the traumatic event, while the expression of IgA2
and IgM was not signiﬁcantly altered (Figure 4.26 C-E; two-way ANOVA plus Bonferroni
post-test; PTSD(fewhours,4month): IgG1 Fc: t = 2.960, p < 0.05; IgA2 Fc: t = 0.823, p > 0.05;
IgM Fc: t = 1.443, p > 0.05; 4 month(control,PTSD): IgG1 Fc: t = 2.820, p < 0.05).
Taken together, as summarized in Table 4.4, IgG expression was decreased in PTSD patients
and HAB mice, while it was increased in traumatized mice of the PTSD mouse model.
Although it might have been expected to detect increased expression of IgG in PTSD patients
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similar to the here presented observation in traumatized mice, this nevertheless suggests
that immune system associated proteins and speciﬁcally immunoglobins are an important
stress-modulated parameter not only in the animal model but also in human patients. Besides
probable species speciﬁc eﬀects, an important diﬀerence between the human and the animal
data is that the microarray study analyzed mRNA expression while in the animal models IgG
protein expression was assessed.
4.3. Summary of Results II
To sum up, several novel candidate proteins of PTSD have been identiﬁed in the second part
of this thesis. First, analysis of neurostructural proteins revealed a pronounced long-term
reduction of the synaptic proteins synapsin, synaptophysin, and homer 1b/c and the neuronal
cytoskeleton protein neuroﬁlament H in the hippocampus of mice subjected to a traumatic
footshock, which, in contrast, did not aﬀect the expression of the dendritic protein MAP-2 and
the astroglial marker protein GFAP (summarized in Table 4.1). Second, the electric footshock
elicited a marked decrease of both neuronal (EAAC1) and glial (GLT1) glutamate transporter
expression (summarized in Table 4.2), which was most pronounced on day 2 after footshock.
Chronic ﬂuoxetine treatment alleviated both the PTSD-like symptoms and the reductions in
synapsin, synaptophysin, and GLT1 protein expression. Finally, footshocked mice showed a
delayed onset hippocampal increase in IgG expression which was accompanied by a decreased
expression of Iba1, a marker protein of microglial cells, that has been demonstrated here
to express IgG. Alterations in IgG expression, although in the opposite direction, were also
observed in a mouse model of extremes in trait anxiety and in publicly available gene expression
microarray data of PTSD patients and trauma-exposed controls (summarized in Table 4.3).
Nevertheless, the alteration of IgG expression in diﬀerent mouse models of anxiety disorders
and in diﬀerent species suggest IgG to play an important role in the pathobiology of anxiety
disorders like PTSD. Altogether, these results indicate that in mice traumatic stress induces
substantial and mostly long-lasting alterations in their hippocampal cytoarchitecture, their
cerebral glutamate homeostasis, and their immune system.
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To date, the precise molecular mechanisms underlying anxiety diseases like PTSD and panic
disorder are not completely understood. The ﬁrst part of this thesis strived to elucidate
the transcriptional regulation of the previously identiﬁed anxiety disorder candidate gene
TMEM132D (Erhardt et al., 2011). In a cell culture model of oligodendrocyte diﬀerentiation
the transcription factors MYT1, HES1, ZNF219, and SP1 were identiﬁed as regulators of
TMEM132D gene expression.
Aiming to identify novel candidate proteins for PTSD that might contribute to the elucidation
of PTSD pathogenesis and might serve as diagnostic biomarkers as well as potential drug
targets, in the second part of this thesis, cerebral expression levels of a set of selected
marker proteins were compared between traumatized and control mice. In summary, this
screen revealed that traumatic stress induces alterations of the cerebral protein levels of
synaptic proteins, namely synapsin Ia-b/IIa, synaptophysin, and homer 1b/c, of the glutamate
transporter proteins GLT1 and EAAC1, as well as of the immune factor IgG and of the
microglial marker protein Iba1.
5.1. Identiﬁcation of transcription factors targeting
TMEM132D, a candidate molecule for anxiety disorders
TMEM132D was recently identiﬁed as a potential candidate gene for panic disorder (Erhardt
et al., 2011). TMEM132D function, however, remains elusive and the regulation of its
expression has so far never been studied. In the thesis at hand, for the ﬁrst time, mechanisms
regulating TMEM132D expression were studied by performing a promoter characterization
of the human TMEM132D gene. Using in silico analysis methods and follow-up reporter
gene assays, members of 13 transcription factor families were analyzed for their potential
to regulate TMEM132D expression: 8 of these transcription factor binding sites revealed
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inhibitory eﬀects on TMEM132D promoter activity in the reporter gene assays (HESF,
MYT1, ZBPF, GCMF, MTF1, NFKB, MZF1, SP1), while the others exhibited variable
(NRF1, ZFXY, EGRF, HAML) or no eﬀect (ZF5F) (Figures 3.17 and 3.19, summarized
in Table 5.1 A, B). The fact that here only inhibitory regulators of TMEM132D expression
were identiﬁed might explain the low endogenous gene expression levels of TMEM132D that
have been reported in diﬀerent human tissues (Nagase et al., 2001). According to Nagase et
al. (2001) the highest TMEM132D expression levels are found in the brain, another study
reported also considerable TMEM132D mRNA expression in human lung, pancreas, and testis
(Nomoto et al., 2003). In accordance, the mRNA TMEM132D expression analyses performed
in this thesis support a more widespread expression of TMEM132D since it was found to be
expressed in oligodendroglial, astroglial and neuroblastoma cell lines as well as in an embryonic
kidney cell line (Figure 3.12). Hence, TMEM132D expression is not restricted to the brain.
The present study concentrated on elucidating TMEM132D regulation in oligodendroglial
cells: TMEM132D upregulation during oligodendrocyte diﬀerentiation (Nomoto et al., 2003)
was conﬁrmed here in PMA-diﬀerentiated MO3.13 oligodendrocytic cells. Upregulation of
TMEM132D in diﬀerentiated MO3.13 cells was accompanied by a downregulation of some of
the inhibitory TMEM132D targeting transcription factors identiﬁed in this thesis, namely
HES1, MYT1, ZNF219, and SP1 (Figure 3.21, summarized in Table 5.1 C). These four
transcription factors showed concordant results in all analyses performed (highlighted in Table
5.1). The distinct mechanisms leading to the determination of the oligodendroglial cell fate
are still not fully understood. Epigenetic as well as miRNA mediated, i.e. posttranscriptional,
mechanisms have been described to control oligodendrocyte diﬀerentiation (Liu and Casaccia,
2010; Yu et al., 2010; Dugas and Notterpek, 2011). In accordance with the ﬁndings presented
here, three of the identiﬁed regulators of TMEM132D gene expression, namely SP1, HESF, and
MYT1, have been previously shown to be involved in oligodendrocyte diﬀerentiation: SP1 is
a common transcription factor that binds to GC-rich motifs and plays a major role in various
biological processes including cell proliferation and growth (Wierstra, 2008). Interestingly,
SP1 has been linked to oligodendrocyte diﬀerentiation by modulating the expression of the
myelin gene MBP (Guo et al., 2010).
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5. Discussion
MYT1 (Myelin transcription factor 1) is important for the induction of myelin gene expression,
in particular MYT1 has been shown to increase the expression of the myelin component
proteolipid protein (PLP) (Kim and Hudson, 1992). Myelination of axons is probably
the most important function of mature oligodendrocytes. Furthermore, MYT1 has been
shown to be downregulated in diﬀerentiated oligodendrocytes (Armstrong et al., 1995).
The downregulation of MYT1 levels (paralleling TMEM132D upregulation) in diﬀerentiated
MO3.13 cells presented in Figure 3.21 conﬁrmed the ﬁndings of Armstrong et al. (1995) on
MYT1 downregulation during oligodendrocyte maturation. Furthermore, the phylogenetic
analysis of the TMEM132D promoter using the GEMS Launcher tool revealed the MYT1
binding site to exhibit conservation in the human, murine, and equine TMEM132D promoter
sequence, while none of the other transcription factor binding sites was conserved in all three
species thereby further stressing the importance of MYT1 for TMEM132D regulation.
The HES transcription factors, especially HES1 and HES5, have been reported to inhibit
oligodendrocyte diﬀerentiation (Wu et al., 2003). Interestingly, HES1 was shown to be
upregulated by the Notch signaling pathway thereby inhibiting oligodendrocyte diﬀerentiation
(Li et al., 2011; Ohtsuka et al., 1999). Thus, downregulation of HES1 during MO3.13
oligodendrocyte diﬀerentiation (Figure 3.21) and inhibition of TMEM132D transcription by
HES1 (Figure 3.17), as observed in this study, conﬁrm the ﬁndings of Wu et al. (2003).
Identiﬁcation of a GCM1 (glial cells missing homolog) binding site further supports a potential
implication of TMEM132D in oligodendrocyte diﬀerentiation. It has been shown that the
absence of GCM1 determines the neuronal cell fate, while the presence of GCM1 enables the
development of both neurons and glia (Altshuller et al., 1996; Iwasaki et al., 2003). However,
it was not possible to detect GCM1 expression in the MO3.13 cell line, but overexpression of
GCM1 resulted in a reduction of TMEM132D promoter activity (Figure 3.17). Taken together,
the fact that four regulatory sites known to play a role in oligodendrocyte diﬀerentiation were
identiﬁed strongly argues for a pivotal role of TMEM132D in this process.
Although ZNF219 has so far not been associated to oligodendrocyte diﬀerentiation, it has
been discussed to be involved in the diﬀerentiation of another cell type, i.e. chondrocytes
(Takigawa et al., 2010). In addition, ZNF219 has been reported to generally function as a
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transcriptional repressor (Sakai et al., 2003), which was also conﬁrmed in the thesis at hand
by identifying ZNF219 as an inhibitory regulator of TMEM132D gene expression.
Nevertheless, the other identiﬁed inhibitory transcription factors, MTF1, NFKB1, and
MZF1, i.e. those factors that revealed concordant results in the reporter gene analyses
but did not show expression level changes in diﬀerentiated versus non-diﬀerentiated MO3.13
oligodendrocytes, might be important for TMEM132D transcriptional regulation in other,
not yet identiﬁed, biological contexts. Furthermore, the regulatory elements analyzed in this
study were all located in the region up to 829 bp upstream of the start codon, while potentially
conserved transcription factor binding sites in the more distally located clusters of conservation
(Figure 3.9) remain to be analyzed in future experiments.
The identiﬁcaton of a cohesin-like domain in the extracellular region of TMEM132D further
stresses the importance of TMEM132D in oligodendrocyte diﬀerentiation. This conserved
protein domain resembles bacterial cohesins, which are cell adhesion proteins expressed in
the cellulosome, a multienzyme complex degrading plant cell wall polysaccharides. In these
cellulosomes, cohesins exert a high aﬃnity interaction with dockerins forming a scaﬀoldin
complex which is attached to the cell surface of the bacterium (Bayer et al., 2004). The
cohesin-like domain identiﬁed in the extracellular region of TMEM132D most likely mediates
cohesin-like function, i.e. extracellular high aﬃnity interactions in cell adhesion processes,
and thus alludes to a potential role of TMEM132D in cell adhesion. The latter is of
great importance inter alia in oligodendroglial diﬀerentiation especially in myelination during
which cell adhesion proteins mediate interactions between the axon and the oligodendrocytic
processes (Laursen and Ffrench-Constant, 2007). However, knockdown of TMEM132D was
not able to prevent diﬀerentiation in the MO3.13 model (Figure 3.22). This suggests that
the low residual expression of TMEM132D might be suﬃcient to stimulate oligodendrocyte
diﬀerentiation, or that TMEM132D, although upregulated during diﬀerentiation, might not
be absolutely necessary for the morphological alterations observed during diﬀerentiation of the
cell line studied. Independent from that, TMEM132D might still play an important role for
the mature oligodendrocytic cell function, e.g. in neuron-glia interactions during the process
of axon myelination.
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The fact that TMEM132D is involved in oligodendrocyte diﬀerentiation, as reported
previously (Nomoto et al., 2003), was conﬁrmed in this study, and it was further elucidated
by the identiﬁcation of transcriptional regulators of TMEM132D gene expression with known
functions in oligodendrocyte diﬀerentiation processes (MYT1, HES1, SP1). Together with
the fact that TMEM132D has been identiﬁed as novel candidate gene for panic disorder,
this motivates the speculation that oligodendrocyte diﬀerentiation might play a role in
the pathobiology of anxiety disorders. Although the exact role of oligodendrocytes in the
pathobiology of anxiety disorders remains to be identiﬁed, recent reports note a role of
myelin proteins in the context of anxiety phenotypes (Kodama et al., 2008; Klempan et al.,
2009; Pasquini et al., 2011; Ono et al., 2008), as described in further detail in section 1.6.
Additionally, oligodendrocyte dysfunction has also been related to other psychiatric diseases
like schizophrenia (Martins-de-Souza, 2010; Takahashi et al., 2011).
In conclusion, this is the ﬁrst study which explored the regulatory mechanisms of TMEM132D
expression. Here, the transcription factors MYT1, HES1, ZNF219, and SP1 were found to
inhibit TMEM132D expression. In addition, the downregulation of these four TFs was found
to parallel TMEM132D upregulation in a cell culture model of oligodendrocyte diﬀerentiation.
With exception of ZNF219, these regulators have already been implicated in oligodendrocyte
diﬀerentiation as discussed above.
This study provides the ﬁrst insights into TMEM132D regulation - further studies are clearly
needed to extend them: Addressing the upstream signalling pathways of these transcription
factors might open up opportunities to pharmacologically modulate TMEM132D expression
levels both during oligodendrocyte diﬀerentiation and eventually also in anxiety disorders. To
further elucidate the role of TMEM132D regulation in anxiety disorders, in future experiments
it would be interesting to analyze expression levels of the candidate transcription factors
identiﬁed here in cingulate cortex samples of HAB and LAB mice which have been previously
reported to diﬀerentially express TMEM132D in this brain region. Additionally, it might also
be interesting to investigate TMEM132D function in other cell types like neuronal cells.
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5.2. Identiﬁcation of novel PTSD candidate proteins
5.2.1. Traumatic stress induces a long-lasting hippocampal synaptic protein
loss
The thesis at hand revealed a long-lasting decrease in the hippocampal expression of
the synaptic proteins synapsin Ia-b/IIa, synaptophysin, and homer 1b/c to accompany a
PTSD-like syndrome in mice (Figure 4.4 and 4.5), while in this mouse model of traumatic
stress the expression levels of the dendritic marker protein MAP-2 (Figure 4.7) and the glial
marker protein GFAP (Figure 4.12) were not signiﬁcantly altered. Moreover, traumatic stress
combined with re-exposure stress was found to induce a long-lasting decrease in hippocampal
expression of the neuronal marker neuroﬁlament H in the long-term (Figure 4.7). Stressing
the validity and signiﬁcance of these results, treatment with the antidepressant ﬂuoxetine was
found to alleviate the behavioral symptoms and to counteract the observed synaptic protein
loss (Figure 4.9 and 4.10). Statistical analyses revealed the expression of these synaptic
proteins to speciﬁcally correlate with the intensity of the conditioned and generalized fear
response but not with the intensity of the hyperarousal phenotype (Figure 4.8). Pointing
to an overall signiﬁcance of synaptic proteins in the cerebral stress response, hippocampal
synapsin Ia-b/IIa protein was found to be reduced also in another mouse model, namely in
mice having been subjected to acute repetitive stress. This decrease of synapsin protein
levels was, in contrast to footshocked mice (Figure 4.4), accompanied by an increase in
synaptophysin protein levels both in the hippocampus and interestingly also in the prefrontal
cortex (Figure 4.3).
Hippocampal synapsin and synaptophysin expression changes on mRNA and protein levels
have been widely studied in various animal models of stress: both in rats and mice,
stress-induced reduction of hippocampal synapsin and synaptophysin has been repeatedly
reported in various paradigms of chronic and acute stress including prenatal stress, early life
stress, chronic social stress, chronic footshock, and chronic restraint stress (Briones et al.,
2012; Cunha et al., 2006; Dagyte et al., 2011; Khurana and Devaud, 2007; Llorente et al.,
2011; Lui et al., 2011; Silva et al., 1996; Thome et al., 2001; Xu et al., 2004; Adlard et al., 2011;
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Afadlal et al., 2010; Aisa et al., 2009; Alfonso et al., 2006; Elizalde et al., 2010; Sterlemann
et al., 2010). In contrast to these studies, one single study in rats and another study in mice
also reported a stress-induced upregulation of hippocampal synapsin (Revest et al., 2010)
and synaptophysin (Gao et al., 2006). The expression of both synapsin and synaptophysin
were repeatedly reported to be regulated by diﬀerent drugs, i.e. by the steroid pregnenolone
(Shirayama et al., 2005) as well as by atypical antipsychotics (Guest et al., 2010) and, more
importantly, by the antidepressant ﬂuoxetine (O’Leary et al., 2009; Reinés et al., 2008), which,
like other SSRI-antidepressants, is frequently used in PTSD treatment. Against this literature
background, the ﬁndings presented in the thesis at hand demonstrate for the ﬁrst time a
long-lasting reduction of hippocampal synapsin and synaptophysin protein levels in a mouse
model of PTSD, and furthermore, conﬁrm ﬂuoxetine to be able to counteract this synaptic
protein loss.
In contrast to synapsin and synaptophysin, not much is known about the regulation of homer
1b/c in the cerebral stress response of rodents. So far, expression of the isoforms homer 1a and
homer 2a/b has been reported to be modulated by stress exposure (Ary et al., 2007; Qi et al.,
2010). One single study showed decreased interaction of homer 1b/c with the metabotropic
glutamate receptor in mice subjected to immobilization stress thereby alluding the stress
responsivity of the homer 1b/c protein (Tronson et al., 2010). Since the protein expression of
this postsynaptic protein has never been shown to be regulated by stress, the thesis at hand
provides the ﬁrst evidence for a stress-induced downregulation of homer 1b/c expression.
Furthermore, this thesis comprises the ﬁrst study addressing the long-term molecular sequelae
of acute traumatic stress, which is of special importance in PTSD pathogenesis, as symptoms
usually appear with a delayed-onset of at least 4 weeks, and furthermore, are reinforced by
re-exposure to traumatic cues.
In accordance with previous studies showing a diﬀerential regulation of diﬀerent synaptic
proteins (Thome et al., 2001; Müller et al., 2011), here, acute repetitive stress was
demonstrated to diﬀerentially regulate synapsin and synaptophysin in the hippocampus and,
in contrast to traumatic footshock stress, also in the prefrontal cortex (Figure 4.3). The
opposite regulation of synaptophysin in the two diﬀerent mouse models of stress employed here
138
5.2. Identiﬁcation of novel PTSD candidate proteins
emphasizes the complex regulation of synaptic proteins which is crucial for synaptic plasticity.
The expression levels of other plasticity-related proteins, i.e. the cell adhesion molecules of
the immunoglobin superfamily (NCAM), have been shown to depend on the intensity of the
electric footshock stressor and the post-stress time-interval (Merino et al., 2000).
The post-stress time-interval also plays an important role for the molecular alterations in the
PTSD mouse model employed here: while on day 2 after footshock the expression of synaptic
proteins was signiﬁcantly reduced, on day 28 after footshock, i.e. in mice not subjected
to the stressful behavioral testing, the expression of none of the synaptic proteins tested
was signiﬁcantly altered. Remarkably, on day 60 after footshock, i.e. in mice subjected to
behavioral testing on days 28-30 after footshock, the expression levels of all synaptic proteins
were signiﬁcantly reduced (Figure 4.5 and 4.4). This leads to the conclusion that the stressful
behavioral testing on days 28-30 after footshock, which includes re-exposure to the shock
chamber, ampliﬁes the trauma stress-elicited synaptic protein loss, probably by acting as a
retraumatizing stressor. As from day 28 on this synaptic protein loss sustainably persisted to
at least day 60 after footshock without any application of additional stressors, this justiﬁes
classifying the then observed changes in protein levels as ‘long-term alterations’.
The fact that chronic ﬂuoxetine treatment counteracted these long-term molecular alterations
in the hippocampus and, furthermore, alleviated the PTSD-like symptoms strongly suggests
the hypothesis that hippocampal synaptic protein loss contributes to the pathogenesis of the
murine PTSD-like syndrome. Although in addition to the hippocampus, also prefrontal cortex
and amygdala play a major role in the fear circuitry and have been repeatedly proposed to play
a role in the pathogenesis of PTSD (Shin et al., 2006; Rauch et al., 2006; Gamo and Arnsten,
2011; Hughes and Shin, 2011), the prefrontal cortex has not been studied extensively and
molecular changes in the amygdala have not been investigated at all since the thesis at hand
concentrated on deciphering the molecular correlates of the PTSD-associated hippocampal
volume loss (as introduced in section 1.2.4.1).
The fact that acute repetitive stress, which was considered to be more stressful than the single
electric footshock, led to a reduction of synapsin expression not only in the hippocampus but
also in the prefrontal cortex (Figure 4.3), and together with the ﬁndings of a recent report
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demonstrating that in rats the hippocampus was found to be the most vulnerable region
during the extremely stressful condition of experimental sepsis (Semmler et al., 2005), this
suggests the hypothesis that the hippocampus might exhibit a higher stress-responsivity than
the prefrontal cortex.
Hippocampal shrinkage has been frequently associated with stress-related disorders like major
depression and post-traumatic stress disorder (McEwen, 1997; Apfel et al., 2011; Gurvits
et al., 1996; Cole et al., 2011). The molecular correlates of this stress-associated hippocampal
volume loss, however, remain unknown. As published recently, the development of PTSD-like
symptoms in footshocked mice of the PTSD mouse model used here is also accompanied
by a hippocampal shrinkage (Golub et al., 2011). This leads to the hypothesis that the
footshock induced synaptic protein loss observed here might causally contribute to footshock
induced hippocampal shrinkage. This hypothesis and the results presented in the thesis at
hand are in accordance with previous reports suggesting that synapse loss contributes to
stress induced hippocampal volume loss (Tata and Anderson, 2010). Besides synapse loss, a
reduction in neuronal and glial cell numbers as well as dendritic atrophy have been discussed
previously as other possible correlates of hippocampal shrinkage (Czeh and Lucassen, 2007).
In rats subjected to chronic unpredictable stress or to chronic glucocorticoid administration,
the total number of DG-CA3 synapses of the mossy ﬁber pathway was reported to be reduced
in comparison to untreated control rats (Sousa et al., 2000). Interestingly, recovery from
stress or glucocorticoid exposure resulted in increased synapse numbers (Sousa et al., 2000),
argueing for a potential reversibility of both the synapse loss and the hippocampal volume
loss. Importantly, the hippocampal shrinkage and the behavioral symptoms observed in
the PTSD mouse model employed here have been previously shown to be prevented by
environmental enrichment (Golub et al., 2011). In addition, a reversibility of hippocampal
shrinkage has also been reported after exercise training in humans (Erickson et al., 2011)
as well as after antidepressant treatment of stressed tree shrews (Czeh et al., 2001; van der
Hart et al., 2002). Together with the reversibility of hippocampal shrinkage and PTSD-like
symptoms in the animal model, a clinical study reporting PTSD duration to negatively
correlate with hippocampal volume (Felmingham et al., 2009) suggests that hippocampal
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volume loss not exclusively represents a vulnerability factor, as it has been suggested by twin
studies (Gilbertson et al., 2002; Pitman et al., 2006), but rather underlies the behavioral
alterations.
A reduction in astrocyte numbers has been previously suggested to contribute to stress-induced
hippocampal volume loss (Czeh et al., 2006). The fact that in traumatized mice hippocampal
GFAP expression levels remained unchanged (Figure 4.12) argues against a major contribution
of a loss of astrocytes to the hippocampal shrinkage in the PTSD mouse model analyzed here.
Furthermore, neuronal cell loss due to increased apoptosis or decreased neurogenesis has been
discussed repeatedly to underlie hippocampal shrinkage (Czeh and Lucassen, 2007; DeCarolis
and Eisch, 2010). However, most studies failed to detect a reduction in neuronal cell numbers
(Lucassen et al., 2001), which is in agreement with the results presented in Figure 4.7 showing
that the dendritic marker protein MAP-2 was not signiﬁcantly altered at any time-point of the
analysis. In addition, the fact that both the volume reduction and the associated behavioral
eﬀects are reversible upon treatment strongly argues against neuronal cell death. In contrast
to apoptosis, decreased neurogenesis has been shown to be reversible and has previously been
associated with an increase of the hippocampus volume (Czeh et al., 2001; van der Hart
et al., 2002). However, as hippocampal neurogenesis is a rare event that only occurs in the
dendate gyrus, some authors regard decreased neurogenesis to be not suﬃcient to explain the
marked hippocampal volume loss associated with stress (Czeh and Lucassen, 2007). Finally,
hippocampal dendritic atrophy has been repeatedly reported in animal studies of chronic
stress (Bock et al., 2011; Eiland and McEwen, 2012). However, the fact that footshocked and
mock treated mice did not exhibit signiﬁcant diﬀerences in their hippocampal levels of the
dendritic marker protein MAP-2 (Figure 4.7), strongly suggests that dendritic atrophy most
likely does not grossly contribute to the hippocampal shrinkage in the PTSD mouse model
employed here. The fact that these results diﬀer from literature ﬁndings might result from
the mouse strains or the stress paradigms employed here, and moreover, it is feasible that
although both chronic and acute stress paradigms result in hippocampal volume loss, their
underlying ultrastructural correlates might be diﬀerent.
Interestingly, PTSD patients have been reported to exhibit the most pronounced hippocampal
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volume loss in the CA3/DG region (Wang et al., 2010b). This agrees well with the ﬁndings
of the immunohistochemical analysis presented in Figure 4.6 which shows that synapsin is
mainly expressed in the CA3/DG region.
Hippocampal shrinkage as well as a general hypoactivity of the hippocampus have been
associated with cognitive impairments in PTSD patients (Dickie et al., 2011; Hayes et al.,
2011). The fact that synapsin knockout mice show a pronounced impairment in their
cognitive performance (Corradi et al., 2008; Silva et al., 1996) leads to the speculation that
the here observed trauma stress induced loss of synapsin protein might causally contribute
to PTSD-associated cognitive impairment in mice. The correlation analysis presented in
Figure 4.8 showing a signiﬁcant correlation of synaptic protein expression levels with the
conditioned and generalized fear response but not with the intensity of the hyperarousal
behavior furthermore suggests that synaptic proteins diﬀerentially contribute to fear and
hyperarousal phenotypes and thus derive from diﬀerent pathogenetic mechanisms.
As hippocampal shrinkage is associated with both the murine (Golub et al., 2011) and the
human (Gurvits et al., 1996) PTSD syndrome and as ﬂuoxetine not only alleviates the
PTSD-like symptoms in mice but also leads to PTSD symptom reduction in humans (Berger
et al., 2009), it can be speculated that ﬂuoxetine treatment might also counteract synaptic
protein loss in PTSD patients. Hence, synapsin, synaptophysin, and homer 1b/c might
possibly represent novel candidate molecules for the neuropathology of PTSD. Synaptic protein
alterations have already been detected in post-mortem brain specimens of patients with other
psychiatric disorders like schizophrenia and bipolar depression (Beasley et al., 2005; Eastwood
et al., 1995; Eastwood et al., 2000; Porton and Wetsel, 2007; Vawter et al., 2002), but not in
patients who had suﬀered from major depression (Beasley et al., 2005; Müller et al., 2001). To
date, there are no studies having analyzed synaptic protein expression in post-mortem brain
specimens of PTSD patients.
Interestingly, synapsin expression has been reported to inﬂuence the expression of other
synaptic marker proteins: experimental depletion of synapsin in neuronal cultures as well
as in the mouse model was found to be accompanied by a downregulation of other synaptic
vesicle proteins like synaptophysin and synaptotagmin (Ferreira et al., 1994; Rosahl et al.,
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1995). These reports suggest that restoring synapsin expression levels can also have beneﬁcial
eﬀects on other synaptic proteins or even the structure of the whole synapse and stresses the
fact that synapsin protein expression is highly dynamic and presents an attractive target to
modulate the stress induced eﬀects on the synapse.
In order to pharmacologically target synaptic protein expression, the mechanisms underlying
synaptic protein loss have to be elucidated. The fact that glucocorticoids have been repeatedly
reported to induce synapsin expression in animals (Nestler et al., 1981; Garcia-Caceres et al.,
2010; Wu et al., 2007) and the fact that human PTSD has been associated with decreased
glucocorticoid levels (Yehuda, 2009) as exempliﬁed in further detail in section 1.2.1, lead
to the speculation that decreased corticosterone levels might underlie the here observed
trauma stress induced hippocampal synaptic protein loss. In contrast to glucocorticoids, the
eﬀects of epinephrine or norepinephrine, which are known to be increased in human PTSD
(Dikanović et al., 2011), on synapsin expression have so far not been studied, but it has
been repeatedly shown that norepinephrine increases synapsin phosphorylation and thereby
modulates synaptic activity (Mobley and Greengard, 1985; Parﬁtt et al., 1991).
In conclusion, in this thesis the synaptic proteins synapsin, synaptophysin, and homer 1b/c
were identiﬁed as novel candidate proteins for the murine PTSD-like syndrome and especially
for the accompanying hippocampal shrinkage (Golub et al., 2011). To further conﬁrm the
hypothesis of synaptic degeneration, in future experiments synapse structure and numbers
should be analyzed by electron microscopy of hippocampal slices of traumatized and control
mice. Furthermore, in order to translate these ﬁndings to the clinical setting, i.e. to the
diagnosis and treatment of PTSD patients, and to evaluate the synaptic candidate proteins
as future PTSD biomarkers, analysis of synaptic protein expression in human post-mortem
specimens as well as blood plasma and CSF samples of PTSD patients will be necessary.
As most post-mortem brain samples, however, derive from medicated patients it might be
problematic to conﬁrm the ﬁndings from the animal models because, as discussed above,
many drugs used in pharmacotherapy of PTSD have been reported to modulate synaptic
protein expression (O’Leary et al., 2009; Iwata et al., 2006).
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5.2.2. Traumatic stress induces a reduction of glutamate transporter
expression
In addition to the trauma stress-induced hippocampal synaptic protein loss, also the expression
levels of the glutamate transporter proteins GLT1 and EAAC1 were found to be decreased in
the hippocampus of footshocked mice with the most pronounced eﬀects appearing early, i.e.
on day 2, after footshock (Figure 4.11), while the expression levels of the astrocytic marker
protein GFAP remained unchanged at any time point tested (Figure 4.12). Interestingly,
chronic ﬂuoxetine treatment of footshocked mice enhanced the expression of GLT1 but not
the expression of EAAC1 or GFAP (Figure 4.13).
So far, there was no report on the association of GLT1 with the murine PTSD-equivalent
syndrome, but only one study reporting a reduction of GLT1 protein expression in response
to sub-chronic immobilization stress in mice (Zoppi et al., 2011). In rats, however, several
research groups have analyzed the eﬀect of mainly chronic and early life stress on glutamate
transporter expression resulting in inconsistent ﬁndings: while some reported a reduction
of GLT1 (García-Bueno et al., 2007; Madrigal et al., 2003; Zink et al., 2010), others
observed increased GLT1 expression after stress exposure (Martisova et al., 2012; Wood et al.,
2004; Raudensky and Yamamoto, 2007; Reagan et al., 2004). Similarly, animal studies on
stress-induced expression changes of the glutamate transporter EAAC1 provided inconsistent
results (García-Bueno et al., 2007; Madrigal et al., 2003; Zink et al., 2010). This thesis
demonstrates for the ﬁrst time GLT1 and EAAC1 expression to be associated with the stress
response in a mouse model of PTSD. Furthermore, in agreement with previous reports showing
the tricyclic antidepressant amitriptyline, the mood stabilizer valproic acid (VPA), as well as
the β-lactam antibiotic ceftriaxone and, most importantly, the SSRI antidepressant ﬂuoxetine
to induce glutamate transporter expression (Tai et al., 2006; Perisic et al., 2009; Valentine and
Sanacora, 2009; Zink et al., 2011), in this thesis chronic ﬂuoxetine treatment of footshocked
mice was found to increase hippocampal GLT1 protein levels (Figure 4.13) and, moreover, to
alleviate PTSD-like symptoms (Figure 4.9).
Typically, glutamate homeostasis in the synaptic cleft is tightly controlled by astrocytes which
wrap the pre- and postsynapse thereby forming a tripartite synapse (Perea et al., 2009)
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(Figure 5.1 A). The fact that the expression levels of both the dendritic marker protein
MAP-2 as well as the astrocytic marker protein GFAP were not changed in footshocked mice
(Figure 4.7 and 4.12), leads to the hypothesis that a decrease in neuronal or astrocytic cell
numbers does not grossly contribute to trauma-induced reduction of glutamate transporter
expression. The decrease of glutamate transporter expression levels in mice subjected to a
single electric footshock motivates the speculation that glutamate clearance from the synaptic
cleft might be reduced in traumatized mice which, in turn, might lead to increased extracellular
concentrations of glutamate. Unbalanced levels of glutamate can result in excitotoxicity
(Forder and Tymianski, 2009; Dong et al., 2009) which, in turn, might probably also contribute
to the synaptic protein loss discussed in section 5.2.1.
These speculations are corroborated by the fact that increased glutamate release from
presynaptic terminals has been discussed as a crucial step in the trauma stress-induced
hippocampal volume loss (Musazzi et al., 2011). Moreover, excessive glutamate levels are
well known to be tightly involved in the stress-induced structural remodeling of synapses
by initiating excitotoxic processes via NMDA receptor mediated calcium inﬂux (McEwen,
2010). This leads to the speculation that the degradation of synapses suggested by the here
reported footshock induced long-term downregulation of synaptic proteins might represent an
adaptation mechanism inhibiting further trauma stress-induced harmful excitatory input. To
test this hypothesis of trauma stress-induced increase in glutamate levels in the synaptic cleft,
microdialysis measurements of extracellular glutamate levels in the hippocampus should be
performed in future experiments.
The ﬁndings that the antidepressant ﬂuoxetine is able to counteract both the trauma
stress-induced decrease of GLT1 protein levels (Figure 4.13) and the behavioral symptoms
in mice (Figure 4.9) reveal GLT1 as an interesting candidate molecule for clinical PTSD trials
and post-mortem studies. The fact that anti-glutamatergic drugs like lamotrigine have been
reported to eﬀectively alleviate symptoms in PTSD patients (Hertzberg et al., 1999) leads
to the speculation that the glutamate homeostasis is disturbed not only in mice but also in
humans with PTSD symptoms.
In summary, the trauma stress-induced loss of hippocampal glutamate transporters observed
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here suggest that a disturbed glutamate homeostasis probably contributes to the development
of hippocampal shrinkage in the PTSD mouse model used here. As the eﬀects on glutamate
transporter expression were most pronounced on day 2 after footshock (Figure 4.11), the
observed glutamatergic alterations probably represent early events in the pathogenesis of
the mouse PTSD-like syndrome and might contribute to the induction of other long-term
molecular changes, e.g. the here described synaptic protein loss, which was demonstrated to
be counteracted by ﬂuoxetine treatment (Figure 4.13).
5.2.3. The expression of immune system associated molecules is altered both
in mice exhibiting a PTSD-like syndrome and in PTSD patients
In contrast to the three synaptic proteins, GLT1, and EAAC1 which were all found to be
decreased in traumatized mice (see sections 4.2.1 and 4.2.2), the protein expression levels of the
antibody molecule immunoglobin G (IgG) were found to be increased in the hippocampus, the
prefrontal cortex, and in the blood of footshocked mice (Figures 4.17 and 4.19); this increase
occurred with a delayed-onset. On the contrary, in an in silico analysis employing data from
Segman et al. (2005) IgG gene expression levels were found to be decreased in peripheral
blood mononuclear cells (PBMC) of PTSD patients in comparison to trauma-exposed controls
(Figure 4.26) suggesting that IgG plays a role both in human PTSD and its murine equivalent
but is obviously regulated diﬀerentially in diﬀerent species. In addition, these contrary ﬁndings
in mice and human patients might also result from the fact that in mice IgG expression was
determined on the protein level and in the clinical study on the mRNA level. However, in
agreement with the data comparing mRNA expression levels in PTSD patients and controls,
reduced IgG protein levels were found to occur in another mouse model for anxiety disorders,
i.e. the high anxiety-related behavior (HAB) mice (Krömer et al., 2005) which in comparison
to low anxiety-related behavior (LAB) mice expressed considerably lower amounts of IgG in the
blood and in all brain regions analyzed, i.e. in the hippocampus and the cerebellum (Figures
4.20 and 4.21). The observation that the Igλ and κ light chain carrying antibodies were
diﬀerentially expressed in the hippocampus and blood samples of shocked mice (Figures 4.18
and 4.19) suggests that preferably Ig κ carrying antibody molecules extravasate from the blood
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by a still to be determined mechanism. This region-speciﬁcity was not detectable in HAB and
LAB mice which, in contrast to the PTSD mouse model, do not represent temporary changes
but rather reﬂect permanent alterations of an extreme anxiety phenotype. Interestingly, HAB
mice compared to LAB mice expressed increased Igλ light chain levels, while they exhibited
reduced expression levels of Igκ light chain, IgG Fc, and IgG Fab (Figure 4.20). However, as
only 5 % of murine antibodies carry the Igλ light chain, the increase of the Ig λ light chain
levels observed here might probably have a small impact on total immunoglobin levels, and
therefore this ﬁnding does not contradict the reduction of total IgG levels found here in HAB
mice.
Furthermore, by immunohistochemical analyses in brains of untreated C57BL/6 mice IgG
was identiﬁed to be associated with microglial and endothelial cells (Figure 4.16). Western
blot analysis revealed a decreased hippocampal expression of the microglial marker protein
Iba1 in footshocked mice (Figure 4.22), while in HAB mice compared to LAB mice an
increased cerebellar expression of Iba1 was found (Figure 4.23). The opposite regulation
of immunoglobin IgG and the microglial marker Iba1 in traumatized mice and in HAB mice
might result from the diﬀerent mouse strains, but most likely, it derives from the fact that
footshocked mice suﬀer from state anxiety while HAB mice suﬀer from trait anxiety since they
were selectively bred for an high anxiety phenotype for more than 40 generations (Krömer
et al., 2005). In contrast to Iba1, protein expression levels of the endothelial cell marker CD31,
of CD68, a marker protein for activated microglia, and of the microglial IgG receptor FcγRI
were not signiﬁcantly altered in both the PTSD mouse model and the HAB/LAB mouse model
(Figures 4.22, 4.23 and 4.25).
Increasing amount of evidence supports the immune system to be a major player in stress
adaptation (García-Bueno et al., 2008; Bauer et al., 2010) as well as in the pathogenesis of
stress-related disorders like PTSD (Pace and Heim, 2011). So far, in clinical studies, altered
expression of the cytokines IL-1β, IL-6, TNF-α, IL-2, and IL-8 in blood as well as the CSF
of PTSD patients have been reported (Spivak et al., 1997; von Känel et al., 2007; Maes
et al., 1999; Baker et al., 2001; Song et al., 2007). Furthermore, alterations of immune
cell functions like impaired natural killer cell activity (Gotovac et al., 2010), enhanced T cell
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function (Boscarino and Chang, 1999; Sommershof et al., 2009), and altered epigenetic proﬁles
of immune system associated genes (Uddin et al., 2010) have been reported in PTSD patients.
So far, only few studies employing animal models have addressed the molecular mechanisms
underlying the immune system’s contribution to the psychological stress response. Employing
a predator stress mouse model of PTSD, it has been shown that regulatory T cells suppress the
individual’s ability to adapt to psychosocial stress (Cohen et al., 2006). In addition, another
study showed recently that mice exposed to early life stress exhibit decreased expression
levels of lipopolysaccharide binding protein (LBP), an innate immune system protein, which
is required for synaptic pruning during hippocampal development (Wei et al., 2012).
Sporadic studies have reported increased salivary IgA levels in humans in response to
environmental stress (Kugler et al., 1996; Mishra et al., 2011), but so far no systematic
study neither in human patients nor in animal models has analyzed immunoglobin expression
in response to psychological stress and in the context of stress-related disorders. Against
this background, this thesis shows for the ﬁrst time a trauma stress-induced upregulation of
immunoglobin G expression in both the brain and the blood of traumatized mice.
The presence of IgG in the healthy CNS of rodents has already been shown in both neuronal
(Yoshimi et al., 2002; Upender et al., 1997) and microglial cells (Hazama et al., 2005);
these reports are in agreement with the ﬁndings presented in Figure 4.16 showing IgG to
be associated with microglial cells.
While stress-induced alterations of protein expression levels of the endothelial cell marker
CD31 and the microglial immunoglobin G receptor FcγRI have not been analyzed before,
several reports demonstrated microglial alterations to occur in the aftermath of stress
exposure. Most publications report a stress-induced increase of microglial activation and
of total microglial cell numbers (Diz-Chaves et al., 2012; Espinosa-Oliva et al., 2011; Tynan
et al., 2010). Microglial activation and functions like cytokine secretion have been suggested to
be at least in part mediated by glucocorticoids (Frank et al., 2012) and epinephrine (Wohleb
et al., 2011). In contrast to these reports, decreased levels of the microglia marker protein
Iba1 and unchanged expression of the activated microglia marker CD68 (Figure 4.22) in the
aftermath of traumatic footshock suggest a reduction of total microglia cell numbers and an
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increase in the proportion of activated microglia. Here, western blot analysis revealed IgG
to be upregulated in footshocked and downregulated in HAB mice, while Iba1 expression
was reduced in footshocked animals and increased in HAB animals. This ﬁnding, i.e. that
increased IgG levels were accompanied by decreased Iba1 levels, was unexpected as IgG by
binding to its Fc receptors can induce the activation, and therewith proliferation, of microglia
(Lunnon et al., 2011).
However, the origin of IgG found in the brain remains elusive. By RT-PCR analysis and in situ
hybridization others already have excluded that microglia synthesize IgG, and moreover, it has
been proposed that IgG from the blood is taken up via microglial Fc receptors (Hazama et al.,
2005). The blood-brain barrier (BBB) normally prevents the transfer of many blood proteins
into the CNS, but it has been shown that IgG can pass the BBB during epinephrine-induced
transient hypertension (Kuang et al., 2004). Some studies also showed a stress-induced
increase in BBB permeability (Skultétyová et al., 1998; Esposito et al., 2001; Esposito et al.,
2002), which, however, was not conﬁrmed by others (Park et al., 2008; Amourette et al., 2009).
Provided that the increased epinephrine levels observed in PTSD patients (Dikanović et al.,
2011) are also found in mice subjected to the electric footshock, the epinephrine-induced BBB
leakage might explain the origin of IgG in the brain. Furthermore, a diﬀerential sensitivity
of the analyzed brain regions to stress or epinephrine induced BBB permeability, which has
been reported before (Skultétyová et al., 1998), might explain the region-speciﬁc increase of
IgG levels in the PTSD mouse model.
Strikingly, no evidence for a direct glucocorticoid-dependent regulation of IgG exists, although
glucocorticoids are well-known for their anti-inﬂammatory properties and are commonly
used in the therapy of chronic inﬂammatory diseases (Barnes, 2011). Nevertheless, the
hypocortisolism associated with PTSD patients (Yehuda, 2009) motivates the speculation of a
reduced repression of inﬂammation which, in turn, could possibly contribute to the increased
levels of IgG in traumatized mice. Furthermore, it has been shown that the stress hormone
epinephrine, which is tightly involved in the complex regulation of the immune response
(Elenkov et al., 2000) and is found to be chronically elevated in PTSD patients (Dikanović
et al., 2011), increases IgG production in B cells via β2-adrenergic receptors (Podojil and
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Sanders, 2003). From this it can be speculated that anti-β-adrenergic drugs like propanolol,
which have already been used successfully in the treatment of PTSD patients (see section 1.4),
could counteract IgG upregulation and might possibly also alleviate PTSD-like symptoms in
mice. However, in a recent study one single administration of propanolol did not ameliorate
PTSD-like behavior in a predator scent based PTSD mouse model (Cohen et al., 2011).
Nevertheless, future analysis of the behavioral consequences of anti-β-adrenergic treatment in
footshocked mice might contribute to the elucidation of the mechanism of the here observed
trauma-stress induced IgG upregulation.
Rather than inducing inﬂammation in the brain physiological levels of IgG might mediate
neuroprotective eﬀects, as suggested recently (Hulse et al., 2008). Physiological levels of IgG
have been shown to prevent glutamate induced excitotoxicity in rat hippocampal slices by
activating microglia and subsequent TNFα release (Hulse et al., 2008), which, in turn, has
been reported to enhance synaptic eﬃcacy (Beattie et al., 2002). Thus, a moderate increase
of IgG levels in the hippocampus of footshocked mice could possibly reﬂect a compensatory
mechanism to counteract glutamate excitotoxicity and synaptic loss.
Surprisingly, here, a decreased IgG expression was found in an in silico analysis of PBMC
gene expression data of PTSD patients (Figure 4.26). However, as protein and mRNA
expression levels do not necessarily correlate, IgG protein expression in human PTSD blood
samples should be addressed in future experiments to investigate the potential increase in IgG
expression levels, that might be expected both from the analysis of the PTSD mouse model
presented here and from the repeatedly reported elevated inﬂammatory parameters in PTSD
patients (Spivak et al., 1997; von Känel et al., 2007; Maes et al., 1999; Baker et al., 2001;
Gotovac et al., 2010; Boscarino and Chang, 1999; Sommershof et al., 2009). Importantly, here,
both in PTSD patients and in traumatized mice, alterations of IgG were only detectable in
the long-term, but not shortly after the trauma leading to the speculation that these changes
contribute to the delayed-onset occurrence of PTSD-like symptoms, i.e. the fear generalization
behavior in mice that is also characteristic of the human PTSD syndrome.
In summary, this thesis revealed distinct alterations in immune system proteins by analysis of
two diﬀerent mouse models of pathological anxiety as well as by an in silico analysis of PBMC
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gene expression of PTSD patients. Whether these changes present a cause or a consequence
of the events leading to the development of anxiety disorders like PTSD remains unresolved
and will be addressed in future studies.
5.2.4. Model conception of the speculated trauma stress-induced synapse loss
Figure 5.1 summarizes all factors analyzed in this thesis that possibly contribute to the
speculated trauma stress-induced hippocampal synapse loss in the PTSD mouse model. It
is well-known that astrocytic processes tightly contact the synapse to build the so called
tripartite synapse (Perea et al., 2009) and, by expressing glutamate transporter proteins,
mediate the clearance of glutamate from the synaptic cleft (Danbolt, 2001). In addition to
astrocytes, also microglia have been recently reported to modulate synaptic structures: besides
the secretion of immune molecules like cytokines (Fourgeaud and Boulanger, 2010), microglia
also physically interact with the synapse by forming a quadripartite synapse (Tremblay and
Majewska, 2011) (Figure 5.1 A). Activated by homeostatic imbalances microglia have been
reported to induce synaptic stripping (Perry and O’Connor, 2010), which leads to a separation
of pre- and postsynapse to protect the neurons from further harmful synaptic input (Blinzinger
and Kreutzberg, 1968; Trapp et al., 2007; Tremblay et al., 2010). This leads to the speculation
that the loss of glutamate transporter proteins in response to the traumatic footshock
reported in the thesis at hand (Figure 4.11) probably prevents eﬀective glutamate clearance
and subsequently results in elevated extracellular glutamate levels. Furthermore, it can be
speculated that this imbalance in glutamate homeostasis might activate synaptic stripping to
protect the neurons from glutamate induced excitotoxicity (Figure 5.1 B). Ultimately, both
synaptic stripping and excitotoxic eﬀects could result in the here observed loss of synaptic
proteins.
5.2.5. Conclusions
In conclusion, educated guess-driven screening for novel candidate molecules for PTSD in a
mouse model of PTSD revealed alterations in the expression of hippocampal synaptic proteins.
This synaptic protein loss is speculated to reﬂect a trauma-stress induced synaptic loss, which
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Figure 5.1.: Model conception of the speculated trauma stress-induced synapse
loss. (A) Scheme of the quadripartite synapse as proposed by Tremblay and
Majewska (2011), consisting of pre- and postsynapse, astrocytic and microglial
processes. (B) Red arrows indicate trauma stress-induced alterations of candidate
proteins identiﬁed here: synapsin, synaptophysin, homer 1b/c, GLT1, EAAC1,
GFAP, IgG, Iba1, FcγR. The here observed synaptic protein loss motivates the
speculation of a trauma stress-induced synaptic loss, which might possibly be
induced by insuﬃcient glutamate clearance due to a trauma stress-induced loss
of glutamate transporter proteins and subsequent excitotoxic processes. IgG has
been reported to mediate neuroprotective eﬀects, however, the role of the immune
system in synaptic plasticity has not been fully elucidated yet.
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might contribute to hippocampal shrinkage observed in both the PTSD mouse model employed
here and in human patients. The here observed pronounced decrease of glutamate transporter
expression is speculated to result in increased extracellular glutamate levels. This in turn leads
to the speculation that glutamate induced excitotoxicity might contribute to the here observed
trauma stress-induced synaptic protein loss and possibly also to hippocampal shrinkage. These
neurodegenerative processes might speculatively be counteracted by possible neuroprotective
eﬀects mediated by the here observed increase of hippocampal immunoglobin G protein levels
in traumatized animals. Whether the trauma stress-induced IgG increase is actually protective
or rather promotes the hippocampal synaptic loss, or whether it has a completely diﬀerent
function, has to be addressed by future experiments.
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Figure A.1.: Multiple sequence alignment of TMEM132D paralogs
employing T-coﬀee (www.tcoﬀee.org/). Visualization of
multiple sequence alignment was performed using BOXSHADE 3.21
(http://www.ch.embnet.org/software/BOX_form.html).
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A. Appendix
Table A.2.: TFSEARCH (http://www.cbrc.jp/research/db/TFSEARCH.html)
results identifying potential transcription factor binding sites in the
TMEM132D promoter.
Name Detailed name Position
from-to
Strand Score Sequence
GATA-1 GATA-binding factor 1 88-97 (-) 86.9 catctggccc
MZF1 Myeloid zinc ﬁnger 1 104-110 (+) 96.5 agggggga
NF-kap nuclear factor kappa light chain
enhancer of activated B cells
108-125 (+) 90.7 ggggagcccc
NF-kap nuclear factor kappa light chain
enhancer of activated B cells
119-128 (-) 88.9 gagccccgcg
Sp1 Speciﬁcity Protein 1 188-196 (+) 86.3 ggggccgggc
MZF1 Myeloid zinc ﬁnger 1 212-219 (+) 85.2 gccgggga
E2F E2F transcription factor 1 231-240 (-) 88.5 ttcaaaccg
GATA-2 GATA-binding factor 2 291-300 (+) 90.9 tgggatgggg
GATA-1 GATA-binding factor 1 291-300 (+) 90.6 tgggatgggg
GATA-3 GATA-binding factor 3 292-300 (+) 86.9 gggatgggg
Sp1 Speciﬁcity Protein 1 396-402 (-) 87.7 ccgccac
c-Rel v-rel reticuloendotheliosis viral
oncogene homolog (avian)
531-540 (-) 94.2 aaataccccc
NF-kap nuclear factor kappa light chain
enhancer of activated B cells
531-540 (-) 92.7 aaataccccc
NF-kap nuclear factor kappa light chain
enhancer of activated B cells
531-540 (-) 91.6 aaataccccc
c-Ets v-ets erythroblastosis virus E26
oncogene homolog (avian)
524-536 (+) 86.6 ggaaaggaaatac
CdxA caudal type homeobox 1 552-557 (+) 88.5 atttaaa
CdxA caudal type homeobox 1 562-568 (+) 92.1 aattctg
AML-1a Acute myeloid leukemia 1 protein 560-565 (+) 87.4 tggggt
AML-1a Acute myeloid leukemia 1 protein 589-594 (+) 87.4 tggggt
Sp1 Speciﬁcity Protein 1 585-594 (+) 86.3 gaggtggggt
c-Rel v-rel reticuloendotheliosis viral
oncogene homolog (avian)
580-599 (+) 85.1 ggggtttgcc
MZF1 Myeloid zinc ﬁnger 1 792-799 (+) 85.2 gccgggga
GATA-3 GATA-binding factor 3 841-849 (+) 92.2 gagatgggg
MZF1 Myeloid zinc ﬁnger 1 843-850 (+) 92.2 gatgggga
GATA-1 GATA-binding factor 1 839-849 (+) 91.0 tgagatgggg
GATA-2 GATA-binding factor 2 839-849 (+) 88.9 tgagatgggg
c-Ets v-ets erythroblastosis virus E26
oncogene homolog (avian)
824-833 (+) 87.3 ccaggatgtg
AML-1a Acute myeloid leukemia 1 protein 862-868 (-) 85.4 cactggt
GATA-1 GATA-binding factor 1 879-888 (-) 89.0 catcagcctg
C/EBP CCAAT-enhancer-binding
proteins
899-908 (-) 86.2 tttccaaagg
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